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2 Zusammenfassung 
Das Ribosom ist der zentrale Ort der Proteinsynthese. Hier wird die genetische 
Information, die durch die messenger RNA kodiert wird in Polypeptidketten übersetzt, 
welche sich dann zu aktiven Proteinen falten. Die Beeinträchtigung der ribosomalen 
Translationsgenauigkeit führt zu Übersetzungsfehlern (Mistranslation), was 
fehlgefaltete und funktionsgestörte Proteine zur Folge hat.  
Im Rahmen dieser Arbeit wurden die Auswirkungen der Mistranslation bei höheren 
Eukaryoten untersucht. Aminoglykoside wurden auf ihre Eigenschaft getestet die 
Translokation in Ribosomen höherer Eukaryoten zu hemmen und 
Übersetzungsfehler zu induzieren. Dazu wurden in vitro mittels Kaninchen 
Reticulozyten Lysat und in vivo mittels HEK293 Zellen duale Luciferase Assays 
etabliert. Das Aminoglykosid Geneticin zeigte in beiden Assays eine starke Induktion 
der Mistranslation. Im Gegensatz dazu induzierte das Aminoglykosid Hygromycin B 
keine Translationsfehler, obwohl die Inhibition der Translation vergleichbar mit 
derjenigen von Geneticin war. Die Bindungstelle von Hygromycin B in der 
ribosomalen Dekodierungsstelle ist einige Angström von der Geneticin 
Bindungsstelle entfernt. Mittels Kristallstruktur konnten unterschiedliche 
Konformationsänderungen der Nucleotide A1492 und A1493 gezeigt werden, welche 
entscheidend für die Decodierung sind. Um die zelluläre Reaktion auf Mistranslation 
zu untersuchen, wurde das Proteom von Geneticin und Hygromycin B behandelten 
HEK293 Zellen untersucht. Im Gegensatz zu Hygromycin B führte die Behandlung 
mit Geneticin zu einer ausgeprägten Aktivierung der Unfolded Protein Response im 
Endoplasmatischen Reticulum (erUPR) und der zytosolischen Hitzeschock-Antwort 
(zytoUPR). Daraus lässt sich schlussfolgern, dass Mistranslation in höheren 
Eukaryoten zur Fehlfaltung von Proteinen und zur Aktivierung der UPRs führt. Mehr 
als zwei Drittel der durch Geneticin induzierten Proteine sind Bestandteil des 
Proteinmetabolismus, d.b. Proteine welche bei der Proteinfaltung, Translation, 
Degradation, Transport und Signalübertragung bei proteotoxischen Stress involviert 
sind. Sowohl bei Hygromycin B als auch bei Geneticin behandelten Zellen, wurden 
Proteine der Proteinsynthese hochreguliert, was eine gemeinsame Reaktion auf die 
Inhibition der Translokation andeutet. Neben der gemeinsamen Induktion einiger 
Chaperone welche oxidativem Stress entgegenwirken, waren auch Schlüsselenzyme 
mitochondrialer metabolischer Aktivität herunterreguliert, was auf eine Rückkopplung 
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schliessen lässt, um die Menge mitochondrialer Sauerstoffradikale (ROS) zu 
verringern. Um oxidativem Stress direkt zu untersuchen, wurde die Bildung von ROS 
in HEK293 Zellen gemessen. Die Fähigkeit Sauerstoffradikale zu generieren 
korrelierte gut mit der Inhibition der zytosolischen Translation, wobei Geneticin und 
Hygromycin B die effektivsten ROS-Induktoren waren.  
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3 Summary 
The ribosome is the central machinery in protein synthesis. Here, the genetic 
information encoded by the messenger RNA is translated into polypeptides, which 
fold into functional proteins. Impairment of ribosomal decoding accuracy results in 
mistranslation with the consequence of misfolded and non-functional proteins.  
In this thesis the cellular response to mistranslation in higher eukaryotes was 
investigated. Aminoglycosides were studied for their efficacy to inhibit translation and 
to induce translation errors in ribosomes of higher eukaryotes. For this purpose in 
vitro and in vivo dual luciferase assays were established using rabbit reticulocyte 
lysate and HEK293 cells, respectively. Both in vitro and in vivo, the aminoglycoside 
geneticin was found to induce prominent read-through. In contrast, the 
aminoglycoside hygromycin B did not induce translational errors, although translation 
was inhibited comparable to geneticin. As per crystal structures the ribosomal binding 
site of hygromycin B is a few angstroms away from the binding site of geneticin, 
resulting in distinct conformational changes of key decoding nucleotides A1492 and 
A1493. To study the cellular response to mistranslation in HEK293 cells, quantitative 
proteome analyses were performed and the effect of geneticin and hygromycin B on 
the proteome was studied. In contrast to hygromycin B, geneticin treatment resulted 
in a prominent induction of the cytosolic heat shock response and the endoplasmatic 
reticulum unfolded protein response (erUPR), suggesting that mistranslation in higher 
eukaryotes leads to protein misfolding and to activation of UPRs. More than two 
thirds of the proteins upregulated by geneticin are involved in protein metabolism, i.e. 
protein folding, translation, degradation, protein transport and signal transduction. 
Geneticin and hygromycin B treated cells showed a common upregulation of 
components of the cytosolic translation machinery, indicating a mutual response to 
translation inhibition. In addition to a common minor subset of upregulated 
chaperones involved in scavenging of oxidative stress, key enzymes involved in 
mitochondrial metabolic activity were downregulated, pointing to a feedback 
mechanism to lower mitochondria-derived reactive oxygen species (ROS). To study 
ROS directly, we measured formation of oxidative stress in HEK293 cells. The ability 
to induce oxidative radicals correlated well with the drug’s efficacy to inhibit cytosolic 
translation, with hygromycin B and geneticin as the most active ROS inducers.  
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4 Introduction 
The correct conversion of genetic information into functional proteins is one of the 
most fundamental and complex processes in a cellular organism. The central 
apparatus for protein synthesis is a large ribonucleoprotein complex termed the 
ribosome. By using aminoacyl-transfer RNA (aa-tRNA) as substrates, the ribosome 
translates genetic information encoded by messenger RNA (mRNA) into 
polypeptides.  
The ribosome consists of a small and a large subunit (Fig. 1). Decoding of the mRNA 
message into polypeptides takes place at the small ribosomal subunit. The functional 
sites of the small ribosomal subunit are the path for mRNA guidance during 
translation, the decoding center with the A-, the P- and E-sites. The A-site harbours 
the aminoacyl-tRNA, the P-site serves to bind the tRNA with the growing polypeptide 
chain (peptidyl-tRNA) and the E-site (Exit) is the place where the deacetylated tRNA 
leaves the ribosome. Analogous to the small ribosomal subunit, the large subunit has 
A, P and E- tRNA binding sites. The major functional sites of a large subunit are the 
peptidyl transferase center (PTC) where the amino-acid peptide bond is catalysed 
and the peptide exit tunnel where the growing polypeptide chain is released from the 
ribosome.  
 
 
 
Fig. 1: The ribosomal core functions. The small and the large ribosomal subunits are shown in blue 
and ochre, respectively. The mRNA is shown in green, the tRNA bound to the ribosome in yellow and 
the emerging nascent polypeptide in pink. Adapted from (Melnikov, Ben-Shem et al. 2012). 
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4.1 The eukaryotic ribosome 
Eukaryotic ribosomes are at least 40% larger than their prokaryotic counterpart 
because of additional ribosomal RNA (rRNA) elements and protein moieties (Spahn, 
Beckmann et al. 2001). The molecular weight of eukaryotic ribonucleoprotein-
particles is around 4 MDa, in prokaryotes the molecular weight of the ribosome is 
about 2.5 MDa. The human large 60S subunit (50S in bacteria) comprises three 
rRNA molecules (25S, 5.8S and 5S) and 47 proteins. The small 40S subunit (30S in 
bacteria) is build-up of one 18S rRNA molecule and 33 proteins. Of the 80 ribosomal 
proteins in eukaryotes, there are 32 without homologs in bacterial ribosomes. 
Ribosomal proteins, which show homologies with their prokaryotic counterparts, 
usually have large eukaryote-specific extensions (Lecompte, Ripp et al. 2002). High-
resolution ribosome crystal structures of lower eukaryotes (Saccharomyces 
cerevisiae, Tetrahymena thermophila) have been described (Ben-Shem, Garreau de 
Loubresse et al. 2011, Klinge, Voigts-Hoffmann et al. 2011, Weisser, Voigts-
Hoffmann et al. 2013), as have been high-resolution crystal structures of S. 
cerevisiae 80S ribosomes in complex with distinct translation inhibitors (Garreau de 
Loubresse, Prokhorova et al. 2014). Recently the structure of the human 80S 
ribosome has been determined using high-resolution cryo-electron-microscopy 
density maps (Anger, Armache et al. 2013). 
Although the eukaryotic and prokaryotic ribosomes differ in details of translational 
initiation, termination and regulation (Sonenberg and Hinnebusch 2009, Jackson, 
Hellen et al. 2010) the functional core of the ribosome is universally conserved (Fig. 
2) (Schmeing and Ramakrishnan 2009). Functionally conserved regions of the core 
are the peptidyl transferase center (PTC) and the A-site of the decoding region.  
However, variations in the ribosomal RNA sequences exist. These rRNA variations 
are crucial for specificity of ribosomal inhibitors against bacterial ribosomes as 
opposed to eukaryotic ribosomes. 
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4.2 Protein synthesis in eukaryotes 
In eukaryotes, translation is more complex compared to prokaryotes. Translation is 
initiated by the 43S pre-initiation complex (PIC) which is composed of the 40S 
subunit, the three initiation factors eIF1, eIF1A, eIF3 and a ternary complex (TC) 
consisting of initiator tRNA (tRNAi
Met) and initiation factor eIF2-GTP (Fig. 3) (Jackson, 
Hellen et al. 2010). The messenger RNA (mRNA) is delivered to the 43S PIC by the 
eIF4F complex consisting of eIF4A, eIF4E and eIF4G bound to the mRNA. The 
resulting 48S complex scans an mRNA starting from the 5’ end for the start codon. 
Hydrolysis of eIF2 bound GTP is triggered by eIF5, but inorganic phosphate is not 
released until the start codon is encountered and eIF1 is released (Algire, Maag et al. 
2005). It is still unknown at which stage eIF5 joins the initiation complex. When a 
start codon is encountered the initiation complex switches from an open to a closed 
state. After release of eIF2 and eIF5, the large subunit joins the complex under the 
participation of eIF5B (Singh, Lee et al. 2006). eIF1A and eIF5B dissociate from the 
complex after GTP is hydrolysed by eIF5B. As a result, the initiator tRNA is located in 
Fig. 2: Overview of bacterial and eukaryotic ribosomes. The common core is shown in light blue 
(RNA) and light red (protein). Both prokaryotes and eukaryotes have their specific set of additional 
proteins or extensions or insertions in conserved proteins (red) or extension moieties in rRNA (blue). 
In grey the predicted human 80S ribosome is shown. Dashed lines indicate the probable positions of 
the human-specific long rRNA expansion segments. Adapted from (Melnikov, Ben-Shem et al. 2012). 
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the P-site of the 80S complex and the A-site is vacant. At this stage the ribosome can 
enter the elongation cycle (Sonenberg and Hinnebusch 2009, Jackson, Hellen et al. 
2010, Hinnebusch 2011).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In bacteria, the initial aminoacyl-tRNA binding, codon recognition and GTPase 
activation has been investigated in detail. (Ogle, Brodersen et al. 2001, Schmeing, 
Voorhees et al. 2009, Jenner, Demeshkina et al. 2010, Voorhees, Schmeing et al. 
2010, Schmeing, Voorhees et al. 2011). In eukaryotes these functions are expected 
to be similar, because of the universally conserved core. The eukaryotic elongation 
cycle starts when a ternary complex consisting of aminoacyl-tRNA, eEF1A and GTP 
binds to the ribosomal A-site (Fig. 4). Correct codon-anticodon interaction triggers 
GTP hydrolysis by eEF1A resulting in accommodation of the aminoacyl-tRNA in the 
A-site and eEF1A and GDP are released from the ribosome. After accommodation, 
Fig. 3: Translation initiation in eukaryotes: (1)-(4) illustrates the formation of the 43S preinitiation 
complex (PIC) and scanning for the start codon. (5)-(6) shows the formation of the 80S initiation 
complex (IC), subsequently the 80S ribosome enters the elongation cycle. Adapted from (Voigts-
Hoffmann, Klinge et al. 2012). 
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the peptide bond is formed rapidly with the P-site peptidyl-tRNA by the help of the 
PTC, which positions the substrates appropriately for catalysis. Structures of the PTC 
of S. cerevisiae 80S ribosomes and bacterial ribosomes are almost superimposable, 
suggesting that the peptide bond formation mechanism is universally conserved 
(Ben-Shem, Garreau de Loubresse et al. 2011). Subsequently, the A-site tRNA 
harbours the nascent peptide chain and the A- and P-site tRNAs transit into the 
hybrid state, i.e. the acceptor ends of these tRNAs move to  
 
 
 
 
the P- and E-sites, respectively. Then the ribosome translocates the peptidyl-tRNA 
into the P-site and the deacetylated tRNA into the E-site. This step is catalysed by 
factor eEF2-GTP. After GTP hydrolysis elongation factor G reveals interaction with its 
domain IV and mRNA, P-site tRNA and A-site suggesting that the factor prevents 
backwards movement of the tRNAs (Gao, Selmer et al. 2009). In bacteria, domain IV 
of the elongation factor was shown to be critical for the catalysis of translocation: 
deletion or mutation in domain IV results in the absence of translocation activity of 
elongation factor G (Rodnina, Savelsbergh et al. 1997, Martemyanov and Gudkov 
Fig. 4: The eukaryotic translation elongation cycle. The large ribosomal subunit is shown in light 
grey, the small subunit in dark grey. Accommodation of the tRNA, peptide bond formation and 
translocation are shown. Green ball denotes GTP, red ball denotes GDP. Adapted from (Dever and 
Green 2012). 
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1999). The deacetylated E-site tRNA is released from the ribosome and a new 
ternary complex binds to the A-site (Uemura, Aitken et al. 2010). This cycle continues 
until the ribosome encounters a stop codon (i.e. UAA, UAG, UGA). The peptide 
synthesis ends when the A-site encounters a stop-codon (Fig. 5). The stop codon 
sequence is recognized by a ternary complex consisting of the release factors eRF1, 
eRF3 and GTP, which binds in a pre-accommodated fashion. Upon hydrolysis of 
GTP, eRF3 is released (Frolova, Le Goff et al. 1996). The ATPase ABCE1/Rli1 binds 
to the ribosome and supports accommodation of eRF1. The nascent polypeptide 
chain is released by peptidyl-tRNA hydrolysis mediated by eRF1 in a highly 
discriminative fashion (Salas-Marco and Bedwell 2005). After ATP hydrolysis the 
subunits dissociate and can be reused in the next round of translation initiation 
(Dever and Green 2012). 
 
 
4.3 Ribosomal accuracy 
Ribosomal accuracy is important because genes have evolved to encode for specific 
proteins with optimized function. The error frequency of ribosomal translation is 
estimated to be 1 in 103 to 104 (Edelmann and Gallant 1977, Bouadloun, Donner et 
al. 1983, Kramer and Farabaugh 2007). This level of accuracy is achieved by two 
consecutive selection steps (Fig. 6). The initial selection starts with codon-
independent tRNA selection, where the ternary complex interacts labile with the 
ribosome (rate constants k1 and k-1). The codon-independence is supported by the 
Fig. 5: Translation termination in eukaryotes. The large ribosomal subunit is shown in light grey, 
the small subunit in dark grey. Adapted from (Dever and Green 2012). 
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observation that cognate, near-cognate and non-cognate ternary complexes show 
the same rate of interaction with the ribosome. 
  
 
 
 
This process is rapid and readily reversible. This initial binding is fully dependent on 
the elongation factor of the ternary complex, suggesting an active mechanism for 
initial tRNA loading (Pape, Wintermeyer et al. 1998). The next step of tRNA selection 
is codon-dependent (Rodnina, Fricke et al. 1994). This step is observed for cognate 
and near-cognate tRNAs, but not for non-cognate ternary complexes (Pape, 
Wintermeyer et al. 1998). The rates of codon-recognition (k2) for cognate and near-
cognate tRNA complexes are similar; however, the dissociation rates (k-2) are 1000-
fold higher for near-cognate than for cognate tRNAs (Gromadski and Rodnina 2004). 
The difference in dissociation rates suggests an active involvement of the ribosome, 
by stabilizing correct cognate interactions. The difference in dissociation is larger 
than expected, in comparison to observed free energy of binding between cognate 
and near cognate tRNA codon-anticodon complexes in solution. The around 1000-
Fig. 6: The tRNA selection pathway. The stepwise process of tRNA selection is illustrated. The 
bacterial ribosome with its large subunit (magenta) and small subunit (cyan) is shown. Förster 
resonance energy transfer (FRET) values below the ribosome particles indicate distinct intermediate 
states of the ribosome. Green arrows indicate accelerated reaction rate for cognate tRNAs, whereas 
red arrows indicate accelerated reaction rates for near-cognate tRNAs. Adapted from (Zaher and 
Green 2009). 
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fold difference in free energy of binding for cognate and near-cognate tRNA species 
cannot be explained by the stability differences in the decoding helix (i.e. the 
interaction between mRNA codon and tRNA anticodon), rather the ribosome is 
actively involved in discrimination of cognate and near-cognate tRNAs. Binding of a 
cognate anticodon stem loop stabilizes a significant conformational change of the key 
decoding center nucleotides G530, A1492 and A1493 (Fig. 7). The two adenines 
move from an intrahelical position in helix 44 to an extrahelical position and G530 
flips from a syn- to an anti-conformation (Ogle, Brodersen et al. 2001). As a result, 
the minor groove of the decoding helix is monitored for correct codon/anti-codon 
interaction. The A1492/1493 movement, stabilized by the cognate codon/anti-codon 
interaction, results in a global structural change of the small subunit, i.e. a more 
closed state of the small ribosomal subunit by rotating its head and shoulder 
domains. In contrast, near cognate codon/anti-codon interactions do not induce this 
closed confirmation.  
 
 
 
 
 
The subsequent steps of tRNA selection involve the elongation factor and GTP 
hydrolysis and establish the irreversible step necessary for proofreading. First, a 
Fig. 7: Crystal structures of the bacterial A-site. (A) The vacant A-site is shown with the key 
decoding nucleotides A1492 and A1493 in intrahelical position of helix 44 and G530 in syn-
conformation. (B) A mRNA codon (shown in purple) and a cognate anticodon stem loop (ASL, shown in 
yellow) interact with the A-site. The adenines 1492 and 1493 change their conformation to extrahelical 
position and G530 moves into an anti-conformation. By this conformational change the minor groove of 
the decoding helix is monitored for correct codon anticodon interaction. The ribosomal protein S12 is 
shown in orange. Adapted from (Ogle, Brodersen et al. 2001). 
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structural change the elongation factor is observed (k3) which limits the rate of 
subsequent GTP hydrolysis (kGTP) (Rodnina, Fricke et al. 1995). The following steps 
include inorganic-phosphate release (kPi), elongation factor change to GDP-bound 
state (k4) and irreversible dissociation of the elongation factor from the aa-tRNA (k6) 
(Pape, Wintermeyer et al. 1998). After dissociation of the elongation factor the critical 
branch point termed proofreading of the tRNA selection pathway is reached. The A-
site associated tRNA either accommodates into the A-site (k5) of the large subunit 
and participates in peptidyl transfer (kpep), or is rejected from the ribosome (k7). 
Notably, GTPase activation (k3), and accommodation step (k5) strongly depend on 
the properties of the decoding helix, which is formed by pairing between the codon 
and the anticodon (Pape, Wintermeyer et al. 1999). 
4.4 Aminoglycosides and translation 
Aminoglycosides form a large family of poly-cationic, water soluble antibacterial 
agents (Kotra, Haddad et al. 2000). Most aminoglycosides occur naturally and are 
isolated from actinomycetes Streptomyces (“-mycin” suffix) or Micromonaspora (“-
micin” suffix) (Zembower, Noskin et al. 1998).  
Aminoglycosides share as a common feature the neamine core, which is composed 
of a glucopyranosyl (ring I) glycosidically linked to position 4 of the 2-
deoxystreptamine (2-DOS) (ring II) (Busscher, Rutjes et al. 2005).  Additional sugars 
are attached to the 5’ or 6’ position of the 2-DOS. Representatives of the 4,5-
disubstituted deoxystreptamines are paromomycin and neomycin (Fig. 8A). Members 
of the 4,6-disubstituted deoxystreptamines are geneticin, gentamicin C1a, kanamycin 
A, amikacin and tobramycin (Fig. 8C). Apramycin and hygromycin B have unique 
structures within the group of aminoglycosides. Apramycin has a bicyclic sugar 
moiety and a 4-monosubstituted 2-deoxystreptamine (Fig. 8B) (Matt, Ng et al. 2012). 
Hygromycin B has a dual ether linkage between its second and fourth rings, resulting 
in a third ring (Fig. 8D). The 2-deoxystreptamine ring I of hygromycin B is 5-
monosubstituted, resulting in unique functional properties (Borovinskaya, Shoji et al. 
2008).  
Aminoglycosides target the rRNA of helix 44 located in the A-site of the small 
ribosomal subunit. As a result, aminoglycosides affect protein synthesis by inducing 
mistranslation and inhibition of the mRNA-tRNA complex translocation from the A to 
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the P-site (Davies, Gorini et al. 1965, Noller 1991, Spahn and Prescott 1996). 
Aminoglycosides are effective against both gram-positive and gram-negative 
bacteria. Anaerobic bacteria are not susceptible to aminoglycosides due to the lack 
of an oxygen dependent electron transport system, which delivers energy for the 
uptake of the drug (Rasmussen, Bush et al. 1997). 
 
 Fig. 8: Chemical structures of aminoglycosides. (A) 4,5-disubstituted aminoglycosides, (B) 4,6-
aminoglycosides with corresponding substituents R1-R7 of ring I and III, note that amikacin has an 
additional (l)-α-hydroxy-γ-aminobutyric amide (L-HABA) chain at the C1 amino-group of ring II, (C) 
apramycin,  (D) hygromycin B. The 2-deoxystreptamine ring is shown in red. 
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4.5 Interactions of aminoglycosides with the bacterial ribosome 
The secondary structure of helix 44 of the 16S rRNA is shown in Fig. 10A. The 
bacterial A-site nucleotides are boxed in red. As a result of sequence variations in 
nucleotide positions 1408 and/or 1491 in helix 44, aminoglycosides have a higher 
affinity to bacterial than to eukaryotic ribosomes. The aminoglycoside drug binding 
 
pocket is stabilized by the G1405-C1496, C1407-G1494 and C1409-G1491 base pair 
interactions. As shown in Fig. 10A and B, ring I (shown in yellow) is located in the 
internal rRNA loop formed by A1408, A1492, A1493 and the C1409-G1491 base 
pair. In bacterial ribosomes, ring I forms a pseudo-base pair interaction by two direct 
hydrogen bonds with A1408. The oxygen of ring I accepts a hydrogen bond from the 
N6 of adenine and the amino or hydroxyl group donates a hydrogen bond to the N1 
of the adenine (Fig. 11) (Vicens and Westhof 2003, Francois, Russell et al. 2005). In 
eukaryotic cytoplasmic ribosomes the G1408 nucleotide cannot form a hydrogen 
bond with the 6’ amino group of ring I. In addition, the positive charge of the 6’ amino 
group is repulsed by the N1 and N2 amino groups of guanine. If a 6’ hydroxyl group 
of ring I is present, a hydrogen bond can be formed between the 6’OH and N1 or N2 
of guanine (Pfister, Hobbie et al. 2003). Ring I also forms a stacking interaction with 
nucleotide G1491 and additional hydrogen bonds with hydroxyl groups at position 
O3’ and O4’ of the phosphate groups of flipped out adenines A1492 and A1493, 
which further stabilizes the pseudo base pair interaction of ring I with A1408 (Fig. 11) 
(Vicens and Westhof 2001, Vicens and Westhof 2002).  
Fig. 9: Secondary Structure 
of the ribosomal A-site. The 
secondary structures of 
bacterial, mitochondrial and 
eukaryotic cytoplasmic helix 
44 are shown. The bacterial 
A-site nucleotides are boxed 
in red. 
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Fig. 10: Tertiary structures of the ribosomal A-site. (A) Tertiary structure of the bacterial A-site in 
complex with paromomycin. The ring I, III and IV are shown in yellow, the 2-DOS ring II in green, and 
the rRNA nucleotides are shown in grey. The two hydrogen bonds formed by ring I and A1408 are 
illustrated by red dashed lines. Adapted from (Vicens and Westhof 2001) (B) Tertiary structure of the 
bacterial A-site in complex with kanamycin A. The ring I and III are shown in yellow, the 2-DOS ring II 
in green, and the rRNA nucleotides are shown in grey. The two hydrogen bonds formed by ring I and 
A1408 are illustrated by red dashed lines. Adapted from (Francois, Russell et al. 2005). (C) Tertiary 
structure of the bacterial A-site in complex with apramycin. Helix 44 of 16S rRNA is shown in grey, 
apramycin in yellow, with the 2-DOS ring I highlighted in green. The two hydrogen bonds formed by 
A1408 and ring II are illustrated by red dashed lines. Adapted from (Matt, Ng et al. 2012). (D) Tertiary 
structure of the bacterial A-site in complex with hygromycin B. The helix 44 of 16S rRNA is shown in 
grey, hygromycin B in yellow, with the 2-DOS ring I highlighted in green. Adapted from 
(Borovinskaya, Shoji et al. 2008).  
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Ring II of the neamine core (shown in green) forms hydrogen bonds between its N1 
and O4 of U1495 and between its N3 and N7 of G1494. In addition, the N3 makes 
two hydrogen bonds with the phosphate groups of A1493 and G1494 (Vicens and 
Westhof 2001, Vicens and Westhof 2002, Vicens and Westhof 2003, Francois, 
Russell et al. 2005). The sugars attached to position 5’ or 6’ to the neamine core 
results in additional interactions with the nucleotides of the A-site. As shown in Fig. 
10A and B the orientation of the additional sugars differs significantly for 4,5- and 4,6-
aminoglycosides. Ring III and IV of the 4,6-aminoglycosides reaches up towards 
U1406, while ring III of the 4,5-aminoglycosides reaches down to U1406 (Vicens and 
Westhof 2001, Vicens and Westhof 2002). 
  
 
 
 
 
 
The tertiary structures of apramycin and hygromycin B in complex with the bacterial 
A-site are shown in Fig. 10C and D. The hydrogen-bonding pattern and position of 
the 2-DOS moiety (ring I) of apramycin is similar to that of the 2-DOS moiety (ring II) 
of 4,5- and 4,6-aminoglycosides. Hydrogen bonds are formed between the N3 of 
apramycin and N7 of G1494 and the N1 of apramycin and O4 of U1495. The bicyclic 
ring II of apramycin is located above and parallel to the guanine of the C1409-G1491 
Fig. 11: Detailed view of interaction between paromomycin ring I and A-site nucleotides. 
Hydrogen bonding of ring I (shown in yellow) with A1408 and A1493 indicated by red dashed lines. 
For clarity only hydrogen bond between 4’OH and O2P of A1493 is shown. Interaction of 3’OH and 
phosphate group of A1492 is not illustrated. Stacking interaction between G1491 and ring I is shown. 
Adapted from (Perez-Fernandez, Shcherbakov et al. 2014). 
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base pair. The ring II oxygen and the 6’ hydroxyl form hydrogen bonds to N6 and N1 
of A1408, resulting in a pseudo base pair interaction with A1408. The ring III of 
apramycin directs into the solvent, with close proximity of its O6 to the N3 of A1491 
and its 2-OH to the no bridging phosphate oxygen of A1493 (Matt, Ng et al. 2012).  
The binding site of hygromycin B in helix 44 is a few angstroms away from the 
binding site of the other aminoglycosides. Due to the rigidity of the molecule, 
hygromycin B does not fit in the 2-DOS drug binding pocket. Ring I forms a network 
of hydrogen bonds that spans the major groove of nucleotides C1404, G1405, U1406 
and G1494-C1496, to the phosphate of G1494. The ring II forms hydrogen bonds to 
C1403. The ring IV interacts with A1493 and the phosphate of U1495 by hydrogen 
bonds. Hygromycin B induces A1493 to flip out from helix44 and changes the 
conformation of A1492 (Borovinskaya, Shoji et al. 2008).  
4.6 Aminoglycosides and mistranslation 
The estimated error frequency of translation ranges from 10-3 to 10-4 per codon 
(Kramer and Farabaugh 2007). As a result of misreading, the amino acid carried by a 
near-cognate tRNA is incorporated into the growing polypeptide chain. Read-through 
is a special form of misreading: here, an amino acid is incorporated at a stop codon. 
Misreading and read-through can be enhanced by aminoglycosides in prokaryotes 
and eukaryotes. In the late 1970’s, aminoglycoside-induced mistranslation was first 
described in vivo in E. coli (Edelmann and Gallant 1977). In subsequent publications 
aminoglycoside-induced read-through was also shown in lower and higher 
eukaryotes, demonstrating that aminoglycosides can impair eukaryotic translational 
fidelity (Palmer and Wilhelm 1978, Wilhelm, Jessop et al. 1978, Palmer, Wilhelm et 
al. 1979, Abraham and Pihl 1983, Stansfield, Jones et al. 1998)  
Structural analyses revealed that upon binding of aminoglycosides the vacant A-site 
changes its conformation and both adenines 1492 and 1493 move from an 
intrahelical position to an extrahelical position. Normally, these two adenines monitor 
the cognate tRNA-mRNA complex by flipping out of the interior helix 44 into the 
minor groove of the codon-anticodon helix. By acting as a molecular ruler this 
mechanism is part of the tRNA selection pathway during translation. However, 
binding of aminoglycosides stabilizes the flipped-out position of the adenines similar 
to the conformation during correct codon-anticodon interaction. This conformational 
change makes it more likely for a near-cognate tRNA to accommodate in the A-site 
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leading to misincorporation of amino acids into the growing polypeptide chain (Ogle, 
Brodersen et al. 2001).  
Aminoglycoside-induced stop-codon read-through is caused by the flip-out of A1493 
sterically preventing the binding of the release factor (Laurberg, Asahara et al. 2008). 
Instead, a near-cognate tRNA can accommodate in the A-site and its amino acid can 
be incorporated into the growing polypeptide chain. As a result read-through leads to 
continuation of translation beyond the stop-codon. The suppressive effect of 
aminoglycosides on termination has been suggested to be useful for treatment of 
patients with genetic diseases caused by nonsense mutations (Finkel 2010, 
Nudelman, Glikin et al. 2010, Shulman, Belakhov et al. 2014). Here, a sense codon 
in the open reading frame is mutated into a premature stop codon resulting in 
synthesis of truncated and usually inactive proteins. For example, patients suffering 
from cystic fibrosis can carry a nonsense mutation in the cystic fibrosis 
transmembrane conductance regulator (CFTR) gene. A partial reconstitution of a 
functional CFTR in patients with a premature stop codon mutation after gentamicin 
treatment has been described (Wilschanski, Yahav et al. 2003).  
4.7 Cellular stress responses to misfolded proteins 
In higher eukaryotes there is no direct evidence that aminoglycosides induce 
misreading which would result in protein misfolding and cellular stress. In prokaryotes 
increasing the capacity of the folding machinery by chaperonine overexpression 
reduces the misfolded protein stress induced by aminoglycosides and improves the 
survival of cells (Goltermann, Good et al. 2013).  
Corresponding mechanisms to cope with unfolded proteins also exist in eukaryotic 
cells. Unfolded proteins response pathways in eukaryotic cells include the 
cytoplasmic unfolded protein response (cytUPR), the endoplasmatic reticulum (ER) 
unfolded protein response (erUPR) and the mitochondrial unfolded protein response 
(mitUPR) (Fig. 12). 
If chaperones, proteasome system and mitophagy fail to re-establish protein 
homeostasis during severe or persistent protein misfolding stress, cells will undergo 
apoptosis (Fig. 12). In particular, prolonged ER stress triggers CHOP-induced 
apoptosis (Matsumoto, Minami et al. 1996, McCullough, Martindale et al. 2001, 
Harding, Zhang et al. 2003, Ohoka, Yoshii et al. 2005).  
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4.8 The cytosolic unfolded protein response 
In the cytosol two distinct chaperone networks are described (Albanese, Yam et al. 
2006). The first cytosolic chaperone network interacts with nascent peptide chains 
and consists of a variety of chaperones and assistant factors, i.e. prefoldin (PFD), 
TCP-1 ring complex (TRiC), nascent-polypeptide-associated complex (NAC), heat 
shock proteins (Hsps) Hsp40 and Hsp70 (Hartl and Hayer-Hartl 2002). The majority 
of small peptides require no further folding assistance besides NAC activity to reach 
their native state, whereas some proteins need folding capacities of Hsp40 and 
Hsp70 chaperones to reach their native state. From these nascent proteins, some 
need to be transferred to Hsp90 for the final folding reaction (Fig. 13A). By another 
route of nascent peptide folding, prefoldin mediates the peptide-NAC-Hsp40-70 
complex to chaperonine TRiC in co-or posttranslational fashion (Fig. 13B, C) (Hartl 
and Hayer-Hartl 2002). If the folding process is stuck or the interaction with TRiC is 
prolonged, the peptide is degraded by the ubiquitin proteasome system (McClellan, 
Scott et al. 2005).  
Fig. 12: Overview of mechanisms defending against unfolded protein stress.  Misfolded proteins 
are substrate for the distinct unfolded protein responses. In case of severe or prolonged stress, 
dysfunctional mitochondria are eliminated to protect the cell. If the stress still persists cells undergo 
apoptosis or necrosis. Adapted from (Gregersen and Bross 2010). 
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The second cytosolic chaperone network is termed the cytosolic heat shock 
response or cytosolic UPR (cytUPR). Master regulator of the cytUPR is the heat-
shock factor 1 (HSF1). Under non-stressed conditions HSF1 is bound as an inactive 
monomer to Hsp40, Hsp70 or Hsp90 proteins (Zou, Guo et al. 1998, Morimoto 2008). 
Upon accumulation of misfolded proteins Hsps are recruited to denaturated proteins 
and HSF1 is released (Fig. 14). The HSF1 monomers translocate into the nucleus, 
undergo a conformational change, form trimers, become phosphorylated and bind to 
heat-shock promotor elements (HSE) of various genes, including chaperones . When 
Hsp70 accumulates it interacts with HSF1 and inhibits the binding of HSF1 to the 
HSE promotor elements. This negative feedback from the Hsp70 expression levels, 
controls the transcriptional activity of HSF1 (Morimoto 2008). 
 
Fig. 13: Overview of chaperones associated with nascent peptide chains. The ribosome is 
shown in yellow, the nascent peptide chain in magenta; N, native protein. (A) Nascent peptide chains 
generally interact with the nascent-polypeptide-associated complex (NAC) and the majority folds 
without further assistance. About 15-20 % of proteins fold need help of Hsp70 and Hsp40 proteins 
and some need further assistance by Hsp90. Around 10% of peptides are posttranslationally (B) or 
cotranslationally (C) passed to chaperonine TCP-1 ring complex (TRiC) mediated by prefoldin (PFD). 
Adapted from (Hartl and Hayer-Hartl 2002). 
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4.9 The unfolded protein response (UPR) in the ER 
Folding in the ER is accomplished by a specialized set of chaperones, including BiP 
(GRP78) and GRP94, lectin chaperones like calnexin and calreticulin and protein 
disulfide isomerases (PDIs) (Malhotra and Kaufman 2007). The erUPR is regulated 
by three different pathways. Each pathway has a distinct sensor for misfolded 
proteins in the ER lumen. The three sensors are the membrane spanning proteins 
activating transcription factor 6 (ATF6), protein kinase RNA (PKR)-like ER kinase 
(PERK) and inositol-requiring enzyme 1 (IRE1), which are kept inactive in complex 
with BiP (Fig. 15) (Shi, Vattem et al. 1998, Tirasophon, Welihinda et al. 1998, 
Yoshida, Okada et al. 2000). Accumulation of misfolded proteins in the ER releases 
BiP from the transmembrane proteins and leads to the activation of the signaling 
cascade.  
i) ATF6 translocates into the Golgi apparatus where S1P and S2P proteases cleave 
and activate ATF6, which is then trafficked to the nucleus and activates 
cytoprotective genes.  
ii) PERK dimerizes, subsequently autophosphorylates and phosphorylates eukaryotic 
initiation factor 2 alpha (eIF2α), which leads to a general inhibition of translation.  
 
Fig. 14: The cytosolic heat shock response. HSF transcription factors are bound to Hsp 
proteins in the cytoplasm (here only Hsp70 and HSF1 are indicated). Upon accumulation of 
unfolded proteins Hsps preferentially interact with denatured proteins and HSF1 is released. 
HSF1 translocates into the nucleus, trimerizes and activates genes containing HSF1 binding 
sites or heat shock elements (HSE). Adapted from (Haynes and Ron 2010). 
Adapted from (Haynes and Ron 2010). 
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By decreasing the translation rate, the burden of newly synthesized polypeptides is 
reduced, enabling folding and degradation mechanisms to eliminate the misfolded 
proteins. At the same time p-eIF2α activates the translation of Atf4 mRNA. ATF4 is a 
transcription factor that activates cytoprotective genes upon mild stress, but also can 
induce proapoptotic factors like C/EBP homology protein (CHOP) during permanent 
or severe ER stress.  
iii) IRE1 dimerizes and forms an active endonuclease which removes a 26-nucleotide 
intron from the X-box binding protein 1 (XBP1) mRNA. Translation of spliced XBP1 
mRNA results in a transcription factor, which activates transcription of cytoprotective 
genes (Schroder and Kaufman 2005, Hetz 2012). An additional mechanism to reduce 
the protein load in the ER during prolonged stress is the regulated IRE1-dependent 
decay (RIDD) of ER-bound mRNA (Hollien and Weissman 2006). As shown in Fig. 
15C ribosomes connected with the ER membrane (rough ER) hold mRNA which is 
selectively degraded by RIDD to decrease the synthesis of new ER associated 
proteins. 
Fig. 15: Overview of the erUPR pathways. Unfolded proteins are sensed by BiP in the ER lumen 
and the three distinct UPR pathways are activated: (A) ATF6, (B) PERK, (C) IRE1. Upon mild ER 
stress cytoprotective genes are induced whereas severe or persisting ER stress leads to an apoptotic 
response, e.g. upregulation of CHOP. Adapted from (Walter and Ron 2011). 
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4.10 The unfolded protein response in mitochondria 
Mitochondria are composed of around 1000 different nuclear encoded proteins, 
which are synthesized by the cytosolic ribosome. In addition, 13 proteins are 
encoded by the mitochondrial DNA (mtDNA) and are translated by the mitochondrial 
ribosome. The mitochondrial proteins of cytosolic origin are kept in an unfolded state 
and shielded during synthesis by cytosolic chaperones. This nascent polypeptide 
chaperone complex is trafficked to the outer membrane of the organelle, where they 
interact with receptors and the peptides become imported. Depending on the import 
signal the proteins are placed into the outer membrane, the inner membrane (IM), the 
intermembrane space or the matrix of the mitochondria (Dudek, Rehling et al. 2013). 
Small proteins may fold to their functional conformation without further assistance, 
larger proteins are target for the mitochondrial chaperonines Hsp60 and Hsp10 
(Ostermann, Horwich et al. 1989, Dubaquie, Looser et al. 1997).  
 
 
 
Folding of cytosolic synthesized proteins destined for the mitochondrial matrix and IM 
is supported by mtHsp70. Proteins which cannot be properly folded are substrate for 
proteases, i.e. LON in the matrix and AAA-proteases of the IM (Ngo and Davies 
2007, Tatsuta and Langer 2008). The detailed signaling pathway of the mtUPR is 
currently not known. It has been suggested that c-Jun N-terminal kinase 2 (JNK2) 
becomes phosphorylated by an unknown stress signal. Activated JNK2 and 
transcription factor Jun induce transcription of CHOP and C/EBPβ, by binding to their 
AP1 promotor element (Horibe and Hoogenraad 2007). In turn, CHOP and C/EBPβ 
activate mitochondrial chaperones like Hsp60 and Hsp10 and proteases. In addition 
Fig. 16: The mitochondrial organelle. The structural components of the mitochondria are indicated. 
The organelle consists of one outer and one inner membrane, which enclose the intermembrane space. 
The inner membrane is compartmentalized into cristae to expand its surface and encompasses the 
mitochondrial matrix. Adapted from (Blanco, Rego et al. 2011).  
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to the CHOP binding site there exist two other conserved promotor sequences, 
named mitochondrial UPR elements (MURE) (Fig. 17) (Aldridge, Horibe et al. 2007). 
Transcription factors interacting with the MURE are currently unknown and the 
presence of additional signaling pathways is likely. 
 
 
 
 
4.11 Formation of ROS 
In eukaryotes, oxidative phosphorylation is the main metabolic energy pathway. This 
pathway uses five multisubunit complexes of the mitochondrial respiratory chain to 
produce ATP (Fig. 18). Here, electrons are donated from NADH to complex I or from 
FADH2 to complex II and are carried by coenzyme Q to complex III. Complex III 
passes the electrons to cytochrome C which finally transfers them to complex IV 
where hydrogen (H+) ions and oxygen form water (H2O). During the movement of the 
electrons through the complexes I, III and IV, H+ ions are pumped across the inner 
membrane from the mitochondrial matrix into the intermembrane space. The 
resulting electrochemical gradient is used by complex V (ATP-synthase) to generate 
ATP from ADP and inorganic phosphate (West, Shadel et al. 2011). As a result of a 
leaky electron transport, electrons can be transferred to molecular oxygen, 
generating superoxide (O2.-). Under normal physiological conditions 1-2% of the 
consumed oxygen is transformed into O2.- (Orrenius, Gogvadze et al. 2007). The 
electron leakage occurs at complexes I, II and III (Orrenius, Gogvadze et al. 2007, 
Fig. 17: Activation of the mitUPR: Upon an unknown stress signal the kinase JNK2 and 
transcription factor Jun activate CHOP and C/EBPβ, which in turn activate the mitochondrial 
chaperones and proteases. Besides CHOP, an unknown signaling pathway is proposed because of 
conserved regions MURE1 and 2. Adapted from (Haynes and Ron 2010). 
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Koopman, Nijtmans et al. 2010). At all three sites superoxide is released into the 
matrix, whereas complex III also can release it into the intermembrane space 
(Murphy 2009).  
 
 
 
 
 
By a voltage-dependant anion selective channel (VDAC) superoxide can cross the 
outer membrane. Highly toxic superoxide can be converted by the matrix resident 
superoxide dismutase 2 (SOD2) or by the intermembrane space/cytoplasm located 
SOD1 to hydrogen peroxide (H2O2) (Han, Antunes et al. 2003). H2O2 can freely cross 
membranes and gets further converted and detoxified by antioxidant enzymes like 
catalase. Under certain stress conditions leakiness of the respiratory chain increases 
and mitochondrial superoxide production is aggravated. Mitochondrial oxidative 
stress occurs as a result of an imbalance between ROS production and ROS 
elimination if the antioxidant defence is overwhelmed or downregulated. 
Mitochondrial enzyme deficiencies and misfolded proteins may contribute to oxidative 
Fig. 18: Overview of the mitochondrial respiratory chain. Superoxide is formed by electron 
leakage from complexes I-III and can be aggravated under certain stress conditions. Antioxidant 
enzymes located in the mitochondrial matrix, intermembrane space and cytoplasm counteract against 
oxidative stress. Figure from (West, Shadel et al. 2011). 
 
Introduction  23 
  
 
stress due to loss of enzyme function and accumulation of toxic metabolites (Tonin, 
Ferreira et al. 2010, Schmidt, Corydon et al. 2011, Tonin, Amaral et al. 2013).  
Cytosolic misfolded proteins can also induce mitochondrial ROS. Misfolded proteins 
may form fibril-like aggregates, which permeabilize membranes of intracellular 
compartments like the ER (Varadarajan, Yatin et al. 2000). The ER possesses Ca2+ 
at a concentration 100-fold higher than the cytoplasm. Release of ER-stored Ca2+ 
ions results in activation of mitochondrial metabolic processes and subsequently 
increases production of ROS (Zhang 2010).  
Mitochondrial ROS formation can also be induced by impairment of the proteasome. 
Misfolded proteins may affect proteasome function. In neurodegenerative diseases 
like the prion, Alzheimer or Parkinson disease, accumulation of misfolded proteins is 
accompanied by increased levels of ubiquitin conjugates and decreased function of 
the proteasome (Rubinsztein 2006). The β-sheet-rich isoform of the cellular prion 
protein has been shown to directly impair the function of the proteasome (Deriziotis, 
Andre et al. 2011). Impairment of the proteasome in turn results in accumulation of 
polyubiquitinated proteins in the mitochondrial outer membrane, loss of mitochondrial 
membrane potential and increased generation of mitochondrial derived superoxide 
(Maharjan, Oku et al. 2014).  
In the ER, ROS can be generated in presence of misfolded proteins by a process 
called oxidative protein folding. The ER has an oxidative milieu with distinct 
oxidoreductases like protein disulfide isomerases (PDIs). Together with ER 
oxidoreductin 1 (Ero1) PDIs form the mayor stress-induced oxidative folding 
pathway. These enzymes can create, disrupt and redistribute disulfide bonds. Ero1 
catalyzes the generation of disulfide bonds by transferring electrons from dithiols to 
molecular oxygen. As a result, the activity of Ero1 produces one molecule H2O2 per 
de novo generated disulfide bond (Gross, Sevier et al. 2006). In the presence of an 
overload of misfolded proteins, hyperactivity of this enzyme results in elevated H2O2 
production which contributes to the total ROS amount in a cell (Pagani, Fabbri et al. 
2000, Araki, Iemura et al. 2013). 
4.12 Aminoglycosides, ROS, and ototoxicity 
Aminoglycosides have a higher affinity for bacterial ribosomes as compared to the 
cytoplasmic and mitochondrial ribosomes of eukaryotes. This is a result of the 
Introduction  24 
  
 
phylogenetic sequence variability in positions 1408 and/or 1491 of the highly 
conserved helix 44 of the ribosomal A-site, the drug-binding pocket. However, 
aminoglycoside treatment is associated with severe side effects like ototoxicity 
(Keene and Hawke 1981).  
Aminoglycoside-induced ototoxicity is irreversible and manifests in the cochlea and 
by aminoglycoside-induced hair cell loss (Ruedi, Furrer et al. 1952, Forge and 
Schacht 2000). Hair cells are the primary targets of aminoglycosides (Lautermann, 
Dehne et al. 2004, Schacht, Talaska et al. 2012). The exact mechanism of hair cell 
degradation is still unclear, but the formation of reactive oxygen species (ROS) 
presumably is an important factor. Addition of a ROS scavenger was able to protect 
hair cells from cell death after aminoglycoside treatment and overexpression of the 
superoxide dismutase rescued mice from kanamycin induced ototoxicity (Sha, Zajic 
et al. 2001). Since mitochondria are a major source of ROS (Brown and Borutaite 
2012), aminoglycoside-induced ototoxicity is most likely mediated by these 
organelles. However, the exact mechanism of aminoglycoside-induced ROS 
formation is still speculative. Gentamicin may induce oxidative stress due to its 
chemical properties by forming a redox-active iron chelate (Sha and Schacht 1999).  
Anecdotal evidence indicates that aminoglycosides induce mistranslation in 
eukaryotes in vitro and in vivo (Buchanan, Stevens et al. 1987). From an evolutionary 
point of view, the mitochondrial ribosome is more related to bacterial ribosomes than 
to the eukaryotic cytoplasmic ribosome. Structural similarity of the A-sites of the 
bacterial and the mitochondrial rRNAs allows aminoglycosides to bind to 
mitochondrial ribosomes inhibiting their translation (Hobbie, Akshay et al. 2008). The 
susceptibility of mitochondrial ribosomes to aminoglycosides correlates with their 
relative cochleotoxicity (Hobbie, Akshay et al. 2008). In addition, sequence 
alterations of the mitochondrial small ribosomal RNA, namely A1555G and C1494T, 
result in hyper-susceptibility to aminoglycosides and may lead to ototoxicity (Prezant, 
Agapian et al. 1993, Zhao, Li et al. 2004). Altogether these findings suggest that the 
mitochondrial ribosome is a key target for aminoglycosides.   
Results  25 
  
 
5 Results 
5.1 Dual luciferase read-through reporters  
Dual luciferase constructs were used to investigate the efficacy of aminoglycosides to 
inhibit translation and to induce read-through of stop-codons. In these assays, N-
terminal humanized renilla luciferase (hRluc) and C-terminal humanized firefly 
luciferase (hFluc) genes were fused together by a peptide linker (STCDQPFGF) 
using the PCR based overlap extension method. Two different reporter constructs 
were created for read-through assessment. The first construct was used for in vitro 
assays (Fig. 19A). Here, the peptide linker is used as a recoding site by mutating the 
CAA codon (encoding for glutamine) into a nonsense TGA stop codon (Salas-Marco 
and Bedwell 2005). The dual luciferase construct was cloned into a pT7 vector, 
where gene expression is driven by a T7 promotor, allowing in vitro transcription by 
the T7 polymerase. The resulting reporter mRNA was used for in vitro rabbit 
reticulocyte lysate (RRL) translation assays. The luminescence of hFluc is a direct 
measure of read-through events and the signal of hRluc permits for normalization to 
translation efficiency. 
 
 
Fig. 19: Read-through reporter constructs. (A) in vitro read-through reporter construct used for RRL 
translation assays. (B) in vivo read-though reporter used in HEK cells. The nonsense stop codons are 
indicated in red. 
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The second read-through reporter construct shown in Fig. 19B was used for in vivo 
experiments. The dual luciferase construct was cloned into a pRM vector, where 
gene expression is driven by a cytomegalovirus (CMV) promotor. The SV40 late 
poly(A) signal is attached to the reporter gene, ensuring proper mRNA processing in 
eukaryotic cells. The nonsense stop codon mutation D357XTGA is located at the 3’ 
end of the hFluc gene. This codon position was chosen because structural analysis 
revealed that amino acid 357 is located in an unstructured and little conserved loop 
of hFluc providing high probability that any amino acid incorporated in this position 
will result in a functional protein.  
To validate the read-through assay, autoradiography using S35-labeled methionine 
was used to analyze the proteins translated in an in vitro RRL translation assay. 
Without drug treatment the N-terminal hRluc protein of the read-through reporter was 
exclusively translated. As shown in Fig. 20A, the hRluc-TGA-hFluc construct showed 
in the absence of paromomycin a pattern identical to the single hRluc reporter. 
Exposure to paromomycin, an efficient read-through inducer, resulted in increased 
synthesis of the hRluc-hFluc fusion protein. Drug titration demonstrated an increase 
in translation of a protein, which runs at the same position as the control hRluc-hFluc 
fusion protein without nonsense stop codon. This pattern indicated that the TGA stop 
codon of the linker was suppressed by paromomycin and a full-size fusion product 
was synthesized. No single hFluc bands were detected in the read-through reporter 
samples, revealing that hFluc was exclusively synthesized when a read-through 
event occurred. Densitometric analysis of the protein bands corresponding to the 
hRluc-hFluc fusion protein and hRluc demonstrated read-through induction (Fig. 20B) 
and translation inhibition (Fig. 20C) in a dose dependent manner. Beyond 20 µM 
paromomycin, the effect of translation inhibition exceeded the read-through effect 
and the intensities of the hRluc-hFluc fusion protein bands decreased. 
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Fig. 20: Autoradiography of read-through reporter construct. (A) Autoradiography of RRL in vitro 
translation assay using S
35
-labeled methionine. Paromomycin (Par) was used as bona fide inducer of 
read-through, the Par concentrations are indicated. The black arrow marks the position of the hRluc-
hFluc fusion protein. Single hRluc, single hFluc and fusion hRluc-hFluc mRNAs were used as controls. 
The asterisk indicates the position of single hRluc protein, the double asterisk the position of single 
hFluc protein. (B) Densitometric analysis of the protein bands corresponding to the hRluc-hFluc 
protein, indicated by the black arrow in Fig. 20A. (C) Densitometric analysis of the protein bands 
corresponding to the single hRluc protein, indicated by the asterisk in Fig. 20A.  
 
5.1.1 Aminoglycoside-induced read-through in vitro 
Various aminoglycosides were tested in the in vitro RRL translation assay to 
determine their read-through activity. Geneticin, gentamicin and paromomycin were 
chosen as highly effective inducers of mistranslation (Buchanan, Stevens et al. 1987, 
Clancy, Bebok et al. 2001) and compared to tobramycin, neomycin, kanamycin A and 
its derivative amikacin. Apramycin, a structurally unique aminoglycoside was also 
included (O'Connor, Lam et al. 1976). As a control we used the translocation inhibitor 
hygromycin B (Manuvakhova, Keeling et al. 2000). 
Among the aminoglycosides tested, hygromycin B and geneticin are the strongest 
translation inhibitors (IC50: 0.04 µM and 0.43 µM, respectively) (See Table 1 and Fig. 
21A). Apramycin, kanamycin A and amikacin showed modest translation inhibition 
with IC50 values of 93.5, 147.8 and 207.3 µM (Fig. 21A, B). Stop codon read-through 
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was 4 to 5-fold increased by geneticin, paromomycin and gentamicin compared to 
non-induced levels (Fig. 22A). Amikacin and neomycin showed minor effects on 
read-through (Fig. 22A,B), while apramycin, kanamycin A and hygromycin B had 
virtually no effect on read-through of stop codons (Fig. 22A, B). Relative read-through 
levels, i.e. the ratio of read-through induction and translation efficiency, revealed that 
geneticin, gentamicin and paromomycin effectively induced read-through. In contrast, 
apramycin, hygromycin B and kanamycin A do not induce any read-through (Fig. 
23A, B). 
 
Fig. 21: Dual luciferase in vitro translation assay using RRL. Drug-induced translation inhibition 
measured by hRluc luminescence. (A) Apramycin (Apr), geneticin (Gen), gentamicin (Gm), neomycin 
(Neo), paromomycin (Par) and hygromycin B (Hyg). (B) Amikacin (Amik), kanamycin A (KanA) and 
tobramycin (Tobr), Gen and Gm are included for comparison (n=3, ±SEM). 
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Table 1: Inhibition of protein synthesis. In vitro-IC50 values of aminoglycoside antibiotics measured 
by in vitro dual luciferase assay using RRL ribosomes. 
Antibiotic IC50 values [µM] 
Hyg 0.04 
Gen 0.43 
Gm 12.6 
Par 12.9 
Neo 51.2 
Tobr 88.9 
Apr 93.5 
Amik 147.8 
KanA 207.3 
 
 
 Fig. 22: Dual luciferase in vitro translation assay using RRL. Drug-induced read-through measured 
by hFluc luminescence. (A) Apramycin (Apr), geneticin (Gen), gentamicin (Gm), neomycin (Neo), 
paromomycin (Par) and hygromycin B (Hyg). (B) Amikacin (Amik), kanamycin A (KanA) and tobramycin 
(Tobr), Gen and Gm are included for comparison (n=3, ±SEM). 
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5.1.2 Aminoglycoside-induced read-through in vivo 
The efficacy of aminoglycosides to induce read-through was studied in vivo. The dual 
luciferase reporter construct was cloned into the pRM vector, which is under the 
control of the CMV promotor. As host cell the HEK293 cell line was chosen. HEK 
cells are derived from human embryonic kidney cells, but do not have the megalin-
mediated aminoglycoside endocytosis system in contrast to nephritic tubular cells. 
HEK cells rather show characteristics of neuronal than of endothelial, epithelial or 
fibroblast cells (Shaw, Morse et al. 2002). However, for our purposes it was important 
that HEK cells are easy to transfect and show a high translation rate (Geisse and 
Voedisch 2012), facilitating the use of reporter constructs to study drug-induced 
mistranslation. Following transfection with the pRM hRluc-hFluc D357XTGA reporter 
Fig. 23: In vitro read-through relative to translation efficiency. Relative read-through induction 
has been calculated by the ratio of hFluc/hRluc (n = 3, +SEM). The untreated samples were set as 1. 
(A) Apramycin (Apr), geneticin (Gen), gentamicin (Gm), neomycin (Neo), paromomycin (Par), 
hygromycin B (Hyg). (B) Amikacin (Amik), kanamycin A (KanA) and tobramycin (Tobr), Gen and Gm 
are included for comparison. 
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construct, the HEK293 cells were incubated in F10 media supplemented with 
saponin and serially diluted antibiotics. After 24 hours cells were lysed and luciferase 
activities were monitored.  
In HEK293 cells hygromycin B was the most potent translation inhibitor (IC50 = 2.6 
µM), followed by geneticin (IC50 = 9.0 µM) (See Table 2 and Fig. 24A). Paromomycin 
and gentamicin also inhibited translation but at a 30-fold higher concentration (IC50 = 
376 and 337 µM, respectively). Apramycin, tobramycin, kanamycin A and neomycin 
had IC50 values higher than 450 µM (Fig. 24A, B).  
 
Table 2: Inhibition of protein synthesis. In vivo-IC50 values of aminoglycoside antibiotics measured 
by in vivo dual luciferase assay in HEK293 cells. 
Antibiotic IC50 values [µM] 
Hyg 2.6 
Gen 9.0 
Gm 337 
Par 376 
Apr 486 
Amik > 500 
KanA > 500 
Neo > 500 
Tob > 500 
 
In agreement with the in vitro hFluc data, geneticin, gentamicin and paromomycin 
induced read-through (Fig. 25A), while amikacin and hygromycin B showed little 
effect on read-through (Fig. 25A. B). Apramycin had no impact on read-through in 
this assay (Fig. 25A).  
Calculation of the relative read-through induction confirmed that geneticin, 
gentamicin and paromomycin are strong inducers of read-through. (Fig. 26A, B). 
Comparison of the IC50 values determined by the in vivo and in vitro assays 
demonstrated a good correlation with a squared Pearson product-moment correlation 
coefficient R2 = 0.8749 (Fig. 27). The results demonstrate that the in vitro assays 
adequately reflect that of the whole cell in-vivo.  
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Fig. 24: Dual luciferase in vivo translation assay using HEK293 cells. Drug-induced translation 
inhibition measured by hRluc luminescence. (A) Apramycin (Apr), geneticin (Gen), gentamicin (Gm), 
neomycin (Neo), paromomycin (Par) and hygromycin B (Hyg). (B) Amikacin (Amik), kanamycin A 
(KanA) and tobramycin (Tobr), Gen and Gm are included for comparison (n=3, ±SEM). 
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Fig. 25: Dual luciferase in vivo translation assay using HEK293 cells. Drug-induced read-
through measured by hFluc luminescence. (A) Apramycin (Apr), geneticin (Gen), gentamicin (Gm), 
neomycin (Neo), paromomycin (Par) and hygromycin B (Hyg). (B) Amikacin (Amik), kanamycin A 
(KanA) and tobramycin (Tobr), Gen and Gm are included for comparison (n=3, ±SEM). 
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Fig. 27: Comparison of in vivo and in vitro IC50 values. Correlation of IC50 values determined in 
vitro and in vivo from the tested aminoglycosides. Squared Pearson product-moment correlation 
coefficient R
2
 and the slope (m) of the regression line are indicated. 
Fig. 26: In vivo read-through relative to translation efficiency. Relative read-through induction has 
been calculated by hFluc/hRluc (n = 3, +SEM). The untreated samples were set as 1. For simplicity, 
the drug concentrations 200, 400, 800, 1200 and 1600 µM are plotted beyond 100 µM. (A) apramycin 
(Apr), geneticin (Gen), gentamicin (Gm), neomycin (Neo), paromomycin (Par). (B) amikacin (Amik), 
kanamycin A (KanA) and tobramycin (Tobr), Gen and Gm are included for comparison. 
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5.2 Aminoglycosides and ROS formation 
Aminoglycosides were tested for their efficiency to induce reactive oxygen species 
(ROS), since increased ROS production is a hallmark of aminoglycoside-induced 
ototoxicity (Forge and Schacht 2000). For this purpose we used the MitoSOX dye 
which detects specifically mitochondrial superoxide. As a positive control, 20 µg/ml 
Antimycin A were used, which inhibit mitochondrial complex III and induce formation 
of superoxide (Ksenzenko, Konstantinov et al. 1983). HEK293 cells were incubated 
for 24 h and 48 h in F10 medium supplemented with saponin and serially diluted 
geneticin. HEK293 APH(3’) cells served as a control. Geneticin can be modified by 
the 3’ aminoglycoside-phosphotransferase APH(3’). As a result, geneticin loses its 
affinity towards the ribosome, which allows to test for ribosomal involvement of 
geneticin-induced ROS. Geneticin-treated cells incubated for 24 h showed minor 
elevated superoxide levels compared to the untreated control (Fig. 28A). Further 
incubation up to 48 h demonstrated in the HEK293 wt cell line an induction of 
MitoSOX fluorescence in a dose dependent manner (Fig. 28B). In contrast, the 
HEK293 APH(3’) cells showed no induction of MitoSOX fluorescence, demonstrating 
that the action of geneticin on the ribosome is responsible for oxidative stress 
induction. 
 
 
 
To test for the specificity of mitochondrial superoxide detection by MitoSOX, 
osteosarcoma 143B wt and derived rho-0 cells were treated with geneticin. Rho-0 
Fig. 28: Superoxide anion detection using MitoSOX dye. Cells were incubated for 24 h (A) or 48 
h (B) with indicated geneticin concentrations and stained with MitoSOX. Fluorescence was 
measured by FACS, 10000 cells were gated. Antimycin A was used as a positive control. 
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cells lack their mitochondrial DNA and as a result have no functional mitochondrial 
respiratory chain (King and Attardi 1989), which is the main source of mitochondrial 
ROS. Cells were incubated in DMEM, because F10 and saponin treatment was 
harmful for the osteosarcoma cells (data not shown). As a consequence higher 
geneticin concentrations were used. Antimycin A was used as a positive control. The 
143B wild type cells showed an increase of MitoSOX fluorescence upon geneticin 
treatment in a dose dependent manner (Fig. 29). In contrast, the rho-0 cells did not 
show any induction of MitoSOX fluorescence in the geneticin and the Antimycin A 
treated sample, indicating that a functional respiratory chain is essential to increase 
superoxide levels upon geneticin or Antimycin A treatment. 
 
 
 
In subsequent experiments, additional aminoglycosides were studied. Geneticin, 
hygromycin B, gentamicin and neomycin were tested. Hygromycin B was included to 
examine the influence of translocation inhibition on ROS generation. HEK293 cells 
were incubated for 48 h in F10 media supplemented with saponin. In addition to 
superoxide anions, total ROS levels were measured using the CM-H2DCFDA dye. 
Mitochondria specific- and total ROS measurements revealed that hygromycin B 
induces the most intense oxidative stress at low drug concentrations. Geneticin is 
also a potent inducer of ROS, but 4-fold higher drug concentrations were needed to 
achieve similar ROS levels compared to hygromycin B treated cells. Gentamicin 
induced similar ROS levels at a 10-fold higher concentration compared to geneticin. 
Neomycin induced modest oxidative stress (Fig. 30A, B). In general, the ability to  
Fig. 29: Superoxide anion detection in osteosarcoma 143B cells. 143B wt and rho-0 cells were 
incubated for 48 h with indicated geneticin concentrations and stained with MitoSOX. Fluorescence 
was assessed by FACS, 10000 cells were gated. Antimycin A was used as a positive control. 
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Fig. 30: Drug-induced mitochondrial superoxide and total ROS. HEK cells were incubated for 48 h 
with indicated drug concentrations. The induction of MitoSOX fluorescence (A) and the induction of 
CM-H2DCFDA fluorescence (B) are shown. Antimycin A was used as a positive control. IC50 values 
are indicated by the red arrowheads (N > 3, except Gm MitoSOX, SEM is indicated). 
 
Fig. 31:  Correlation of MitoSOX and CM-H2DCFDA fluorescence induction and translation 
inhibition. Fold inductions of MitoSOX (A) and CM-H2DCFDA (B) fluorescence were plotted against 
the corresponding drug concentration expressed by the ratio of tested drug concentration divided by the 
corresponding IC50 value. Squared Pearson product-moment correlation coefficient R
2
 and the 
regression line are indicated. 
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induce oxidative stress correlates well with the IC50 values (Fig. 31), with hygromycin 
B as most potent ribosome inhibitor and ROS inducer, followed by geneticin, 
gentamicin and neomycin. Hygromycin B is a translocation inhibitor which interacts 
with both cytoplasmic and mitochondrial ribosomes (Gale 1981). To test for the 
involvement of either cytosolic or mitochondrial translation in ROS generation, the 
cytoplasmic translation inhibitor cycloheximide (Schneider-Poetsch, Ju et al. 2010) 
and the mitochondrial translation inhibitor linezolid were used. The IC50 concentration 
of CHX for cytosolic translation (IC50 = 1.2 µM) was determined using the dual 
luciferase assay. The IC50 concentration of linezolid for mitochondrial translation (IC50 
≈ 9 µg/ml) was assessed using a whole cell assay and autoradiography to determine 
S35 Methionine incorporation by the mitochondrial ribosome. Cycloheximide treatment 
induced significant MitoSOX and CM-H2DCFDA fluorescence at a drug concentration 
< 50 µM. In contrast, linezolid did not show induction of oxidative stress at the 
maximum drug concentration (Fig. 32A, B).  
 
 
 
 
The data suggest that formation of ROS occurs as a result of translation inhibition of 
the cytoplasmic, but not of the mitochondrial ribosome. Simultaneous induction of 
fluorescence of CM-H2DCFDA and MitoSOX dyes indicates that the main source of 
ROS is of mitochondrial origin (Fig. 33). ROS formation is dependent on time of 
incubation (Fig. 28) and a functional respiratory chain (Fig. 29), suggesting that the 
mitochondrial organelle is sensitive to cytoplasmic translation inhibition. 
Fig. 32: Drug-induced mitochondrial superoxide and total ROS. HEK293 cells were incubated for 
48 h with indicated drug concentrations. (A) MitoSOX fluorescence and (B) CM-H2DCFDA 
fluorescence are shown for cycloheximide (CHX) and linezolid (Lin). Antimycin A was used as a 
positive control. The corresponding IC50 values are indicated by the red arrowheads (N > 3, SEM is 
indicated).  
 
 
Results  39 
  
 
 
 
 
 
5.3 Alterations of the proteome after aminoglycoside treatment 
By an unbiased mass spectrometry (MS) approach we wanted to study the effects of 
translocation inhibition and misreading on the proteome in higher eukaryotes. As 
shown in chapter 3.1, mistranslation is always accompanied by translation inhibition. 
To distinguish translation inhibition from mistranslation, two different aminoglycosides 
with comparable IC50 values were chosen. Hygromycin B was used to assess the 
cells’ response to translocation inhibition. In addition, the effects of geneticin on the 
proteome were studied and were compared to those of hygromycin B to determine 
the pathways exclusively regulated in the geneticin-treated sample. These unique 
regulated pathways should give a good approximation on how higher eukaryotic cells 
react to mistranslation. Using the iTRAQ (isobaric tag for relative and absolute 
quantification) approach, whole cell protein extracts of geneticin and hygromycin B 
treated HEK293 cells were studied. In total two separate 4-plex iTRAQ-Mass 
spectrometry (MS) experiments were performed. 
5.3.1 Effects of hygromycin B on the proteome 
In the first experiment, two samples of untreated HEK293 cells and two samples of 
HEK293 cells  treated with 7 µM hygromycin B for 32 h were analyzed. As a result, 
Fig. 33: Comparison of MitoSOX and CM-H2DCFDA fluorescence. Correlation of MitoSOX and 
CM-H2DCFDA fluorescence using tested aminoglycosides and cycloheximide. Squared Pearson 
product-moment correlation coefficient R
2
 and the slope (m) of the regression line are indicated.  
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1385 proteins were identified and quantified. However, the iTRAQ label 114 of one 
untreated sample was not detected in any spectrum, suggesting a manufacturer error 
of the reagent. Consequently, the hygromycin B data discussed here are result of 
one untreated (label 116) and two drug treated (labels 115 and 117) samples. 
Quantitative testing using permutation test and further correction by Bonferroni 
corrected p-value resulted in 90 significantly regulated proteins (p<0.05) (Fig. 34). 
Forty-six proteins were found up- and 44 were found downregulated.  Table 3 shows 
the regulated proteins with their corresponding fold inductions and p-values.  
Functional classification of the enriched proteins resulted in the main categories 
translation, mRNA metabolism, metabolism, cellular organization and protein folding. 
Proteins of the translation category are involved in translational initiation (EIF3D), 
elongation (EEF1A1, EEF2, and EEF1G), ribosome structure (RPLP0, RPL5) and 
aminoacyl tRNA synthesis (VARS). In addition, proteins involved in mRNA 
processing (CSDE1, YBX1, and DDX5) and nonsense mediated mRNA decay (NMD, 
PABPC1, GSPT1) are enriched, suggesting a general response towards a reduced 
translation rate and stalled ribosomes. The chaperones HSPH1, HSPA8 and FKBP4, 
which rescue stress denatured proteins are upregulated as are CCT4, a subunit of 
the nascent peptide folding complex TRiC, and PSMD6 and UBAP2L, two proteins of 
the protein degradation pathway. The category metabolism can be subgrouped in 
carbohydrate metabolism (LDHA, LDHB, GPI, GAPDH, and PGD), nucleic acid 
biosynthesis (CTPS1, ATIC, CAD, and PFAS) and fatty acid metabolism (FASN, 
ACAT2). Proteins involved in the structure of the cytoskeleton (TUBA1C, MYH9, 
FLNA and NEFM) are enriched. Other less represented functional categories 
comprised transport (TFRC, IPO5, and CAPRIN1), and DNA maintenance (IMPDH1, 
PFAS). 
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Table 3: Significantly regulated proteins in HEK293 cells treated with hygromycin B. 90 
regulated proteins with a significance level of p < 0.05 are shown. Proteins were grouped according to 
their function and sorted according to their log2 change. 
metabolism biological function short name p-value (BF-corrected) log2 
Isoform 3 of L-lactate dehydrogenase A chain Carbonhydrate metabolism LDHA 0.00017 0.5
L-lactate dehydrogenase B chain Carbonhydrate metabolism LDHB 0.0001 0.4
Phosphoribosylformylglycinamidine synthase purine metabolism PFAS 0.0023 0.4
Acetyl-CoA acetyltransferase, cytosolic acyltransferase ACAT2 0.0029 0.4
Glucose-6-phosphate isomerase Carbonhydrate metabolism GPI 0.0001 0.35
Fatty acid synthase Fatty acid metabolism FASN 0.0001 0.35
6-phosphogluconate dehydrogenase, decarboxylating Carbonhydrate metabolism PGD 0.05 0.3
Glyceraldehyde-3-phosphate dehydrogenase Carbonhydrate metabolism GAPDH 0.0001 0.3
Bifunctional purine biosynthesis protein PURH purine biosynthesis ATIC 0.0001 0.3
CTP synthase 1 nucleoside biosynthesis CTPS1 0.0027 0.3
CAD protein nucleoside biosynthesis CAD 0.001 0.25
Trifunctional enzyme subunit alpha, mitochondrial Fatty acid metabolism HADHA 0.0058 -0.25
D-3-phosphoglycerate dehydrogenase aminoacid biosynthesis PHGDH 0.0032 -0.3
Isoform 2 of Triosephosphate isomerase Carbonhydrate metabolism TPI1 0.0001 -0.3
Adenylate kinase 2, mitochondrial nucleoside biosynthesis AK2 0.013 -0.45
Acetyl-CoA acetyltransferase, mitochondrial Carbonhydrate metabolism ACAT1 0.0001 -0.5
6-phosphogluconolactonase Carbonhydrate metabolism PGLS 0.0001 -0.55
Phosphoglycerate mutase 1 Carbonhydrate metabolism PGAM1 0.0001 -0.55
Asparagine synthetase [glutamine-hydrolyzing] aminoacid biosynthesis ASNS 0.011 -0.7
DNA maintenance
Nucleosome assembly protein 1-like 1 modulating chromatin formation NAP1L1 0.0001 0.5
Isoform 2 of Inosine-5'-monophosphate dehydrogenase 1 de novo synthesis of guanine nucleotides IMPDH1 0.023 0.45
Single-stranded DNA-binding protein, mitochondrial mitochondrial DNA replication SSBP1 0.0081 -0.2
Isoform 3 of Nuclear autoantigenic sperm protein DNA replication NASP 0.0068 -0.25
Structural maintenance of chromosomes protein 3 DNA replication / repair SMC3 0.0001 -0.3
DNA mismatch repair protein Msh2 post-replicative DNA mismatch repair sytem MSH2 0.0094 -0.35
Flap endonuclease 1 DNA replication / repair FEN1 0.018 -0.4
DNA replication licensing factor MCM2 replication MCM2 0.00042 -0.45
Proliferating cell nuclear antigen DNA replication PCNA 0.0001 -0.55
Histone acetyltransferase type B catalytic subunit histone modifying enzyme HAT1 0.0017 -0.55
Histone H2B type 3-B histone HIST3H2BB 0.044 -0.8
Histone H2A.Z histone H2AFZ 0.0043 -0.85
Replication protein A 14 kDa subunit DNA replication RPA3 0.0001 -1.2
Histone H4 histone HIST1H4A 0.0001 -1.9
translation
Elongation factor 1-alpha 1 elongation EEF1A1 0.0001 0.7
Guanine nucleotide-binding protein subunit beta-2-like 1 translation (inhibition) GNB2L1 0.0079 0.55
Valine--tRNA ligase aminoacyl tRNA synthetase VARS 0.0001 0.45
Elongation factor 1-gamma elongation EEF1G 0.0001 0.45
Elongation factor 2 elongation EEF2 0.0001 0.3
60S acidic ribosomal protein P0 elongation RPLP0 0.0001 0.3
Eukaryotic translation initiation factor 3 subunit D initiation EIF3D 0.0001 0.3
60S ribosomal protein L5 ribosome component RPL5 0.011 0.2
Nucleolin ribosome assembly NCL 0.019 -0.2
40S ribosomal protein S5 ribosome component RPS5 0.0001 -0.3
Glycine--tRNA ligase aminoacyl tRNA synthetase GARS 0.00085 -0.45
Ubiquitin-40S ribosomal protein S27a ribosome component RPS27A 0.012 -0.75
mRNA metabolism
Polyadenylate-binding protein 1 component of autoregulatory ribonucleoprotein complex PABPC1 0.0001 1.3
Isoform Short of Cold shock domain-containing protein E1 component of autoregulatory ribonucleoprotein complex CSDE1 0.0001 0.8
Nuclease-sensitive element-binding protein 1 pre-mRNA alternative splicing regulation YBX1 0.0001 0.75
Probable ATP-dependent RNA helicase DDX5 pre-mRNA alternative splicing regulation DDX5 0.0037 0.35
Isoform 2 of Eukaryotic peptide chain release factor GTP-binding subunit ERF3A recruits UPF1 to stalled ribosomes (NMD)+ stimulates termination GSPT1 0.0056 0.25
Heterogeneous nuclear ribonucleoprotein M mRNA splicing HNRNPM 0.045 -0.15
Isoform 2 of Heterogeneous nuclear ribonucleoprotein A3 mRNA splicing HNRNPA3 0.0014 -0.3
Exosome complex component MTR3 component of the RNA exosome complex EXOSC6 0.019 -0.4
Isoform 2 of Heterogeneous nuclear ribonucleoprotein K pre-mRNA-binding protein HNRNPK 0.0033 -0.7
cellular organization
Tubulin alpha-1C chain cytoskeleton TUBA1C 0.0001 0.4
Myosin-9 cytoskeleton MYH9 0.0011 0.25
Neurofilament medium polypeptide cytoskeleton NEFM 0.0016 0.25
Isoform 2 of Filamin-A cytoskeleton FLNA 0.0001 0.15
Ras GTPase-activating-like protein IQGAP1 actin cytoskeleton reorganisation IQGAP1 0.017 -0.2
Plastin-3 Actin-bundling protein PLS3 0.0001 -0.4
Isoform 2 of Septin-2 organization of the actin cytoskeleton SEPT2 0.0001 -0.4
Neuroblast differentiation-associated protein AHNAK neuronal cell differentiation AHNAK 0.0001 -0.5
protein degradation
26S proteasome non-ATPase regulatory subunit 6 proteasome PSMD6 0.041 0.5
Isoform 2 of Ubiquitin-associated protein 2-like ubiquitination UBAP2L 0.0003 0.4
Ubiquitin carboxyl-terminal hydrolase 7 ubiquitination USP7 0.00075 -0.3
Lon protease homolog, mitochondrial protease LONP1 0.0018 -0.5
Palmitoyl-protein thioesterase 1 lysosomal degradation PPT1 0.0001 -0.85
protein folding
Heat shock cognate 71 kDa protein folding of stress denatured protein HSPA8 0.0001 0.45
Isoform Beta of Heat shock protein 105 kDa folding of stress denatured protein HSPH1 0.0001 0.4
Peptidyl-prolyl cis-trans isomerase FKBP4 folding of stress denatured protein FKBP4 0.0019 0.3
T-complex protein 1 subunit delta folding of nascent peptide chains CCT4 0.00055 0.25
Stress-70 protein, mitochondrial folding of stress denatured protein HSPA9 0.015 -0.2
transport
Transferrin receptor protein 1 iron uptake TFRC 0.0001 0.95
Isoform 2 of Caprin-1 regulates transport and translation of mRNA CAPRIN1 0.047 0.65
Isoform 3 of Importin-5 nuclear protein import receptor IPO5 0.014 0.2
E3 SUMO-protein ligase RanBP2 nuclear protein export RANBP2 0.0001 -0.4
signal transduction
Acidic leucine-rich nuclear phosphoprotein 32 family member A proliferation, differentiation, caspase-dependent apoptosis ANP32A 0.00066 0.6
BolA-like protein 2 cell proliferation BOLA2 0.0055 -0.35
14-3-3 protein epsilon regulator protein YWHAE 0.027 -0.35
Programmed cell death protein 4 apoptosis PDCD4 0.0001 -1.4
others
Nuclear migration protein nudC cell proliferation (spindle apparatus) NUDC 0.0001 0.65
Spermidine synthase Spermidine biosynthesis SRM 0.0001 0.6
Isoform 1 of Four and a half LIM domains protein 1 involved in hypertrophy and muscle development FHL1 0.00034 0.55
Obg-like ATPase 1 ATPase OLA1 0.037 0.3
Inorganic pyrophosphatase hydrolase PPA1 0.0027 0.25
Carbonic anhydrase 2 alpha-carbonic anhydrase CA2 0.0096 0.25
Electron transfer flavoprotein subunit alpha, mitochondrial electron transport ETFA 0.0037 -0.3
Vacuolar protein sorting-associated protein 35  component of the retromer complex VPS35 0.016 -0.35
Isoform 2 of Spectrin alpha chain, non-erythrocytic 1 secretion SPTAN1 0.0001 -0.4
Annexin A5 anticoagulant protein ANXA5 0.017 -0.45
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Downregulated proteins could be classified in the functional categories DNA 
maintenance, metabolism, RNA metabolism, cellular organization, protein 
degradation and translation. The proteins of the DNA maintenance group comprise 
histones and a histone modifying enzyme both involved in DNA organization 
(HIST1H4A, H2AFZ, HIST3H2BB, HAT1). Further proteins were involved in nuclear 
DNA replication (RPA3, MCM2, PCNA and NASP), mitochondrial DNA replication 
(SSBP1) and DNA damage repair (FEN1, MSH2, SMC3). Factors responsible for 
protein degradation (USP7, LONP1, PPT1), translation (RPS5, RPS27A, GARS, 
NCL), mRNA splicing (EXOSC6, HNRNPA3, HNRNPM, HNRNPK), cellular 
organization (SEPT2, PLS3, AHNAK, IQGAP1), and transport (RANBP2) were also 
identified. The category metabolism consisted of the 4 subgroups carbohydrate 
metabolism (PGAM1, PGLS, TPI1 and ACAT1), amino acid biosynthesis (ASNS, 
PHGDH), nucleic acid metabolism (AK2) and lipid metabolism (HADHA).  
 
 Fig. 34: Hygromycin B regulated proteins. 90 proteins were significantly regulated upon hygromycin 
B treatment (p-value<0.05). Of those, 46 proteins were upregulated, 44 were downregulated. 
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5.3.2 Effects of geneticin on the proteome 
The second iTRAQ experiment consisted of two samples of untreated HEK293 cells 
and two samples of HEK293 cells treated with 16 µM geneticin for 32 h. As a result, 
1785 proteins could be detected and quantified. The permutation test and further 
Bonferroni correction identified 74 proteins to be significantly regulated with a p-
Value < 0.05 (Fig. 35). Table 4 contains these 74 proteins, their corresponding p-
values and fold inductions. 
40 of the 74 proteins were upregulated. Analysis of their biological function revealed 
that almost half of the upregulated proteins are involved in protein folding (Fig. 35). 
These seventeen proteins are part of the cytosolic and ER resident folding 
machinery. Proteins of the Hsp40 (DNAJA1), Hsp70 (BiP, HSPA1A, HSPA8), Hsp90 
(Endoplasmin or GRP94) and Hsp110 (HSPH1) families were found enriched. Also, 
foldases and chaperones of the ER (PDIA3, PDIA4, PDIA6, P4HB, CALR, ERP44) 
and cytoplasm (FKBP4, ST13, STIP1) were induced upon geneticin treatment. Two 
chaperones linked to proteins synthesis (CLIPS) were upregulated (CCT2, PFDN5) 
as well. These chaperones participate in folding of nascent polypeptide chains, while 
the other chaperone network is responsible for folding of stress denatured proteins. 
Besides folding, the ubiquitin-conjugating enzyme E2 S (UBE2S), tagging proteins for 
proteasomal degradation, was induced. 
Proteins involved in ribosomal translation were enriched. In addition to initiation 
factors (EIF1B, EIF3A, EIF4A1) and elongation factor eEF1G, structural ribosomal 
proteins were induced (RPLP2, RPL9, RPLP1). Other functional categories 
comprised proteins involved in transport, signal transduction and mRNA metabolism. 
The functional category transport included Importin subunit alpha (KPNA2) and 
nuceloporin NUP43, both involved in transport of de novo synthesized proteins. 
NACA and SRPRB which regulate targeting of nascent proteins to the ER were 
upregulated. The cell signaling group included the erUPR marker MANF (Apostolou, 
Shen et al. 2008). MANF regulates ER-stress mediated apoptosis and inhibition of 
cell proliferation and was highly enriched in geneticin treated samples. G3BP1, an 
effector of stress granule assembly is positively regulated as well. NUDC, which 
positively affects cell proliferation and CDKN2A, which negatively regulates cell 
proliferation were equally induced. ATXN-10, which promotes maintenance of 
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intracellular glycosylation levels, is found upregulated. Two proteins, which promote 
assembly of the mRNA spliceosome complex, are induced (CLNS1A, SMNDC1).  
 
Fig. 35: Geneticin regulated proteins: 74 proteins were significantly regulated upon geneticin treatment 
(p-value<0.05). Of those, 40 proteins were upregulated, 34 were downregulated. 
Results  45 
  
 
 
Table 4: Significantly regulated proteins in HEK293 cells treated with geneticin. Shown are 74 
regulated proteins with a significance level of p < 0.05. Proteins were grouped according to their 
function and sorted according to their log2 change. 
 
protein folding biological function short name p-value (BF-corrected) log2 
Heat shock 70 kDa protein 1A/1B cytosolic HSP70 HSPA1A 0.0001 0.95
78 kDa glucose-regulated protein ER HSP70 HSPA5 0.0001 0.75
DnaJ homolog subfamily A member 1 cytosolic Hsp40, import into mitochondria DNAJA1 0.0001 0.65
Protein disulfide-isomerase A4 ER isomerase PDIA4 0.0001 0.6
Isoform Beta of Heat shock protein 105 kDa cytosolic Hsp110 HSPH1 0.0001 0.6
Prefoldin subunit 5 folding of nascent peptide chains PFDN5 0.026 0.55
Heat shock cognate 71 kDa protein cytosolic Hsp70 HSPA8 0.0001 0.4
Endoplasmin ER Hsp90 HSP90B1 0.0001 0.4
Isoform 2 of Protein disulfide-isomerase A6 ER isomerase PDIA6 0.0001 0.4
Protein disulfide-isomerase ER isomerase P4HB 0.00014 0.4
Endoplasmic reticulum resident protein 44 ER chaperone ERP44 0.0092 0.4
Peptidyl-prolyl cis-trans isomerase FKBP4 cytosolic and mitochondrial isomerase FKBP4 0.0001 0.3
Protein disulfide-isomerase A3 ER isomerase PDIA3 0.00033 0.3
Hsc70-interacting protein cytosolic chaperone ST13 0.006 0.3
Stress-induced-phosphoprotein 1 cytosolic cochaperone STIP1 0.00039 0.3
Calreticulin ER lectin chaperone CALR 0.0063 0.3
T-complex protein 1 subunit beta folding of nascent peptide chains CCT2 0.0001 0.2
DNA maintenance
Isoform 3 of Histone-binding protein RBBP4 regulates chromatin metabolism RBBP4 0.00024 0.2
RuvB-like 1 DNA replication / repair RUVBL1 0.0001 -0.2
X-ray repair cross-complementing protein 5 DNA repair XRCC5 0.0001 -0.25
Structural maintenance of chromosomes protein 1A DNA repair SMC1A 0.0001 -0.35
Poly [ADP-ribose] polymerase 1 DNA repair PARP1 0.0001 -0.4
DNA replication licensing factor MCM6 replication MCM6 0.0001 -0.4
DNA-dependent protein kinase catalytic subunit DNA repair PRKDC 0.0001 -0.45
DNA mismatch repair protein Msh2 DNA repair MSH2 0.0001 -0.45
DNA damage-binding protein 1 DNA repair DDB1 0.00032 -0.45
Isoform 2 of DNA (cytosine-5)-methyltransferase 1 methylation of DNA during replication DNMT1 0.018 -0.5
DNA replication licensing factor MCM5 replication MCM5 0.0001 -0.55
translation
Eukaryotic translation initiation factor 1b initiation EIF1B 0.00099 0.7
60S acidic ribosomal protein P2 ribosome component RPLP2 0.0001 0.5
60S acidic ribosomal protein P1 ribosome component RPLP1 0.0012 0.45
Eukaryotic translation initiation factor 3 subunit A initiation EIF3A 0.0001 0.3
60S ribosomal protein L9 ribosome component RPL9 0.013 0.25
Eukaryotic initiation factor 4A-I initiation EIF4A1 0.017 0.25
Elongation factor 1-gamma elongation EEF1G 0.014 0.15
Isoleucine--tRNA ligase, cytoplasmic aminoacyl tRNA synthetase IARS 0.0014 -0.35
Tyrosine--tRNA ligase, cytoplasmic aminoacyl tRNA synthetase YARS 0.048 -0.35
metabolism
Isoform 2 of Triosephosphate isomerase Carbohydrate metabolism TPI1 0.046 -0.15
C-1-tetrahydrofolate synthase, cytoplasmic methionine purine Synthesis MTHFD1 0.028 -0.25
Acetyl-CoA acetyltransferase, mitochondrial Carbohydrate metabolism ACAT1 0.0001 -0.3
Transketolase pentose phosphate pathway TKT 0.0001 -0.3
Glycogen phosphorylase, liver form Carbohydrate metabolism PYGL 0.003 -0.3
Trifunctional enzyme subunit alpha, mitochondrial fatty acid metabolism HADHA 0.0001 -0.3
Dihydrolipoyllysine-residue acetyltransferase component of pyruvate dehydrogenase complex, mitochondrial Carbohydrate metabolism DLAT 0.0039 -0.35
Enoyl-CoA delta isomerase 1, mitochondrial (Fragment) fatty acid metabolism ECI1 0.0001 -0.45
Phosphoserine aminotransferase amino acid biosynthesis PSAT1 0.00019 -0.5
signal transduction
Mesencephalic astrocyte-derived neurotrophic factor erUPR induced inhibitor of proliferation and cell death MANF 0.0001 1.1
Growth factor receptor-bound protein 2 Ras signaling pathway, triggers active programmed cell death GRB2 0.0043 0.6
Ras GTPase-activating protein-binding protein 1 effector of stress granule assembly G3BP1 0.0001 0.45
Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3 negative regulator of the proliferation CDKN2A 0.026 0.45
Isoform 2 of Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform regulates substrate's selectivity and catalytic activity PPP2R2A 0.0093 0.35
Ataxin-10 survival of cerebellar neurons, maintenance of intracellular glycosylation level ATXN10 0.0031 0.35
Programmed cell death protein 4 apoptosis, inhibits translation initiation PDCD4 0.0045 -0.3
Acidic leucine-rich nuclear phosphoprotein 32 family member A apoptosis, proliferation, differentiation ANP32A 0.0068 -0.3
mRNA metabolism
Methylosome subunit pICln chaperone regulating the spliceosome CLNS1A 0.039 0.45
Survival of motor neuron-related-splicing factor 30 spliceosome assembly SMNDC1 0.0001 0.35
Heterogeneous nuclear ribonucleoprotein M mRNA splicing HNRNPM 0.00031 -0.15
Heterogeneous nuclear ribonucleoprotein L mRNA splicing HNRNPL 0.0001 -0.25
Isoform 2 of Spliceosome RNA helicase DDX39B spliceosome assembly and splicing DDX39B 0.0001 -0.35
Isoform 2 of Heterogeneous nuclear ribonucleoprotein K pre-mRNA-binding protein HNRNPK 0.001 -0.5
Protein FAM98B component of tRNA splicing ligase complex FAM98B 0.0001 -0.6
transport
Importin subunit alpha-2 nuclear protein import KPNA2 0.0001 0.65
Nucleoporin Nup43 nuclear pore complex NUP43 0.024 0.65
Isoform 2 of Caprin-1 transport and translation of mRNA CAPRIN1 0.016 0.55
Signal recognition particle receptor subunit beta targeting of the nascent secretory proteins to the ER SRPRB 0.0003 0.3
Nascent polypeptide-associated complex subunit alpha Prevents inappropriate targeting of non-secretory prot. to the ER NACA 0.012 0.3
cellular organization
Neuroblast differentiation-associated protein AHNAK neuronal cell differentiation AHNAK 0.0001 -0.35
Cytoplasmic dynein 1 heavy chain 1 motor for intracellular retrograde motility at microtubules DYNC1H1 0.00085 -0.35
Profilin-1 binds actin and affects cytoskeleton structure PFN1 0.0001 -0.55
degradation
Ubiquitin-conjugating enzyme E2 S ubiquitination UBE2S 0.025 0.8
others
Nuclear migration protein nudC neurogenesis and cell proliferation NUDC 0.0001 0.45
Nucleolar protein 58 60S subunit biogenesis NOP58 0.018 -0.25
Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial electron transport SDHA 0.00046 -0.3
Nucleolin ribosome assembly, chromatin condensation, transcriptional elongation NCL 0.0015 -0.4
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Functional classification of the 34 significantly downregulated proteins showed that 
they can be grouped into four main families: DNA maintenance, metabolism, RNA 
metabolism, and cellular organization. The DNA maintenance group contained 10 
proteins involved in DNA damage repair (DDB1, MSH2, XRCC5, RUVBL1, SMC1A, 
PARP1, PRKDC) and replication (MCM5, MCM6, DNMT1). The metabolism group 
can be divided into three subgroups, namely carbohydrate metabolism (TPI1, TKT, 
PYGL, ACAT1, DLAT), lipid metabolism (ECI1, HADHA) and amino acid metabolism 
(PSAT1, MTHFD1). This shows that geneticin treatment negatively influences main 
metabolic groups. Proteins of the RNA metabolism are involved in mRNA splicing 
(HNRNPM, HNRNPL, HNRNPK), assembly of the spliceosome (DDX39B) and tRNA 
splicing ligase complex (FAM98B). Interestingly, the aminoacyl tRNA synthetases for 
isoleucine (IARS) and tyrosine (YARS) were downregulated. Proteins involved in 
cellular organization include AHNAK, DYNC1H1 and PFN1, which are involved in 
neuronal cell differentiation, transport of vesicles and organelles along microtubules 
and regulation of cytoskeleton structure, respectively. 
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5.3.3 Comparison of functional categories  
In each iTRAQ experiment, the total amount of upregulated proteins was set as 
100% and the percentages of proteins belonging to the distinct functional categories 
were calculated and plotted side by side for geneticin and hygromycin B (Fig. 36A). 
Accordingly, the percentages of the downregulated proteins were calculated and 
plotted (Fig. 36B). Significant differences were found for upregulated proteins in the 
functional groups protein folding, signal transduction and metabolism (Fig. 36A). In 
contrast to hygromycin B, geneticin treatment resulted in an enrichment of 
chaperones (Fig. 36A). As shown by the mistranslation assay in chapter 5.1, 
geneticin but not hygromycin B induced mistranslation. As a result of mistranslation,  
 
 
 
 
Fig. 36: Comparison of functional categories. Enrichment of proteins in their corresponding functional 
categories. For geneticin and hygromycin B the total amount of upregulated or downregulated proteins was 
set as 100% and the percentages of proteins belonging to the distinct categories was calculated. 
Distribution of (A) upregulated proteins and (B) downregulated proteins in their functional categories in 
geneticin and hygromycin B treated cells.  
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 proteins can become misfolded and the cellular proteostasis becomes disturbed. 
Consequently, the unfolded protein responses of the cytosol and the ER are 
activated to restore homeostasis. As described in chapter 5.3.2, cytosolic 
chaperones of the HSP70, 90 and 110 families and erUPR markers BiP, GRP94 and 
PDIs are upregulated. In contrast, the translocation inhibitor hygromycin B does not 
induce UPRs and little accumulation of chaperones is found by MS.    
Compared to hygromycin B treated cells, geneticin treatment results in a pronounced 
enrichment of proteins belonging to the functional category signal transduction. The 
geneticin group is composed of 6 proteins, including the erUPR marker MANF and 
the effector protein of stress granule assembly G3BP1. Both proteins are linked to 
misfolded protein stress responses, again pointing to geneticin as a mistranslator. In 
contrast, hygromycin B treatment resulted in upregulation of one regulatory protein 
involved in proliferation and caspase-dependent apoptosis (ANP32A), demonstrating 
distinct responses in signaling.  
In hygromycin B treated cells, approximately 25 % of the upregulated proteins are 
involved in metabolism. As mentioned in chapter 5.3.1 the metabolic proteins of the 
hygromycin B treated samples can be subdivided in carbohydrate metabolism, 
nucleic acid biosynthesis and fatty acid metabolism. Notably, the geneticin treated 
samples lack an induction of metabolism-related proteins.  
Hygromycin B and geneticin induced similar proteins involved in protein synthesis. 
Translation initiation factors, elongation factors, and ribosomal proteins were 
upregulated, revealing that the common translocation inhibition induces similar 
responses in geneticin and hygromycin B treated cells. Moreover, the response to 
hygromycin B mainly involves elongation factors (EEF1A1, EEF1G, EEF2) while 
geneticin treatment results in upregulation of initiation factors (EIF1B, EIF3A and 
EIF4A1).  
Within the functional categories the distribution of downregulated proteins showed 
similar patterns for geneticin and hygromycin B. Minor exceptions exist in categories 
transport, protein folding and protein degradation. The main downregulated 
categories are DNA maintenance and metabolism. This seems to be a common 
response to the drugs, suggesting that translocation inhibition of aminoglycosides 
results in metabolic inactivity and reduced DNA repair and replication. 
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5.3.4 Proteins regulated by geneticin and hygromycin B 
Comparison of proteins affected by geneticin and hygromycin B treatment identified 
16 commonly regulated proteins (Fig. 37 A). The fold-changes and corresponding p-
values of the proteins are shown in Table 5. Plotting the log2 values of the proteins 
regulated by geneticin and hygromycin B revealed that 15 of 16 proteins were 
regulated similarly (Fig. 37 B). As an exception, the proapoptotic factor ANP32A 
(acidic leucine-rich nuclear phosphoprotein 32 family member A) is downregulated in 
geneticin but upregulated in hygromycin B treated samples.  
Three chaperones (HSPH1, HSPA8, FKBP4), which are part of the cytosolic heat 
shock response in the cytoplasm, were consistently upregulated as were translation 
elongation factor EEF1G, and CAPRIN1, which regulates transport and translation of 
mRNA. HSPA8 is a chaperone involved in spliceosome assembly and is a repressor 
of transcriptional activation (Yahata, de Caestecker et al. 2000). In contrast, HSPH1 
can inhibit HSPA8 and is a chaperone which prevents aggregation of proteins, 
activates HSP70 and suppresses oxidative stress (Yamagishi, Saito et al. 2008, 
Yamagishi, Goto et al. 2010). 
 
 
 
 
Fig. 37: Comparison of proteins regulated by geneticin and hygromycin B. (A) Venn diagram, (B) 
plotted log2 values of the 16 common regulated proteins. Red dots indicate proteins involved in folding, 
green dots mark DNA maintenance, dark blue indicates proteins of metabolism, and light blue 
indicates proteins of mRNA metabolism. Squared Pearson product-moment correlation coefficient R
2
 
of the regression line is indicated. 
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FKBP4 has besides its chaperone function also a protective a role against oxidative 
stress in mitochondria (Gallo, Lagadari et al. 2011), suggesting the chaperones might 
be regulated upon oxidative stress during drug exposure. NUDC a protein necessary 
for correct formation of mitotic spindles and chromosome separation during mitosis is 
also upregulated in geneticin and hygromycin B treated cells. 
Downregulated proteins can be grouped into metabolism, mRNA splicing, DNA repair 
and cell signaling. The proteins of the metabolic group are involved in glycolysis, 
ketone body metabolism and mitochondrial fatty acid β-oxidation (TPI, ACAT1, 
HADHA). Other downregulated proteins are involved in mRNA splicing (HNRNPM, 
HNRNPK), post replicative DNA mismatch repair (MSH2), neuronal cell 
differentiation(AHNAK) and ribosome assembly (NCL). Programmed cell death 
protein 4 (PDCD4), an apoptosis promoting factor, is also decreased in both drug 
treated samples. The pattern of the downregulated proteins suggests that part of the 
general energy metabolism is affected by translation inhibition.  
 
 
5.3.5 Drug-regulated proteins and corresponding mRNAs   
Significantly regulated proteins (p < 0.05) of the geneticin and the hygromycin B 
treated samples were compared with their corresponding mRNA levels. Data of two 
microarray experiments (geneticin and hygromycin B treated HEK293 cells) were 
log2 change p-value log2 change p-value
HSPH1 0.4 0.0001 0.6 0.0001
CAPRIN1 0.65 0.047 0.55 0.016
NUDC 0.65 0.0001 0.45 0.0001
HSPA8 0.45 0.0001 0.4 0.0001
FKBP4 0.3 0.0019 0.3 0.0001
EEF1G 0.45 0.0001 0.15 0.014
HNRNPM -0.15 0.045 -0.15 0.00031
TPI1 -0.3 0.0001 -0.15 0.046
ACAT1 -0.5 0.0001 -0.3 0.0001
PDCD4 -1.4 0.0001 -0.3 0.0045
ANP32A 0.6 0.00066 -0.3 0.0068
HADHA -0.3 0.0058 -0.25 0.0001
AHNAK -0.5 0.0001 -0.35 0.0001
NCL -0.2 0.019 -0.4 0.0015
MSH2 -0.35 0.0094 -0.45 0.0001
HNRNPK -0.7 0.0014 -0.5 0.001
Hygromycin Geneticin
Table 5: Fold-induction and p-values of proteins regulated by geneticin and hygromycin B. 
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used to plot log2 fold change of the mRNA against the respective log2 fold-change of 
the protein levels measured by the iTRAQ experiment (Fig. 38).  
Fig. 38A shows the comparison of transcriptome and proteome data of the geneticin 
treated samples. Components of the folding machinery (marked in red) reveal an 
upregulation at both the transcriptomic and the proteomic level. Proteins involved in 
DNA maintenance and metabolism are mostly downregulated at both levels. As 
indicated by the squared Pearson product-moment correlation coefficient of 0.4184 
the scattering of the data follow a rather linear distribution, suggesting similar 
regulation at the mRNA and protein levels. A different distribution is present in the dot 
plot of hygromycin B treated HEK293 cells (Fig. 38C). Here, the regulation of the 
proteome is not accompanied by the mRNA fold change. The squared Pearson 
product-moment correlation coefficient of 0.0051, points to a random distribution. 
Chaperones, which were upregulated at the proteomic level, are not induced at the 
transcriptomic level. Proteins involved in metabolic pathways are found up- and 
downregulated on the proteomic level, however, their corresponding mRNA levels 
revealed a common negative regulation. The DNA maintenance promoting proteins 
were up and downregulated at the proteomic level, but induced or not regulated at 
the transcriptomic level. As shown in Fig. 38B, the distribution of dots in geneticin plot 
without the folding machinery proteins shows not an identical pattern to the 
hygromycin B plot in Fig. 38C. The squared Pearson product-moment correlation 
coefficient of 0.2380 is low, but shows rather a weak linear distribution than a random 
distribution. 
The comparison of the transcriptome and the proteome data demonstrated a robust 
induction of cytUPR and erUPR in geneticin, but not in hygromycin B treated 
samples. This suggested that mistranslation mediated by geneticin results in 
misfolded proteins and in an upregulation of distinct chaperone networks. 
Translocation inhibition in both drug treatments leads to similar, but not identical 
patterns. In both conditions translation machinery components i.e. initiation factors, 
elongation factors and ribosomal proteins were upregulated. Another similar pattern 
is the downregulation of proteins involved in metabolism of the mitochondria, which 
suggests that the mitochondrial activity is reduced in order to minimize drug-induced 
oxidative stress. 
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Fig. 38: Comparison of significantly regulated proteins and their corresponding mRNA levels. (A) 
geneticin treated HEK cells, (B) geneticin treated HEK cells without the proteins of the protein folding 
machinery (C) hygromycin B treated HEK cells. Red dots indicate proteins of the protein folding 
machinery, blue dots show proteins involved in metabolism and green dots highlight proteins responsible 
for DNA maintenance. Squared Pearson product-moment correlation coefficient R
2
 of the linear 
regression line (not shown) is indicated. 
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6 Material and Methods 
6.1 Cell lines and culture conditions 
HEK293 wild-type (Innoprot) and HEK293 APH(3’) cells (officially named 293FT, Life 
technologies) were cultured in DMEM medium (Life technologies) supplemented with 
10% fetal bovine serum (Life technologies). Serum free F10 media (Life 
technologies) supplemented with 15 µg/ml saponin (Sigma) was used during drug 
treatment. The osteosarcoma cell lines 143B and its rho-0 derivative without 
mitochondrial DNA were kindly provided by Dr. Rafael Garesse Alarcón. Cells were 
kept with DMEM supplemented with 10% FBS or DMEM supplemented with 10% 
FBS and 50 µg/ml uridine, respectively (Chomyn, Lai et al. 1994). DMEM was used 
for 143B cells and DMEM with 50 µg/ml uridine was used for rho-0 cells during drug 
treatment.  
6.2 Assessment of stop-codon read-through in vitro 
For in vitro translation assays luciferase mRNA was produced in vitro using T7 
polymerase (Thermo). The mammalian promotors of pGL4.14 (firefly luciferase, 
hFluc) and pGL4.75 (renilla luciferase, hRluc, both Promega) were replaced by T7 
bacteriophage promotor resulting in pT7-hFluc and pT7-hRluc vectors, respectively. 
hRluc and hFluc were fused by a 27-nucleotide linker encoding the polypeptide 
STCDQPFGF (Salas-Marco and Bedwell 2005) using overlap PCR mutagenesis to 
result in the pT7 hRluc-hFluc vector. In addition, the first codon of the hFluc gene 
encoding for methionine (ATG) was replaced by CTC (Leucine) codon using site 
directed PCR mutagenesis to prevent internal ribosomal binding. To create the read-
through construct a TGA nonsense codon was introduced instead of the glutamine 
residue (wild type CAA) in the linker sequence by site directed PCR mutagenesis. A 
standard 15 µl in vitro translation reaction contained 10 µl rabbit reticulocyte lysate 
(Promega), 2 µg reporter mRNA, amino acid mixture (final concentration of each 
amino acid 200 µM), 12 units RiboLock (Thermo), 1x Protease Inhibitor complete 
(Roche). Following addition of serially diluted aminoglycosides, the reaction mixture 
was incubated at 37°C for 35 min and stopped on ice. Firefly activities were 
determined using a luminometer FLx800 (BioTek Instruments). Luciferase activities 
of hRluc were always used to assess translation inhibition and relative read-through 
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induction was calculated by hFluc luminescence/hRluc luminescence. The basal 
error frequency rate of the eukaryotic cytoplasmic ribosome is 4 x 10-4 to 10-5. For the 
untreated samples, the hFluc/hRluc ratio was set as 1, which reflects the basal error 
frequency. 
6.3 Assessment of stop codon read-through in vivo 
Read-through in HEK293 cells was determined using the pRM hRluc-hFluc D357X 
vector, where the Asp357 (GAC codon) of the firefly gene was replaced by a TGA 
nonsense codon in the pRM hRluc-hFluc vector (Matt, Ng et al. 2012). The construct 
was generated by site directed PCR mutagenesis. HEK293 wild-type cells were 
grown until 80% confluency in 6-well plates at 37°C, 5% CO2 in DMEM supplemented 
with 10% FBS (vol/vol) (Life technologies) and subsequently transfected with 3 µg 
reporter plasmid using TurboFect transfection reagent (Thermo) according to 
manufacturer’s protocol. Cells were incubated for 24 h and medium was replaced by 
F10 (Life technologies). Serially diluted antibiotics were added together with 
saponine (15 µg/ml final concentration) and cells were incubated for another 24 h. 
Cells were lysed using 1x passive lysis buffer (Promega) and luciferase activities 
were determined using the FLx800 luminometer (Bio-Tek Instruments).  
6.4 Autoradiography 
A standard 15 µl reaction contained 10 µl rabbit reticulocyte lysate (Promega), 2 µg 
reporter mRNA, amino-acid mixture without methionine (each 200 µM), 200 µM S35-
methionine (Hartmann Analytic), 12 units RiboLock (Thermo), 1x Protease Inhibitor 
complete (Roche). Following addition of serially diluted paromomycin the reaction 
mixture was incubated at 37°C for 35 min and stopped on ice. To analyze the 
translational products, 5 µl of each reaction was mixed with 5 µl of 2x SDS sample 
buffer (125 mM Tris-HCl pH 6.8, 4% SDS, 20% Glycerol, 0.02% Bromphenol Blue, 8 
mM β-mercapto-ethanol), incubated at 95°C for 5 min and loaded on a 13.3% SDS-
PAGE gel. After running the gel for 1 hour at 150 V, the SDS-PAGE was fixed using 
a buffer containing 40% methanol and 10% acetic acid. After drying, the gel was 
exposed to an IP-detection plate for at least 1h. The FLA-5100 imaging system was 
used to detect the resulting bands on the IP detection plate. 
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6.5 ROS detection 
HEK293 cells were grown in DMEM supplemented with 10% FBS in 12-well plates 
until 80% confluency. For antibiotic treatment the growth medium was replaced by 
F10 (Life technologies) supplemented with 15 µg/ml saponin and serially diluted 
antibiotics were added. After 24 or 48 h of incubation the cells were stained for 30 
min with 5 µM MitoSOX (Life technologies) in FACS buffer (1x PBS supplemented 
with 2% FBS) or 5 µM CM-H2DCFDA (Life technologies) in FACS buffer. Cells were 
detached using accutase (Life technologies) and resuspended in FACS buffer. Prior 
to measurement the CM-H2DCFDA- but not the MitoSOX-stained samples were 
washed three times using FACS buffer. The Fluorescence of both MitoSOX and CM-
H2DCFDA stained samples was measured using a FACS Canto II (BD). Data were 
analyzed using FlowJo software.  
6.6 Isobaric Tag for relative and absolute quantitation (iTRAQ) assay 
Cells were grown in DMEM supplemented with 10% FBS in 6-well plates until 70-
80% of confluency were reached. Then media was replaced by F10 supplemented 
with saponin and 16 µM geneticin or 7 µM hygromycin. After 32 h, media was 
removed and cells were washed with 1x PBS. Subsequently, samples were 
incubated with lysis buffer (150 mM NaCl, 0,1% SDS, 0,5% Na-deoxycholat, 50 mM 
Tris, 1x complete protease inhibitor (Roche) for 10 min at room temperature and 
shaking. Subsequently, the lysate was ultrasonicated in a water bath for 10 min and 
centrifuged for 20 min at 13200 rpm at 4°C. The supernatant was used for further 
analysis. Protein quantification was performed using the Qubit kit (Invitrogen). 80 µg 
of total protein from each sample was used for iTRAQ labeling (AB SCIEX).  
Two iTRAQ 4-plex experiments were performed. One 4-plex consisted of 2 biological 
replicates of untreated HEK293 cells (114 and 116 label) and 2 biological replicates 
of HEK293 cells treated with geneticin (16 µM) for 32 h (115 and 117 label). The 
other 4-plex experiment consisted of 2 untreated independent samples (114 and 116 
label) and 2 independent samples treated with hygromycin (115 and 117 label) The 
cell lysates were first precipitated with 20% TCA and dried pellets were reconstituted 
in 50 mM triethyl ammonium bicarbonate buffer (TEAB), pH 8,5 supplemented with 
0,1% SDS. Protein samples were reduced using tris-(2-carboxyethyl)phosphine 
(TCEP) and alkylated with methyl methane-thiosulfonate (MMTS). For digestion a 
ratio of trypsin to protein content of 1:50 was used and samples were incubated for 4 
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h at 37°C. For labeling the iTRAQ vials were reconstituted with 70 µl of ethanol and 
the tryptic digested peptides were added. Labeling reaction was performed for 2 h at 
room temperature. The labeling reaction was quenched for 10 min at room 
temperature using 10 mM of ethanolamine.  iTRAQ samples were pooled, dried and 
reconstituted in 75% acetonitrile (ACN) with 8 mM KH2PO4, pH 4.5 and fractionated 
by HILIC-HPLC (Pack Polyamine II, 250 x 4mm, 120 Å S-5 µm, YMC) using a linear 
gradient with 5% ACN, 100 mM KH2PO4, pH 4.5.  The eluted fractions were desalted 
using Zip Tip C18 cartridges (Millipore), dried and reconstituted in 15 µl 3% ACN and 
0,1% formic acid for LC-MS/MS analysis. Samples were injected into an Eksigent-
nano-HPLC system (Eksigent Technologies, Dublin (CA), USA) by an auto sampler 
and separated on a self-made reverse-phase  column (75 µm x 150 mm) packed with 
C18 material (Magic C18, AQ, 3 µm, 200 Å, Bischoff GmbH, Leonberg, Germany). 
The column was equilibrated with 95% solvent A (0.1% formic acid (FA) in water) and 
5% solvent B (0.1% FA in ACN). Peptides were eluted using the following gradient: 
0-3 min; 1-5% B, 3-57 min; 5-35% B, 57-63 min; 35-50% B and 63-70 min; 50-99% 
B, at a flow rate of 0.3 µl/min. High accuracy mass spectra were acquired with an AB 
Sciex 5600 (AB Sciex, Concord, Canada) in the mass range of 385-1250 m/z. Up to 
36 data dependent MS/MS were recorded in high sensitivity mode of the most 
intense ions with charge state 2+, 3+ and 4+ using collision induced dissociation. 
Target ions already selected for MS/MS were dynamically excluded for 90 s after 
three occurrences. After data collection the peak lists were generated using AB 
SCIEX MS Data Converter 1.3 (AB Sciex, Concord, Canada). All MS/MS data were 
analyzed using Mascot 2.4 (Matrix Science, London, UK). MS data were searched 
against a decoyed human database from Swissprot (release December 2012) 
concatenated with an in-house build contaminant database. Precursor ion mass 
tolerance was set to 20 ppm and the fragment ion mass tolerance was set to 0.05 
Da. The following search parameters were used: Trypsin digestion (no missed 
cleavage allowed), fixed modifications of methyl methanethiosulfonate (MMTS) 
labelled cysteine, 4-plex-iTRAQ modifications of free amines at the N-termini and of 
lysine, and as variable modification 4-plex-iTRAQ of tyrosine. The peptides without 
any 4-plex-iTRAQ label at the N-terminus or at a lysine were excluded from the 
analysis. After the Mascot search the data were further evaluated by using Scaffold 
4.3 software. In Scaffold the following parameters were used: protein threshold 95%, 
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minimum 2 peptides for identification of a protein, and a minimum Mascot Ionscore 
40. 
6.7 Microarray 
HEK cells were treated with 16 µM geneticin in F10 medium with 15 µg/mL saponin 
at 37 °C for 32 h. RNA was extracted from four independent samples for each 
condition (geneticin-treated, untreated). Total RNA was processed and hybridized on 
GeneChip Human Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA) by the IGBMC 
Microarray and Sequencing Platform as described (Ravens, Fournier et al. 2014). 
Significance of the difference in expression of each gene between geneticin-treated 
and untreated samples was tested using the TREAT method (McCarthy and Smyth 
2009). Correction of Benjamini-Hochberg (Benjamini and Hochberg 1995) for multiple 
testing was applied in order to take into account the number of tests performed. 
Corrected p-values lower than 0.05 were considered as significant. 
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7 Discussion 
In this thesis the link between mistranslation and cellular stress in eukaryotic cells 
was investigated using antibiotics of the aminoglycoside class. Besides induction of 
general mistranslation, aminoglycosides inhibit ribosomal translocation (Buchanan, 
Stevens et al. 1987). Thus far, it is not possible to manipulate ribosomal translation 
fidelity in higher eukaryotes without affecting translation efficiency. Previously, the 
accuracy of translation has been manipulated by mutating tRNAs or the editing 
domain of a tRNA aminoacyl transferase, which results in codon-specific 
mistranslation (Lee, Beebe et al. 2006, Paredes, Carreto et al. 2012). 
7.1 Aminoglycoside mistranslation and translation inhibition 
As a first step, the effect of various aminoglycosides on eukaryotic translation was 
assessed. For this purpose, we established dual luciferase assays using in vitro RRL 
ribosomes and in vivo HEK293 cells. Comparison of in vitro and in vivo IC50-values 
showed a good correlation, suggesting that the in vitro assay is relevant and properly 
reflects the whole cell situation. Hygromycin B is a strong inhibitor of eukaryotic 
translation and is described as a drug with a subtle effect on decoding fidelity when 
using artificial polyU mRNA as a reporter (Eustice and Wilhelm 1984, Eustice and 
Wilhelm 1984). According to our dual luciferase assay, based on the gain of function 
principle, we could not detect hygromycin B mediated induction of read-through in 
vitro and only little induction in vivo. The relative read-through induction of 
hygromycin B in vivo has to be interpreted with caution. The experimentally 
determined hFluc luminescence showed little read-through induction. The ratio used 
to calculate the relative read-through (hFluc/hRluc), however, is a possible source of 
mathematical artefacts. Thus, little or no read-through induction which is 
accompanied by a strong translation inhibition will result in a prominent relative read-
through induction. It follows that relative data should be always compared with the 
directly experimentally determined values to prevent misleading interpretations. The 
data presented here suggest that hygromycin B acts primarily as a translation 
inhibitor in higher eukaryotes, which is consistent with published data (Manuvakhova, 
Keeling et al. 2000).  
The 4,6-disubstituted aminoglycoside geneticin is a strong translation inhibitor and a 
potent inducer of mistranslation. The 4,5-disubstituted aminoglycoside paromomycin 
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with a 6’ hydroxyl group and the 4,6-disubstituted aminoglycoside gentamicin with a 
6’ amino group shows similar IC50 values and comparable efficacies to induce 
mistranslation. Both drugs can induce read-through in a comparable manner, which 
is in agreement with published data (Manuvakhova, Keeling et al. 2000, Kandasamy, 
Atia-Glikin et al. 2012).  
The exchange of the 6’ OH group in ring I of the 4,5-disubstituted aminoglycoside 
paromomycin by an amino group (neomycin) results in an approximately three-fold 
less active compound with little, if any mistranslation efficacy, revealing the 
importance of the interaction of the 6’ group of ring I with the drug binding pocket. As 
described in the late 1970s, aminoglycosides with a 6’ hydroxyl group in ring I induce 
mistranslation of eukaryotic ribosomes (Wilhelm, Pettitt et al. 1978). Similar, the 6’ 
OH group of ring I in 4,6-disubstituted aminoglycosides gives rise to misreading in 
eukaryotic ribosomes, while a 6’ NH3 group induces little if any mistranslation (Salian, 
Matt et al. 2012). Genetic manipulations of the ribosomal A-site and crystal structures 
of aminoglycosides bound to ribosomes gave further insights. Paromomycin’s 
hydroxyl group at the 6’ position of ring I can accept a hydrogen bond from N1 and/or 
N2 of G1408, which is located in the helix44 of the 18S rRNA. In contrast, the 6’ 
amino group of neomycin cannot interact with G1408 via hydrogen bonds and is 
furthermore sterically repulsed (Pfister, Hobbie et al. 2003, Kondo 2012).  
The read-through data presented here were independently confirmed by studying 
ribosomal misreading (see thesis of Martin Meyer, Böttger group). Misreading was 
measured using a sensitive gain of function assay, i.e. the histidine (CAC) at amino 
acid position 245 in the active center of the firefly luciferase was replaced by an 
arginine, encoded by the near-cognate codon CGC. When arginine is incorporated in 
the active center the enzyme is non-functional. Histidine incorporated by a near-
cognate tRNA at position 245 can restore the enzymatic function of hFluc, i.e. the 
signal of the firefly luciferase is a direct measure of mistranslation. Geneticin, 
paromomycin and gentamicin were the most potent inducer of misreading, whereas 
apramycin and amikacin showed little, if any misreading.  
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7.2 ROS formation by aminoglycosides 
Formation of ROS is a hallmark of aminoglycoside-induced ototoxicity (Forge and 
Schacht 2000) which lead us to investigate a possible link between drug-mediated 
ribosomal malfunction and ROS formation.  
The generation of a gentamicin-Fe2+ complex has been suggested to result in 
aminoglycoside-induced ROS formation. This iron-drug complex activates molecular 
oxygen and reduces it with electrons from a donor like arachidonic acid. Arachidonic 
acid is the main fatty acid in the 2’ position of polyphosphoinositides. As a direct 
consequence, superoxide and lipid peroxides are formed, leading to cell damage. 
The correlation of the binding affinity of aminoglycosides to polyphosphoinositides 
and their ability to cause ototoxicity suggests this as a possible mechanism in vivo 
(Priuska and Schacht 1995, Sha and Schacht 1999, Sha and Schacht 1999). 
Supporting this idea, supplementation of iron in guinea pigs increases 
aminoglycoside ototoxicity (Conlon and Smith 1998). Vice versa, aminoglycoside 
ototoxicity is decreased by antioxidant exposure and iron chelation (Song, Anderson 
et al. 1997, Sha and Schacht 1999).  
We wanted to address the question whether mistranslation or translation inhibition 
leads to increased ROS formation. In a first experiment, ROS generation during 
geneticin treatment was demonstrated and its dependence on the aminoglycosides’ 
anti-ribosomal activity was shown. Inactivation of geneticin’s antiribosomal activity by 
APH(3’)-mediated phosphorylation prevented oxidative stress. Furthermore, ROS 
formation was dependent on a functional mitochondrial respiratory chain as it was 
shown by the 143B and the 143B derived rho-0 cell line. The rho-0 cell line was 
generated by using ethidiumbromide to remove the mtDNA. As a result, rho-0 cells 
possess rudimentary mitochondria, without a functional respiratory chain, due to the 
loss of the 13 mtDNA encoded proteins, which are involved in the respiratory 
complexes I, III, IV and V.  
The HEK data suggest that geneticin-induced oxidative stress is not dependent on a 
proposed aminoglycoside-Fe2+ complex (Priuska and Schacht 1995). ROS in this 
experimental set-up is rather a result of a specific ribosomal impairment and its 
consecutive damages.   
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For further experiments hygromycin B was chosen as an inhibitor of translocation. 
Hygromycin B was found to be the most potent inducer of ROS at relatively low drug 
levels followed by geneticin, gentamicin and neomycin. This hierarchy correlated well 
the corresponding IC50 values, where hygromycin B is the strongest translational 
inhibitor followed by geneticin, gentamicin and neomycin. The data identifying 
hygromycin B as a ROS inducer are in agreement with a publication demonstrating 
that hygromycin B induced oxidative stress in the human retinal pigment epithelial 
cell line ARPE-19 in a dose dependent manner (Hoppe, Chai et al. 2003). As 
described in the literature, geneticin and gentamicin induced oxidative stress in 
mitochondrial and total ROS assays (Sha and Schacht 1999, Villalba, Gomez et al. 
2007).  
The correlation of total ROS levels (measured by CM-H2DCFDA dye) and 
mitochondrial superoxide production (measured by MitoSOX dye) (Fig. 33) suggests 
that mitochondria are the main source of oxidative radical formation. In case of 
mistranslation and subsequent accumulation of misfolded proteins, the upregulation 
of oxidative folding in the ER might also contribute to ROS formation. As a stress 
response, the protein disulfide isomerases (PDIs) in the ER might be upregulated, 
increasing the organelles folding capacity and leading to increased formation of 
hydrogen peroxide.  
Hygromycin B is a universal inhibitor of translation and impairs both the cytoplasmic 
and the mitochondrial ribosome. Incubation of cells using cycloheximide, a specific 
inhibitor of the cytoplasmic translation, resulted in elevated ROS formation. This 
finding indicates that cytosolic translation inhibition is sufficient to result in ROS 
formation and emphasizes that mistranslation is not necessary to induce oxidative 
stress. To test for the contribution of mitochondrial translation inhibition to oxidative 
stress the mitochondrial ribosome-specific inhibitor linezolid was investigated. 
Linezolid induced neither total ROS nor mitochondrial superoxide. Thus, inhibition of 
the mitochondrial ribosome does not induce formation of ROS in vivo under the 
conditions tested.  
7.3 Mistranslation induces unfolded protein responses 
Geneticin induces both mistranslation and translocation inhibition. In contrast, 
hygromycin B induces inhibition of translation. Hygromycin B allowed for the 
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identification of pathways and individual proteins involved in the response to 
translocation inhibition. In contrast, geneticin induced mechanisms which involve 
adaptation to both translation inhibition and misreading. Comparison to hygromycin B 
allowed for the identification of pathways induced by mistranslation. 
A clear difference between geneticin and hygromycin B was found. In the geneticin 
treated samples a predominant upregulation of the folding machinery was detected. 
Thus, the erUPR markers BiP and GRP94 were induced upon geneticin treatment. In 
addition, a strong upregulation of heat shock response components like HSP70 and 
HSPH1 was detected in the cytoplasm and various ER-located isomerases were 
upregulated. These isomerases contribute to the free radical formation in the ER by 
oxidative folding (Araki, Iemura et al. 2013). In total, 17 proteins involved in protein 
folding were enriched in the geneticin treated samples, whereas in the hygromycin B 
treated cells only three chaperones were upregulated. Interestingly, these 3 
chaperones are commonly induced in hygromycin B and geneticin treated samples. 
Upregulation of these three cytosolic chaperones suggests that translation inhibition 
results in a specific stress pattern by production of abnormal proteins, due to 
production of truncated polypeptides. In detail, HSPA8 and HSPH1 are both cytosolic 
chaperones and the latter can inhibit HSPA8. Furthermore, HSPH1 was suggested to 
be involved in protection of cells against oxidative stress. Together with FKBP4 a 
chaperone that can be translocated in mitochondria and protects cells from oxidative 
stress when overexpressed, a common stress response against elevated radical 
formation might be activated. 
It has been suggested, that mistranslation leads to misfolded proteins in higher 
eukaryotes (Drummond and Wilke 2008); the data here demonstrate that 
mistranslation leads to an upregulation of the unfolded protein responses in the ER 
and cytoplasm. In agreement with the proteome data, in yeast paromomycin was 
shown to induce the cytosolic heat shock response marker Hsp70. In contrast, the 
translation inhibitor cycloheximide did not induce Hsp70 (Grant, Firoozan et al. 1989).  
In mitochondria, neither geneticin nor hygromycin B induced chaperones (except 
FKBP4) or proteins of the antioxidant defense. This finding was surprising, because 
the drug concentrations used were shown to increase mitochondrial ROS formation. 
A possible explanation for this finding is the used growth media. Immortalized cell 
lines, as well as cancer cells change their energy metabolism from aerobic 
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respiration to aerobic glycolysis. This metabolic change is called the Warburg effect 
(Hanahan and Weinberg 2011). During the experiments cells were kept in growth 
media with a high glucose concentration. As a result, cells favor aerobic glycolysis 
instead of mitochondrial respiration. Consequently mitochondria are less active in 
respiration and the basal antioxidant defense and chaperone network might be 
capable to cope with the increased mitochondrial stress.  
7.4 Aminoglycosides affect the metabolism of mitochondria 
Mitochondrial metabolic enzymes were downregulated in both geneticin and 
hygromycin B treated cells. Geneticin treatment led to downregulation of enzymes 
involved in carbohydrate (ACAT1, DLAT) and fatty acid metabolism (HADHA, ECI1), 
hygromycin B treatment resulted in downregulation of enzymes involved in 
carbohydrate (ACAT1) and fatty acid metabolism (HADHA). (Carpenter, Pollitt et al. 
1992). Acetyl-CoA acetyltransferase (ACAT1) is involved in both amino acid 
degradation and in fatty acid oxidation catalyzing the conversion of 2-methyl-
acetoacetyl-CoA to propionyl-CoA and acetyl-CoA or the conversion of acetoacetyl-
CoA to two molecules of acetyl-CoA (Huth, Jonas et al. 1975). HADHA is the central 
trifunctional enzyme of -fatty acid oxidation in mitochondria (Carpenter, Pollitt et al. 
1992). It catalyzes three out of four necessary steps of fatty acid oxidation to create 
acetyl-CoA. Acetyl-CoA is a substrate for the mitochondrial citric acid cycle, which 
delivers electrons to the mitochondrial respiratory chain via NADH (Fernie, Carrari et 
al. 2004). This suggests that mitochondrial metabolic activity is downregulated upon 
translation inhibition. As a result, less electrons are delivered to the respiratory chain 
and mitochondrial ATP production in reduced, resulting in reduced ROS formation. 
This decrease of mitochondrial activity helps the cell to reduce the demonstrated 
ROS increase and to resolve the stress condition. The reduced mitochondrial ATP 
production can be readily compensated by glycolysis, because cells were incubated 
in high glucose media. 
7.5 Aminoglycosides upregulate the ubiquitin protease system 
As a response to abnormal protein stress the ubiquitin protease system is 
upregulated (Grant, Firoozan et al. 1989). Both hygromycin B and geneticin 
treatment resulted in an induction of components of the ubiquitin protease system. In 
detail, geneticin treatment resulted in upregulation of the ubiquitin-conjugating 
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enzyme E2 and hygromycin B treatment induced the UBAP2l protein and 
proteasome subunit 6. In yeast, free ubiquitin polypeptides are critical for the survival 
during translation inhibition mediated by cycloheximide or hygromycin B. With a half-
life of 2 h, ubiquitin is rapidly depleted upon translation inhibition. Low levels of free 
ubiquitin result in sensitivity to translation inhibition. In contrast, ubiquitin 
overexpression improves fitness during translocation inhibition (Hanna, Leggett et al. 
2003). Geneticin and hygromycin B presumably promote formation of truncated and 
abnormal proteins, which need to be degraded by the ubiquitin-proteasome pathway 
to avoid cellular intoxication. The levels of free ubiquitin are reduced by binding of 
ubiquitin to abnormal proteins and by subsequent degradation by the proteasome. 
Because recycling of ubiquitin at the proteasome by substrate deubiquitination is not 
100% efficient, the ubiquitin tagged to the substrate becomes expended. We 
hypothesize that in spite of translation inhibition, the translational machinery still can 
synthesize the small 8.5 kDa ubiquitin protein to replenish the decreasing level of 
free ubiquitin.  
7.6 Translocation inhibition upregulates proteins of the translation machinery 
Both hygromycin B and geneticin induced proteins involved in translation initiation, 
elongation factors as well as ribosomal proteins. This finding suggests that the cell 
compensates translation inhibition by increasing the capacity of protein synthesis. In 
order to react to cellular damage stress-related proteins must be synthesized. Thus, 
a residual functional protein synthesis is crucial for cellular survival (Ventoso, 
Kochetov et al. 2012). The upregulation of the translation machinery seems to be a 
specific adaptation to a prolonged translation inhibition.  
Interestingly, proteins upregulated in hygromycin B-treated cells are mainly 
elongation factors, whereas in geneticin-treated cells, initiation factors were primarily 
upregulated. In the geneticin-treated samples the erUPR is activated and the EIF2A 
initiation factor is phosphorylated (p-EIF2A) by PERK (See Chapter 9, Fig.3). The 
phosphorylated EIF2A leads to a decrease in translation initiation by inhibiting EIF2B 
activity and subsequent loss of ternary complexes. In addition, the phosphorylation of 
EIF2A initiates the assembly of stress granules, which are discrete cytoplasmic foci 
where untranslated mRNAs are sequestered (Kedersha, Gupta et al. 1999). In 
geneticin treated cells, the initiation factors EIF1B and EIF3A, part of the 43S PIC 
and EIF4A, involved in mRNA recruitment to the ribosome, are upregulated, 
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suggesting a compensatory response to inhibition of translation initiation. In contrast, 
hygromycin B treated cells show an enrichment of the elongation factors subunits 
EEF1A1, EEF1G and EEF2. This upregulation might represent a compensatory 
response to drug-induced translocation inhibition, by increasing the efficacy of 
translocation by overexpressing elongation factors.  
7.7 Conclusion 
Taken together, aminoglycosides stress eukaryotic cells by impairing translation 
fidelity and efficiency. Inhibition of cytosolic translation leads to oxidative stress and 
changes in the metabolic activity of mitochondria; mistranslation results in activation 
of the cytosolic heat shock response and the erUPR. In case of geneticin more than 
75% of upregulated proteins are involved in protein metabolism (folding, translation, 
degradation and signaling) indicating a strong response against mistranslation. 
Treatment with the translocation inhibitor hygromycin B did not result in a broad 
upregulation of the folding machinery; however, parts of the translational apparatus 
were upregulated. In detail, a distinct pattern is observed: geneticin treatment 
resulted in an upregulation of initiation factors possibly to compensate inhibition of 
translation initiation by erUPR mediated p-EIF2A and hygromycin B treatment 
resulted in upregulation of elongation factors to compensate translocation inhibition.  
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9 XBP1 mitigates aminoglycoside-induced endoplasmic 
reticulum stress and neuronal cell death. 
Naoki Oishi, Stefan Duscha, Heithem Boukari, Martin Meyer, Jing Xie, Gao Wei, 
Thomas Schrepfer, Bernd Roschitzki, Erik C. Boettger, and Jochen Schacht 
Abstract 
Here we study links between aminoglycoside-induced mistranslation, protein 
misfolding, and neuropathy. We demonstrate that aminoglycosides induce 
misreading in mammalian cells and assess ER stress and unfolded protein response 
(UPR) pathways. Genome-wide transcriptome and proteome analyses revealed 
upregulation of genes related to protein folding and degradation. Quantitative PCR 
confirmed induction of UPR markers including CHOP, GRP94, BiP, and XBP1 mRNA 
splicing, which is crucial for UPR activation. We studied the effect of a compromised 
UPR on aminoglycoside ototoxicity in haploinsufficient XBP1 (XBP1+/-) mice. Intra-
tympanic aminoglycoside treatment caused high-frequency hearing loss in XBP1+/- 
mice but not in wild-type littermates. Densities of spiral ganglion cells and synaptic 
ribbons were decreased in gentamicin-treated XBP1+/- mice, while sensory cells were 
preserved. Co-injection of the chemical chaperone tauroursodeoxycholic acid 
attenuated hearing loss. These results suggest that aminoglycoside-induced ER 
stress and cell death in spiral ganglion neurons is mitigated by XBP1, masking 
aminoglycoside neurotoxicity at the organismal level. 
 
Introduction 
Translational fidelity is maintained throughout all three domains of life (archea, 
bacteria, eukaryota), suggesting a high selective pressure during evolution to 
minimize errors in protein synthesis.1 In bacteria, erroneous protein synthesis 
induces protein misfolding.2 In higher eukaryotes, protein misfolding results in 
endoplasmatic reticulum (ER) stress and initiates the unfolded protein response 
(UPR), a cascade of integrated pathways regulating gene expression. The UPRER is 
mediated by three ubiquitously expressed transmembrane proteins in the ER: 
inositol-requiring enzyme 1 (IRE1), PKR–like ER kinase (PERK), and activating 
transcription factor 6 (ATF6).3-7 Under normal conditions, the luminal domains of 
IRE1, PERK, and ATF6 are bound by the ER chaperone binding immunoglobulin 
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protein (BiP) which inhibits self-dimerization and activation of the cytosolic domain.8,9 
Under ER stress, BiP is released resulting in dimerization of IRE1 and ATF6 and 
multimerization of PERK, initiating the UPR signaling cascades.8,9 The initial UPR 
response is protective, increasing the expression of chaperone proteins promoting 
refolding and, if unsuccessful, the degradation of misfolded proteins.10-13 Prolonged 
or severe stress triggers additional pathways that eventually lead to cellular 
apoptosis.14-16 
Aminoglycoside antibiotics are well known to affect translational fidelity in bacteria 
and lower eukaryotes17-20 but only few reports suggest that aminoglycoside antibiotics 
may also induce misreading in higher eukaryotes.21-23 Aminoglycoside-mediated 
read-through activity has been exploited for therapy of human genetic diseases 
associated with premature stop codons.24-27 In addition, aminoglycosides have been 
shown to induce apoptosis in human cell cultures accompanied by ER stress and 
mitochondrial cytochrome c release.28,29 It was suggested that the observed ER 
stress may be the result of protein misfolding, reflecting aminoglycoside-induced 
mistranslation.28 Despite this potential for misreading induced by aminoglycosides in 
eukaryotes, aminoglycoside treatment in animal models and in patients is well 
tolerated. Side effects are highly organ-specific, limited to the kidney and the inner 
ear,30 while toxicity to the nervous system is not evident even in long-term 
aminoglycoside treatment.31 In the case of ototoxicity, the primary drug target are the 
sensory hair cells, as convincingly demonstrated in various animal models, 
regardless of whether the drug is given systemically32 or directly introduced into the 
cochlea.33 Degeneration of spiral ganglion cells observed after ototoxic dosages of 
aminoglycosides are thought to occur only as a sequel to the loss of sensory hair 
cells in the vast majority of cases. Surprisingly, however, a few analyses of human 
temporal bones have suggested that spiral ganglia can be affected by 
aminoglycosides without overt insult to the hair cells.34,35 This rare pathology, 
unexplained by the treatment modus, suggests individual variability possibly based 
on genetic factors. 
Prompted by the anecdotal reports of aminoglycoside-induced selective spiral 
ganglion damage, the objective of this study was to assess the contribution of ER 
stress to ototoxicity. We first investigated aminoglycoside-induced misreading and 
UPR responses in HEK293 cells in vitro. Next, we examined the role of ER stress in 
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ototoxicity in cochlear organ cultures of CBA/J mice. Finally, we employed an in-vivo 
mouse model36 with a compromised ER stress response due to XBP1 
haploinsufficiency37 in order to probe potential links between aminoglycoside 
neurotoxicity, translation fidelity and protein misfolding. 
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Results 
Aminoglycosides alter translation fidelity. Drug-induced inhibition of translation 
was used to assess aminoglycoside activity on the eukaryotic ribosome. IC50 values 
were 0.3 μM for geneticin and 9.8 μM for gentamicin in the cell-free translation 
assays with rabbit reticulocyte lysate (RRL), and 4.4 μM for geneticin and 812 μM for 
gentamicin in assays with intact HEK293 cells (Supplementary Figure S1a and b). 
The ability of the drugs to induce mistranslation was analyzed using sensitive gain-of-
function dual-luciferase assays to assess near-cognate misreading and stop-codon 
read-through. Near-cognate misreading was studied using constructs with 
substitution of amino acid 245 in the active site of mutated firefly luciferase (wild-type 
His CAC → near-cognate Arg CGC), which results in loss of enzymatic activity with 
enzymatic function restored by misreading; stopcodon read-through was determined 
using constructs with in-frame stop codons abolishing firefly luciferase activity. Both 
geneticin and gentamicin decreased ribosomal accuracy in cell free translation 
assays (RRL) and in HEK cells in a dose-dependent manner (Figure 1). Misreading 
 
 
Figure 1 Aminoglycoside-induced mistranslation. (a–b) Misreading and (c–d) read-through 
measured in rabbit reticulocyte lysate (RRL; a,c) and HEK wild-type cells (b,d). Results are derived 
from the ratio hFluc/hRluc, given in -fold induction. Untreated samples are set as 1 (n = 3; ± SEM). 
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 was induced up to 25-fold in RRL and up to 8.5-fold in HEK cells compared to 
untreated controls; read-through was induced up to 20-fold in RRL and up to 70-fold 
in HEK cells compared to untreated controls (Figure 1). In HEK cells transfected with 
the aminoglycoside phosphotransferase APH(3'), the geneticin-induced but not the 
gentamicin-induced translation inhibition and mistranslation were abrogated 
(Supplementary Figure S1c and d), consistent with the selectivity of the enzyme to 
inactivate geneticin but not gentamicin.38,39 Aminoglycoside-treated and untreated 
HEK wild-type cells showed similar metabolic activities and viability (Supplementary 
Figure S1e and f). 
Aminoglycosides induce genome-wide upregulation of cellular folding 
capacity. In order to study the cellular response to aminoglycoside-induced 
mistranslation, we used whole genome transcriptomic and proteomic analyses. A 
microarray analysis of geneticin-treated versus untreated cells revealed a broad 
transcriptional response totaling 705 genes (selected for a fold change >1.2, 
Benjamini-Hochberg corrected p-value <0.05; Supplementary Figure S2a). Protein 
folding and transcription were among the most enriched functional ontologies 
(Supplementary Figure S2b), including the induction of the ER-specific chaperones 
BiP (HSPA5), glucose-regulated protein 94 (GRP94; HSP90B1), calreticulin (CALR), 
GRP110 (HYOU1), ERdj3 (DNAJB11), and ERdj6 (DNAJC3), the ER foldases PDIA3 
(ERp57), PDIA4 (ERp70), Erp44, and FKBP7, and the N-linked glycosylation factor 
SDF2L1. Likewise, ER-associated degradation (ERAD) components such as VCP 
(p97), Derlin2 (DERL2), and Herp (HERPUD1) were significantly upregulated 
(Supplementary Figure S2c). This transcriptional response indicates a general 
increased folding and degradation capacity in the ER. In addition, a large number of 
cytosolic chaperones40 were upregulated, such as members of the Hsp40, Hsp70, 
Hsp90, and Hsp110 families and to a lesser extent foldases (peptidyl-prolyl cis/trans 
isomerases and protein disulfide isomerases; Supplementary Figure S2d and e), 
indicating an increased folding capacity in the cytosol. Table S1 lists the genes 
included in the analysis. The microarray data have been deposited in NCBI's Gene 
Expression Omnibus and are accessible through GEO Series accession number 
GSE57198 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57198).  
 Proteome analysis found 77 proteins to be regulated by geneticin (Bonferroni-
corrected p-value <0.05). When applying a minimum fold induction of 0.3 (log2 scale) 
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we identified 35 proteins that were upregulated. Grouping according to function 
revealed a predominance of proteins involved in protein folding (Figure 2a). Proteins 
associated with the ER and cytoplasmic UPR, such as BiP, GRP94, calreticulin, 
foldases, and members of the Hsp70, Hsp90, Hsp110, and Hsp40 families, were also 
upregulated (Figure 2b). Comparison with corresponding mRNA levels showed an 
upregulation of the folding machinery both at the transcriptomic and the proteomic 
level (Figure 2c). The mass spectrometry proteomics data have been deposited to 
the ProteomeXchange Consortium via the PRIDE partner repository with the dataset 
identifier PXD000933 and DOI 10.6019/PXD000933. 
 
 
 
 
 
Aminoglycosides induce the UPR. To corroborate the results of the microarray 
analysis, mRNA levels of selected UPR genes were further analyzed by quantitative 
PCR and corresponding protein levels were assessed by Western blotting. Geneticin 
Figure 2 Proteomic analysis of geneticin-treated HEK wild-type cells. (a) Thirty-five upregulated 
proteins were grouped according to their biological function (Bonferroni corrected p-value < 0.05, log2 
FC > 0.3). (b) Upregulation of the geneticin-induced heat-shock proteins, chaperones, and foldases 
(Bonferroni corrected p-value < 0.05, log2 FC > 0.3). (c) Comparison of the significantly regulated 
proteins (Bonferroni corrected p-value < 0.05) and their corresponding mRNA fold-induction. The 
upregulated proteins of the folding machinery are shown in red. 
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and gentamicin induced mRNA expression of C/EBP homologous protein (CHOP), 
GRP94, and BiP in a time-dependent manner (Figure 3a–c). Increased protein levels 
of the two ER chaperones BiP and GRP94 as well as the transcription factor ATF4, 
which is regulated at the translational level,41 were observed in geneticin- and 
gentamicin-treated cells by Western blotting (Figure 3e). As a further element of the 
UPR, we studied splicing of XBP1 mRNA, which is central for UPR activation11. Both 
geneticin and gentamicin induced XBP1 splicing (Figure 3d). In contrast, XBP1 
splicing is induced neither by the non-misreading aminoglycoside hygromycin42 nor 
by cycloheximide, an inhibitor of ribosomal translocation,43 indicating that XBP1 
splicing depends on misreading and not on inhibition of translation. Furthermore, the 
presence of APH(3‘) in HEK cells abrogated geneticin-induced but not gentamicin-
induced XBP1 splicing.  
The activity of transcription factors XBP1 and ATF6 was examined using reporter 
plasmids UPRE (p5xATF6-GL3-luc) and ERSE (pGL3-GRP78P(-132)-luc).44,45 The 
UPRE reporter is specific for ATF6 activity, the ERSE reporter is regulated by both 
ATF6 and XBP1.44,45 Both reporters showed a robust induction by geneticin and 
gentamicin (Figure 3f and g). Cycloheximide failed to induce any reporter activity 
consistent with the XBP1 splicing results (Figure 3d, 3f, 3e). The PERK signaling 
branch was investigated by assessing the formation of stress granules, cytosolic 
protein aggregates composed of 48S preinitiation complexes and other factors. 
Stress granules are induced upon activation of PERK and phosphorylation of 
eIF2α.46 Treatment of HEK wild-type cells with geneticin for 24 h increased 
immunostaining of p-eIF2α in a dotted cytosolic distribution indicative of stress 
granules (Figure 3h). Arsenite treatment served as a positive control. A similar robust 
induction of UPR by aminoglycosides was observed in Hela cells (Figure S3). 
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Figure 3 Aminoglycosides induce the UPR. (a–c) qPCR analysis. HEK wild-type cells were treated with 
geneticin (16 μM) or gentamicin (400 μM) and incubated for the indicated times. Expression of CHOP (a), 
BiP (b), and GRP94 (c) mRNA is shown. Three biological replicates were each run in triplicate assays and 
means + SD of fold induction relative to 0 h (untreated) sample are presented; *P<0.05; **P<0.01; ***P< 
0.005; ****P<0.001. (d) XBP1 splicing assay. HEK wild-type or HEK aph(3’) cells were treated with 
geneticin (16 μM), gentamicin (1250 μM), hygromycin (2 μM), cycloheximide (2 μM), tunicamycin (5 μg/mL) 
for 24 h or left untreated. NTC: no template control. Products of XBP1 PCR were analyzed by gel 
electrophoresis; unspliced and spliced versions of XBP1 are indicated. Tunicamycin was a positive control 
to induce ER stress; GAPDH was a loading control. The asterisk indicates the position of a hybrid amplicon 
(ref 15). (e) Western blot analysis. HEK wild-type cells were treated with geneticin (16 μM) or gentamicin 
(400 μM) and incubated for 24 h. 10 μg of total protein were loaded and BiP, GRP94 and ATF4 were 
detected by immunoblotting using specific antibodies. β-actin was used as a loading control. Tunicamycin 
(2.5 µg/mL) was used as a positive control. (f-g) Reporter assays. HEK cells were transfected with 
luciferase reporter plasmids (f) UPRE (reporter for ATF6 activity) or (g) ERSE (reporter for ATF6 and XBP1 
activity). Cells were treated with geneticin (16 µM) or gentamicin (800 µM) for 24 h. Cycloheximide (16 µM) 
was used as a negative control, tunicamycin (2.5 µg/mL) was used as a positive control for UPR. Luciferase 
activities were determined and the Fluc/Rluc ratios were calculated. Untreated samples are set as 1 and 
fold inductions are given (n = 3-6, ± SEM). **P<0.01, ***P<0.005. (h) Stress granule formation. HEK wild-
type cells were treated with geneticin (16 μM) for 24 h or arsenite (0.5 mM) for 1 h as a positive control. 
Phosphorylated eIF2α was detected by immunofluorescence. Scale bars: 40 μm. The lower panels show 
insets in higher magnification. Bar graph indicates quantification of peIF2α immunofluorescence (n number 
of cells; nuntreated = 540; ngeneticin = 249; narsenite = 648); ****P<0.001. Gen: Geneticin; Gm: Gentamicin; Hyg: 
Hygromycin; Tm: Tunicamycin; CHX: Cycloheximide; Ars: Arsenite; Un: Untreated. 
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Gentamicin induces ER stress in spiral ganglion cells but not in auditory hair 
cells. To study the response of auditory hair cells to ER stress, we first employed 
tunicamycin, an established ER stress-inducer in early post-natal cochlear explants 
of the CBA/J mouse, a common strain for auditory research. Preliminary experiments 
(data not shown) with hair cell counts on surface preparations had established 
incubation with 0.07 μg/mL tunicamycin as a suitable treatment with hair cell death 
beginning at 48 h and progressing to 50% of cells by 72 h. The ER-stress-associated 
pro-apoptotic factor CHOP already appeared after 8 h of incubation with tunicamycin 
and was expressed in the nuclei of most hair cells by 24 h (Figure 4a and 
Supplementary Figure S4). Staining mostly had disappeared at 48 h (Supplementary 
Figure S4) when loss of hair cells became apparent, implicating CHOP in hair cell 
death. In the same explant model, treatment with gentamicin caused significant loss 
of hair cells with the pattern of loss showing the typical progression of 
aminoglycoside damage47 with most destruction in the base (Supplementary Figure 
S5) while inner hair cells were mostly spared. Despite continuing and increasing cell 
death, CHOP was not observed throughout the entire time course up to 72 h (Figure 
4a).  
The response of ganglion neurons to ER stress was studied in spiral ganglion cells 
(SGCs) that were harvested from the base to the middle of the modiolus of cochlear 
explants and similarly treated with tunicamycin or gentamicin (Figure 4b). As 
expected from its activity as an ER stressor, tunicamycin induced CHOP in the nuclei 
of SGCs within 24 h. In contrast to its effect on hair cells, gentamicin increased the 
immunoreactivity to CHOP in SGCs, evident after 48 h of incubation. 
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Gentamicin reduces spiral ganglion cells and synaptic ribbons but not hair 
cells in XBP1+/- mice in vivo. In wild-type strains such as the CBA/J mouse, the 
OHCs are the primary target of chronic aminoglycoside ototoxicity in and very little 
direct effect—if any—can be observed on SGCs. In view of the modest but significant 
gentamicin-induced CHOP expression in SGCs of cochlear explants, we investigated 
potential gentamicin-induced ER stress in a model of compromised UPR, an XBP1-
haploinsufficient mouse. The local route of drug administration to the middle ear, 
chosen for this study, is able to isolate effects to the auditory periphery while avoiding 
Figure 4  ER stress in cochlear tissues. (a) Tunicamycin but not gentamicin causes ER stress in 
hair cells. Tunicamycin (0.07 μg/mL) induced the specific ER stress-associated pro-apoptotic factor, 
CHOP (green), in the nuclei of hair cells in organ of Corti explants by 24 h but was not observed in 
any part of the organ of Corti throughout the entire time course of gentamicin treatment (3.5 µM) until 
hair cell death. Segments shown are from the basal turn. Green: CHOP, red: Myo 7a, blue: Hoechst 
33342 staining for nuclei. The figure represents three different explants at each time point; focal plane 
is the nuclear level of outer hair cells. Scale bar (Gm): 10 μm. (b) Gentamicin induces ER stress in 
spiral ganglion cells (SGCs). Tunicamycin (0.07 μg/mL) treatment for 24 h induced CHOP in the 
nuclei of SGCs (arrows). With gentamicin (3.5 μM) treatment, CHOP appeared in the nuclei of SGCs 
by 48 h (arrows). Green: CHOP, red: neuronal class III β-tubulin staining for SGCs, blue: Hoechst 
33342 staining for nuclei. The figure represents three different explants at each time point. Scale bar, 
10 μm. 
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adverse complications associated with systemic gentamicin treatment in the 
mouse.30   
 
 
 
 
 
 
 
 
 
 
 
Figure 5 Gentamicin reduces the number of SGCs and IHC synapses in XBP1
+/-
 mice. Gentamicin 
(0.56 M) was locally injected into the middle ear through the bulla as described in the Methods section 
“Drug administration in vivo.” (a,b) Gentamicin reduces SGCs in XBP1
+/-
 but not in wild-type (XBP1
+/+
) 
littermates. (a) The number of SGCs was counted from high-magnification images of Rosenthal’s canal 
of saline- and gentamicin-injected wild-type and XBP1
+/-
 mice. Red: neuronal class III β-tubulin staining 
for neural cells, blue: Hoechst 33342 staining for nuclei. The figure represents five different animals at 
each condition. Scale bar: 50 µm. (b) Quantitative evaluation revealed that SGC density in the basal 
turn of XBP1
+/-
 mice but not in wildtype mice was significantly decreased by gentamicin. Filled bars, 
controls; open bars, gentamicin treatment. n = 5 in each group; **P<0.01. Middle and apical turns were 
not affected. (c,d) Gentamicin reduces synaptic ribbons in XBP1
+/-
 but not in wild-type mice. (c) Hair 
cells were stained with anti-Myo7 antibodies (red) and synaptic ribbons with antibodies to CtBP2 
(green). The number of synaptic ribbons per IHC in the basal turn was quantified from 3-D images 
created by using Imaris software. Staining of some nuclei is consistent with a partial nuclear localization 
of this protein,
66
 which has also been confirmed for IHCs.
67
 The figure represents three different 
animals at each condition. Scale bar: 20 µm. (d) Quantitative evaluation demonstrated that synaptic 
ribbon density of XBP1
+/-
 mice but not of wildtype littermates was diminished by local injection of 
gentamicin. Filled bars, controls; open bars, gentamicin treatment. n = 3 in each group; **P<0.01 
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Preliminary experiments with a series of gentamicin concentrations starting at 0.09 M 
established 0.56 M as a suitable dose that caused a moderate threshold shift while 
avoiding major pathology (data not shown).  
Surface preparations from XBP1+/- and wild-type littermates treated with gentamicin 
in vivo were examined from base to apex three weeks after drug injection. OHCs 
were present in all parts of the cochlea in both wild-type and XBP1+/- mice except for 
scattered loss at the very end of the basal turn (Supplementary Figure S5c). 
Quantitation of hair cell loss along the entire cochlea confirmed only minor damage at 
the extreme the basal turn with no difference between wild-type and XBP1+/- mice. 
In the absence of any discernible defects on hair cell integrity and prompted by the 
in-vitro results, we then analyzed spiral ganglion density and synaptic connections. 
Three weeks after gentamicin injection, the SGCs were counted on mid-modiolar 
cryosections stained for β-tubulin and nuclei. There was a significant reduction in 
spiral ganglion density in the basal turn of the cochlea in XBP1+/- mice but not in wild-
type littermates (Figures 5a and 5b). The innervation of hair cells by the spiral 
ganglion was assessed by staining synaptic ribbons with antibody to CtBP2, a 
constituent of the ribbon protein RIBEYE. The number of synaptic ribbons per IHC 
was reduced by approximately 50% in the basal turn of the cochlea of the XBP1+/- 
mice but not of corresponding wild-type littermates (Figures 5c and 5d). 
Auditory physiology corroborates auditory pathology and ER stress. In order to 
assess the impact of the observed pathology on auditory function, we measured 
auditory brain stem responses (ABR) and distortion product otoacoustic emissions 
(DPOAE). ABR provides information on the ascending auditory pathway reflecting 
synaptic and neuronal activity, while DPOAE probes the functional integrity of outer 
hair cells. Deterioration of auditory thresholds was apparent one week after the 
injection of gentamicin and remained stable for up to three weeks, the latest time 
point studied (Figure 6a). Large threshold shifts were observed at 32 kHz in XBP1+/- 
mice but not in wild-type littermates, which were little affected. Consistent with the 
morphological observations of intact outer hair cells, DPOAE remained unaffected by 
gentamicin treatment (Supplementary Figure S6).  
Finally, in order to validate the potential contribution of protein misfolding to the 
changes in auditory thresholds, we treated animals with TUDCA, a clinically used 
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chemical chaperone. Systemic TUDCA co-administration significantly attenuated 
gentamicin-induced ototoxicity in the XBP1+/- mice (Figure 6b) as measured by ABR 
three weeks after the drug treatment. 
 
Figure 6 Auditory threshold shifts 
induced by gentamicin. (a) 
Gentamicin (0.56 M) was locally 
injected into the middle ear through the 
bulla as described in ‘Methods’. Three 
weeks after treatment, large threshold 
shifts had developed at 32 kHz in 
XBP1
+/-
 mice (square symbols) but not 
in wild-type littermates (circles). Data 
are presented as mean + SD for 
XBP1
+/-
 mice and mean - SD for wild-
types. n = 6 in each group; **P<0.01.  
(b) TUDCA attenuates gentamicin 
ototoxicity in XBP1
+/-
 mice. Animals in 
all three groups received the local 
injection of gentamicin and, as 
indicated, TUDCA co-treatment (500 
mg/kg i.p. at 6 d, 3 d, and 3 h before 
gentamicin injection). Data are 
presented as means + SD of threshold 
shifts at 32 kHz, determined three 
weeks after treatment. n = 6 in each; 
**P<0.01 
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Discussion 
Aminoglycoside-induced loss of translational fidelity in eukaryotes is evident from our 
experiments on HEK293 cells and, moreover, is clearly linked to the ribosomal 
activity of the drugs. We have primarily chosen HEK293 cells for study as these cells 
are readily transfected, facilitating the use of reporter constructs to study drug-
induced misreading.49 However, we have obtained similar results in human Hela 
cells. The known misreading-inducers geneticin and gentamicin, but not hygromycin 
or cycloheximide, elicit a UPR. Gentamicin was selected as a classical clinical 
aminoglycoside to bridge the findings from our in-vitro studies to the animal model. 
Geneticin was included because its inactivation by the APH(3‘) enzyme allowed to 
control for the specificity of drug action.39 Modification of geneticin by APH(3‘) (which 
abrogates its anti-ribosomal activity by phosphorylation of the 3‘ OH group) 
eliminates the ability of geneticin to cause both misreading and ER stress. In 
contrast, APH(3‘) did not affect the misreading activity of gentamicin, which lacks the 
3‘ OH group and thus is not a target for APH(3‘). The finding that the cell viability and 
the metabolic activity of HEK wild-type cells remain intact despite drug-induced 
mistranslation attests to the protective efficacy of cellular homeostatic responses 
such as the UPR and allows us to extrapolate that the UPR, at least in part, mitigates 
mistranslation induced by aminoglycosides in eukaryotic organisms. 
Consistent with this notion, XBP1+/- haploinsufficient mice but not wild-type mice 
sustain gentamicin-induced loss of SGCs. XBP1 is one of the central components in 
the three main pathways of the UPR, regulating molecular chaperones and 
promoting ER-associated degradation.50 The crucial function of XBP1 for cell survival 
is indicated by embryonic lethality of homozygous XBP1 knock-out mice.37 
Haploinsufficient mice are viable but are less capable of inducing chaperones and 
promoting ERAD under ER stress conditions.51 Consequently, ER stress is prone to 
damage cells in XBP1+/- but not in wild-type mice. 
Oxidative stress is a major factor in the pathomechanism of aminoglycoside 
ototoxicity,48 but evidence for an involvement of ER stress has been only indirect or 
lacking. Upregulation of heat shock proteins protects the mouse cochlea in part from 
aminoglycoside-induced ototoxicity in vivo.52 However, the ER stress marker m-
calpain is unaffected by aminoglycoside treatment in the mouse cochlea in vivo.53 
Despite the extensive loss of hair cells that gentamicin can cause in cochlear 
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explants, no ER stress marker develops there. This is in contrast to their induction 
with the ER stressor tunicamycin, a finding consistent with previous observations of 
tunicamycin-induced hearing loss in the rat.54 Further distinguishing the pathological 
effects of the two drugs, the damage caused by tunicamycin broadly encompasses 
all regions of the cochlea while the pattern of gentamicin-induced damage in the 
explants follows the base-to-apex gradient characteristic of aminoglycosides.48  
Our results clarify that aminoglycoside-induced ER stress in the cochlea is limited to 
neurons of the spiral ganglion. In the in-vivo model, the local application of a single 
low dose of gentamicin does not lead to hair cell death. However, spiral ganglion 
cells were significantly reduced in the base of the cochlea, corroborating the in-vitro 
results on ER stress in the nerve but not in hair cells. Gentamicin-induced ER stress 
has also been observed in rat kidneys in vivo as part of its nephrotoxic actions,55 a 
result in agreement with our findings that aminoglycosides are capable of inducing 
ER stress in mammalian tissues. In accord with a gentamicin-reduced density of 
spiral ganglion cells, synaptic connections to hair cells are lost, providing an 
explanation for the observed high-frequency hearing loss.  
The selective actions of gentamicin on spiral ganglion cells and synapses suggest a 
heightened sensitivity to neurodegeneration in the XBP1+/- haploinsufficient mice in 
contrast to the more common pathology of hair cell loss. It is interesting in this 
context that a loss of afferent nerve terminals and subsequent degeneration of the 
cochlear nerve has also been observed after moderate noise exposure that leaves 
the sensory cells intact.56  
On a mechanistic level, disruption of translational fidelity causes protein misfolding 
and aggregation. The ability of XBP1 to maintain cell integrity upon drug-induced 
mistranslation appears to be mediated by induction of ER chaperones such as BiP, 
which we also find to be upregulated in response to aminoglycoside challenge. On an 
organismal level, protein misfolding has been associated with a variety of disorders 
collectively termed conformational diseases.57 Presumably, cell-type specific 
differences in the buffering capacity of the proteostasis network account for the cell- 
or organ-selectivity in some of these diseases.58 Aminoglycoside-induced death of 
hair cells has previously been associated with inhibition of host-cell protein 
synthesis47,59 and oxidative stress.48 The hypothesis presented here that 
aminoglycoside-induced loss of SGCs in XBP1+/- haploinsufficient mice is conferred 
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by the drug‘s misreading activity is supported by the observation that administration 
of a chemical chaperone significantly alleviated the hearing loss. Specifically, we 
postulate that the UPR is normally able to maintain a protein folding equilibrium in the 
presence of aminoglycoside-induced mistranslation in SGCs. However, when the 
UPR system is compromised, e.g. by genetic haploinsufficiency of XBP1, 
aminoglycoside-induced mistranslation can manifest as neuropathology. 
  
Manuscript  97 
  
 
EXPERIMENTAL PROCEDURES 
Materials and sources. Monoclonal anti-GADD 153 antibody, Santa Cruz 
Biotechnology (Dallas, TX, USA); polyclonal antibody against neuronal class III β-
Tubulin, Covance (Princeton, NJ, USA); monoclonal anti-CtBP2 antibody, BD 
Biosciences (San Jose, CA, USA); polyclonal antibody against p-eIF2α, Cell 
Signaling (Danvers, MA, USA); polyclonal anti-myosin7a antibody (Proteus 
Biosciences, Ramona, CA, USA); secondary goat anti-rabbit antibody conjugated 
with Texas Red, Abcam (Cambridge, MA, USA); rhodamine phalloidin, Invitrogen 
(Life Technologies, Carlsbad, CA, USA); HEK293 cells, Innoprot (Biscay, Spain); 
geneticin, gentamicin, tunicamycin, cycloheximide, arsenite, saponin, and HEK 
aph(3’) cells, Sigma Aldrich (St. Louis, MO, USA); hygromycin, PAA Laboratories 
(Cansera, Canada); nucleotide primers, Microsynth (Balgach, Switzerland); cell 
culture media and trypsin, Life Technologies (Carlsbad, CA, USA).  
Assessment of mistranslation. Misreading and stop-codon read-through were 
assessed in gain-of-function dual luciferase assays.60,61 For translation in rabbit 
reticulocyte lysates (RRL, Promega, Madison, WI, USA), luciferase mRNA was 
produced in vitro using T7 RNA polymerase (Thermo Scientific, Waltham, MA, USA) 
and plasmids pGL4.14 (firefly luciferase, hFluc) and pGL4.75 (renilla luciferase, 
hRluc; both from Promega), where the mammalian promoter was replaced by the T7 
bacteriophage promoter. For misreading, we replaced residue His245 (CAC codon) 
with Arg245 (CGC near-cognate) in the hFluc protein by site-directed mutagenesis. 
Read-through was assessed with a fusion construct in which hRluc and hFluc were 
fused by a 27-nucleotide linker encoding the polypeptide STCDQPFGF, using 
overlap PCR mutagenesis to result in the pT7 hRluc-hFluc vector; a UGA nonsense-
codon was introduced at the glutamine residue (wild-type CAA) of the linker 
sequence by site-directed PCR mutagenesis. A cell-free luciferase translation assay 
was performed as described.51  Mistranslation in HEK cells was determined using 
the pRM hRluc-hFluc H245R vector, where His245 (CAC codon) was replaced by 
Arg245 (CGC codon) in the pRM hRluc-hFluc vector. Read-through was determined 
by pRM hRluc-hFluc D357X, where Asp357 (GAC codon) was replaced by a UGA 
nonsense-codon in the firefly luciferase transcript. Both constructs were designed by 
site-directed PCR mutagenesis. HEK wild-type cells were transfected with reporter 
plasmid using TurboFect (Fermentas) according to the manufacturer‘s protocol. After 
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a 24-h incubation, medium was replaced by F10 with 15 μg/mL saponin. 
Aminoglycoside antibiotics were added and cells were incubated for another 24 h. 
Cells were lysed and luciferase activities determined; hRluc mRNA was used as an 
internal control and misreading and read-through were quantified by calculating 
mutant firefly/renilla activities. The basal error frequency of the eukaryotic ribosome 
is 4 x 10-4 to 10-5.62 For each set of replicates, the hFluc/hRluc ratio of the untreated 
samples were set as 1, which reflects this basal error frequency. Luminescence was 
measured in a luminometer FLx800 (Bio-Tek Instruments, Winooski, VT). 
Viability assay. HEK cells were grown to 70% confluence and treated with 16 µM 
geneticin or 400 µM gentamicin in F10 medium with 15 µg/mL saponin for the 
indicated time. Ten-percent Alamar Blue solution was added (v/v) for 3 h and 
fluorescence was monitored at 530 nm for excitation and 590 nm for emission. The 
fluorescence level of the control sample (untreated) was set as 100% after 
subtraction of background fluorescence, measured in cell-free wells. 
Sytox dead cell stain. HEK cells were grown to 60% confluence in DMEM with 10% 
FBS. Medium was changed to F10 with 15 µg/mL saponin and aminoglycoside 
antibiotics were added and cells were incubated for 24 h or 48 h. Cells were 
detached by adding 100 µL accutase (Life Technologies) and were resuspended in 
400 µL FACS buffer (1x PBS, 2% FBS) and transferred to FACS tubes. Sytox Red 
(Life Technologies) was added to the cell suspension. The nucleic acid stain 
penetrates cells with compromised plasma membranes but will not cross 
uncompromised cell membranes. The samples were then analyzed with a BD FACS 
Canto II and the FlowJo data analysis software. 
Microarray analysis. See legend to Supplemental Figure S2.  
Proteome analysis. Cell samples were incubated with lysis buffer (150 mM NaCl, 
0.1% SDS, 0.5% Na-deoxycholate, 50 mM Tris pH 7.5, and 1× complete protease 
inhibitor (Roche)) for 10 min at RT on a shaking mixer. The lysate was ultrasonicated 
for 10 min and centrifuged for 20 min at 16,000 × g at 4 °C. Eighty micrograms of 
protein of each sample were used for iTRAQ labeling (AB SCIEX).  
 Each iTRAQ 4-plex experiment was carried out with two biological replicates 
of untreated HEK wild-type cells (114 and 116 label) and two biological replicates of 
cells treated with 16 µM geneticin for 32 h (115 and 117 label) following the 
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manufacturer's protocol. iTRAQ samples were pooled, dried, reconstituted in solvent 
A (5% ACN, 8 mM KH2PO4, pH 4.5), and fractionated by HILIC-HPLC (Pack 
Polyamine II, 250 × 4 mm, 120 Å S-5 µm, YMC). The column was equilibrated with 
solvent A. Peptides were eluted using solvent B (5% ACN, 100 mM KH2PO4, pH 4.5) 
by a gradient of: 0–7.5 min, 0% B; 7.5–37.5 min, 0–50% B; 37.5–42.5 min, 50–100% 
B; 42.5–47.5 min, 100% B at a flow rate of 0.4 mL/min. The resulting 13 fractions 
were desalted using ZipTips (Millipore) according to the manufacturer’s protocol and 
reconstituted in solvent C (3% ACN and 0.1% formic acid) for LC-MS/MS analysis. 
Samples were auto-injected into an Eksigent-nano-HPLC system and separated on a 
custom reverse phase tip column (75 µm × 150 mm) packed with C18 material (3 µm, 
200 Å, AQ, Bischoff GmbH). The column was equilibrated with solvent C and 5% 
solvent D (0.2% FA in ACN). For elution, a flow rate of 300 nL/min was used and a 
gradient of 0–70 min, 5–25% D; 70–85 min, 25–50% D; 85–88 min, 50–98% D. High 
accuracy mass spectra were acquired with an AB SCIEX 5600 mass spectrometer 
(AB SCIEX) in the range of 385–1250 m/z. Up to 36 data-dependent MS/MS were 
recorded in high sensitivity mode of the most intense ions with charge states 2+, 3+, 
and 4+ using collision-induced dissociation. Target ions already selected for MS/MS 
were dynamically excluded for 90 s after three occurrences. MS/MS data were 
analyzed using Mascot 2.4 (Matrix Science) and searched against a decoyed human 
database from Swissprot (release December 2012) concatenated with an in-house 
build contaminant database. The search parameters were: precursor ion mass 
tolerance of 20 ppm, fragment ion mass tolerance of 0.05 Da, trypsin digestion, fixed 
modifications of MMTS-labeled cysteine, 4-plex iTRAQ modifications of free amines 
at the N-termini and of lysine, and variable modification 4-plex iTRAQ of tyrosine. 
Peptides without 4-plex iTRAQ labelling at the N-terminus or at a lysine were 
excluded from the analysis. Scaffold_4.1 (Proteome Software Inc., Portland, OR) was 
used to validate MS/MS-based peptide and protein identifications. We identified and 
quantified 1,785 proteins (protein prophet probability 95%, minimum two peptides for 
identification of a protein, and minimum Mascot Ionscore of 40). After the permutation 
test and further amendment of the p-value with the Bonferroni correction, 77 proteins 
were found to be regulated (p-value < 0.05). Thirty-five proteins were upregulated 
based on a threshold of 0.3 (log2-scale).  
XBP1-splicing assay and qPCR. RNA samples from HEK cells were prepared using 
Trizol extraction (Life Technologies) and were reverse transcribed using a 
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ThermoScript RT-PCR System (Life Technologies) according to the manufacturer‘s 
instructions. The XBP1 splicing assay employed XBP1-specific primers that amplify 
spliced (-26 nt) and unspliced XBP1 mRNA (forward 5‘-
TTACGAGAGAAAACTCATGGCC-3’, reverse 5’-GGGTCCAAGTTGTCCAGAATGC-
3’). PCR products were analyzed on a 2.7% agarose gel. Amplification of GAPDH 
cDNA served as loading control. For qPCR the Quantitect SYBR Green PCR Kit 
(Qiagen) was used together with the 7500 Fast Real-Time PCR System (Applied 
Biosystems). The primers were CHOP: forward 5‘-GCGCATGAAGGAGAAAGAAC-
3‘, reverse 5‘-CCAATTGTTCATGCTTGGTG-3‘; BiP: forward 5‘-
TTTCTGCCATGGTTCTCACTAAAA-3‘, reverse 5‘-
AACATTTAGGCCAGCAATAGTTCC-3‘; GAPDH: forward 5‘-
ACCCACTCCTCCACCTTTGA-3‘, reverse 5‘-CTGTTGCTGTAGCCAAATTCGT-3‘; 
GRP94 forward 5‘-TGGGAAGAGGTTCCAGAATG-3‘, reverse 5‘-
GTTGCCAGACCATCCGTACT-3‘. For relative quantification, GAPDH mRNA served 
as a reference. Measured quantification cycles were analyzed according to Pfaffl63, 
comparing treated with untreated samples. Three biological replicates were run in 
triplicates each and means and standard deviations were calculated. 
Western Blot. HEK cells were grown to 60% confluence in DMEM with 10% FBS. 
Medium was changed to F10 with 15 µg/mL saponin and aminoglycoside antibiotics 
were added and cells were incubated for 24 h. Cells were lysed in hypotonic buffer 
(20 mM HEPES pH 7.5, 10 mM KCl, 3 mM Mg Acetate, 1 mM DTT and 10 µg/ml 
DNase I) and ultrasonicated. Lysates were centrifuged (13.000 rpm, 10 min) and 
protein concentration in the supernatant was measured by the Micro BCA Protein 
Assay Kit (Thermo). Ten µg of total protein were resolved on 10% SDS-
polyacrylamide gels and blotted on nitrocellulose membranes, which were probed 
with specific antibodies. Amersham ECL Prime Western Blotting Detection Reagent 
(GE Healthcare, RPN2232) was used as a substrate for the horseradish peroxidase 
(HRP). The specific antibodies used in this study were: anti-BiP antibody (Abcam, 
ab21685); anti-GRP94 antibody (Abcam, ab87886); anti-ATF4 antibody (Abcam, 
ab23760); anti-β-actin antibody (Sigma, A1978-200UL); HRP-conjugated goat anti-
rabbit (Invitrogen, G-21234) and goat anti-mouse antibodies (Invitrogen, A10551). 
UPR reporter assay. Reporter plasmids UPRE (p5xATF6-GL3) and ERSE (pGL3-
GRP78P(-132)-luc) carrying luciferase under the control of UPR-specific cis-acting 
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elements were kind gifts from Kazutoshi Mori (Kyoto University, Japan). HEK cells 
were grown to 60% confluence and co-transfected with reporter constructs and 
pGL4.75 (Rluc) using TurboFect reagent (Fermentas) according to the 
manufacturer’s protocol. After a 24-h incubation medium was replaced by F10 with 
15 µg/mL saponin. Aminoglycosides were added and cells were incubated for 
another 24 h. Cells were lysed and luciferase activities determined. Normalization of 
luciferase activities was performed as described above. Cycloheximide was used as 
a mistranslation negative control and tunicamycin was used as a positive control for 
UPR. 
P-eIF2α immunofluorescence assay. HEK cells grown on poly-D-lysine (Sigma)-
coated cover slips (Thermo Scientific) were treated for 24 h with geneticin in F10 
medium with 15 µg/mL saponin, or with arsenite for 1 h (positive control). Cells were 
then fixed with 4% paraformaldehyde and methanol and incubated with blocking 
solution (1× PBS with 1% BSA and 0.5% saponin) for 1 h at RT. Immunostaining 
used a rabbit polyclonal antibody against p-eIF2α (1:250) and a secondary goat anti-
rabbit antibody conjugated with Texas Red (1:250) diluted in blocking solution. Cover 
slips were mounted on glass slides (VWR) using Dapi fluoromount (Southern 
Biotech), and cells were imaged using a Lyca Sp2 confocal microscope and a 63× 
objective. p-eIF2α and nuclear signals were quantified using Imaris software 
(Bitplane) and the dots-per-cell ratio was calculated.  
Animals. Male and female CBA/J mice were purchased from Harlan Sprague-
Dawley Co. 
(http://www.harlan.com/products_and_services/research_models_and_services/rese
arch_models/cbaj_inbred_mice.hl) at an age of 6–8 weeks and bred in-house in 
order to obtain pups for organotypic cultures of the post-natal organ of Corti and 
SGCs (see next section). XBP1+/- mice, originally derived from D3 embryonic stem 
cells, were from a stock kindly provided by Dr. Laurie H. Glimcher31 and received via 
Dr. Randal J. Kaufman, University of Michigan. Littermates served as wild-type 
(XBP1+/+) controls. Animals were kept on a 12-h light/12-h dark cycle with free 
access to water and diet (Purina 5001) and used in the in-vivo studies at an age of 
3–4 months. Experimental protocols were approved by the University of Michigan 
Committee on the Use and Care of Animals and animal care was under the 
supervision of the University of Michigan’s Unit for Laboratory Animal Medicine. 
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Organotypic cultures of post-natal organ of Corti and spiral ganglion cells. The 
procedures were as described previously.64 Mice at post-natal day 2–3 (p2–3) were 
euthanized and cochleae dissected in cold Hank’s Balanced Salt Solution to isolate 
the organ of Corti; spiral ganglion cells (SGCs) were dissected from the base to the 
middle of the modiolus. Explants were placed onto a culture dish in 2 mL of medium 
consisting of Basal Medium Eagle, 1% serum-free supplement (Gibco #51500-056, 
Life Technologies), 1% bovine serum albumin, 5 mg/mL glucose and 10 U/mL 
penicillin G, allowed to settle for 4 h (37 °C, 5% CO2) and incubated for 2 d to 
mitigate dissection stress. Medium was then exchanged for new media with or 
without drugs and incubation continued. For immunofluorescent labeling, explants 
were fixed with 4% paraformaldehyde overnight at 4 °C and permeabilized for 30 min 
with 3% Triton X-100 in phosphate buffered saline (PBS) at room temperature. After 
three washes with PBS and blocking with 10% goat serum for 30 min at RT, 
incubation with the primary antibodies followed at 4 °C for 72 h. After three washes 
with PBS, secondary antibodies were applied (Alexa Fluor 488-conjugated goat anti-
mouse and Alexa Fluor 546-conjugated goat anti-rabbit antibody; 1:200 in PBS) at 4 
°C overnight in darkness. After several rinses, specimens were mounted on a slide 
with Prolong Gold anti-fade reagent (Life Technologies) and imaged with an Olympus 
Fluoview Confocal Laser Scanning Microscope-FV500 (Olympus America, Center 
Valley, PA). For staining of hair cells, specimens were incubated at RT with 
rhodamine phalloidin (1:100) for 1 h; or for staining of nuclei with Hoechst 33342 (2 
µg/mL in PBS) for 40 min. Presence or absence of OHCs and IHCs was determined 
on a Leitz Orthoplan microscope (Leica, Wetzlar, Germany) whose right objective 
had a 0.19-mm scale imposed on the field. Successive 0.19-mm fields were 
evaluated beginning at the apex by observers blinded to the experimental conditions. 
Cell counts were compared to a normative database (KHRI Cytocochleogram, 
version 3.0.6, Kresge Hearing Research Institute, University of Michigan, Ann Arbor, 
MI, USA).  
Drug administration in vivo. Gentamicin was locally delivered as previously 
described.65 Mice were anesthetized with an intra-peritoneal injection of xylazine (7 
mg/kg) and ketamine (90 mg/kg) and body temperature was maintained. The 
temporal bone was approached via a retro-auricular incision and a small hole was 
made in the thin part of the bulla with a 30-G needle. Surgical tubing was inserted 
through the hole, and 10 μL of 0.56 M gentamicin dissolved in saline was slowly 
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injected. The skin incision was closed with tissue adhesive. TUDCA (Calbiochem, 
EMD Millipore, Billerica, MA, USA) was dissolved in 0.15 M NaHCO3 (adjusted to pH 
7.4) and injected subcutaneously at 500 mg/kg body weight 6 d, 3 d, and 3 h before 
gentamicin administration. Injections of 0.15 M NaHCO3 served as vehicle controls. 
Injection of TUDCA did not cause any apparent side effects. 
Hair cell counts in adult mice. Three weeks after injections, cochleae were fixed as 
described above. The apical bony capsule was removed and the cochlea decalcified 
in 4% sodium EDTA (adjusted to pH 7.4) for 7 d at 4 °C. Subsequently, cochleae 
were dissected into apical, middle, and basal segments. Segments were 
permeabilized in 3% Triton X-100 for 30 min at room temperature, washed three 
times with PBS, and incubated with rhodamine phalloidin (1:100) at room 
temperature for 1 h. The procedures for cell counting were the same as for explants.  
Quantification of spiral ganglion cells and synaptic ribbons. Following 
decalcification with 4% EDTA, cochleae were cryo-sectioned. Sections of 8 µm 
thickness were incubated in 0.3% Triton X-100 in PBS for 30 min at room 
temperature, blocked with 10% goat serum for 30 min, followed by incubation with 
anti-neuronal class III β-Tubulin antibody (1:2,000) for 48 h at 4 °C. After three rinses 
in PBS, sections were incubated with a secondary antibody (Alexa Fluor 546-
conjugated; 1:500) at 4 °C overnight in darkness. After three washes with PBS, 
sections were stained with Hoechst 33342 (2 µg/mL in PBS) for 40 min at room 
temperature. After a final wash, the slides were mounted with Prolong Gold anti-fade 
reagent. Controls were processed without primary antibody. The number of SGCs in 
Rosenthal’s canal was quantified using ImageJ software (National Institutes of 
Health, Bethesda, MD) by counting the β-tubulin- and Hoechst-positive cells on 
images taken with an Olympus laser confocal microscope. Two mid-modiolar 
sections, separated by 40 to 50 μm, were used to obtain the average for each 
animal. For synaptic ribbon counts, cryo-sections were incubated for 30 min at room 
temperature with 5% donkey serum in PBS with 0.3% Triton X-100 and overnight in 
darkness at 4 °C with antibodies against CtBP2 (1:200) and Myo7a (1:200). After 
three washes in PBS (15 min each), tissues were incubated with secondary 
antibodies (Alexa Fluor 488- and Alexa Fluor 546-conjugated; 1:1,000) at room 
temperature for 1 h. After three washes, the epithelia were mounted and images 
taken on an Olympus laser confocal microscope. Images were reconstructed 3-
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dimensionally using Imaris software (Bitplane). The number of synaptic ribbons was 
quantified per IHC based on an average of 14 IHCs per sample.  
Auditory function measurements. For auditory brainstem responses (ABR), 
animals were anesthetized with an intra-peritoneal injection of xylazine (7 mg/kg), 
ketamine (65 mg/kg), and acepromazine (2 mg/kg), and placed in a sound-isolated 
and electrically shielded booth (Acoustic Systems, Austin, TX, USA). Body 
temperature was maintained near 37 °C with a heating pad. Acoustic stimuli were 
delivered monaurally to a Beyer earphone attached to a speculum inserted into the 
left ear canal. Sub-dermal electrodes were inserted at the vertex of the skull, under 
the left ear, and under the right ear (ground). ABRs were measured at 12 kHz and 32 
kHz using Tucker Davis Technology (TDT) System III hardware and SigGen/Biosig 
software to present the stimuli (15 ms tone bursts, 1 ms rise-fall time) and record up 
to 1024 responses for each stimulus level. Thresholds were determined by reducing 
the intensity in 10-dB increments and then in 5-dB steps until no organized 
responses were detected. Threshold shifts were calculated for individual animals as 
the difference in auditory thresholds between ABR measurements before and at the 
end of the studies. For the DPOAE procedure, see the legend to Supplementary 
Figure S6. 
Statistical analysis. Data were evaluated by one-way ANOVA followed by Tukey’s 
Honestly Significant Difference tests using JMP version 8.0.1 (SAS Institute Inc.) or 
Student’s t-test. All tests were two-sided with significance set at P<0.05.  
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Supplementary Information 
Figure S1 Translation and viability assays  
 
(a–c) Aminoglycoside-induced translation inhibition in (a) Rabbit reticulocyte lysate (RRL), (b) HEK 
wild-type cells, (c) HEK wild-type versus HEK aph(3’) cells. Translation inhibition is measured by 
hRluc activity; hRluc signals of untreated samples are set as 100% luciferase activity. (d) Read-
through, measured in HEK wild-type versus HEK aph(3’) cells, indicated by the ratio hFluc/hRluc and 
given as fold induction. Untreated samples are set as 1. (e) Metabolic activity assay. HEK wild-type 
cells were treated with geneticin (16 µM) or gentamicin (400 µM). The Alamar Blue fluorescence level 
of the untreated samples average was set as 100%. No statistical difference was observed between 
treated and untreated controls. (f) Sytox Dead cell stain. HEK wild-type cells were treated with 
geneticin (16 µM) or gentamicin (400 µM), stained with Sytox Red and analyzed by FACS. Antimycin 
(20 µg/mL for 8 h) was used as positive control for cell death. The fluorescence level of the untreated 
samples average was set as 100% and percentage of living cells are presented. Treatment with 
geneticin and gentamicin slightly decreased cell viability by 5-15% (p<0.05) (a,b,e,f) Data are 
presented as means + SEM (n = 3). Gen: Genteicin; Gm: Gentamicin; Ant: Antimycin; Un: Untreated. 
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Figure S2 Transcriptome analysis of geneticin-treated HEK wild-type cells  
 
(a) A comparison of microarray analyses of four geneticin-treated biological replicates against four 
untreated biological replicates revealed 705 genes induced by geneticin (Benjamini-Hochberg 
corrected p-value < 0.05, FC > 1.2). The figure represents a heat map of the genes. (b) Functional 
ontology enrichment analysis indicating the most significantly enriched networks (p-value < 0.0001) of 
the 705 up-regulated genes. (c, d, e) mRNA fold induction of  individual ER folding machinery and 
ERAD components(c), chaperones of the Hsp70, Hsp90, Hsp110, and Hsp40 protein families (d), and 
foldases (e) (Benjamini-Hochberg corrected p-value < 0.05). 
Methods HEK cells were treated with 16 µM geneticin in F10 medium with 15 ug/mL saponin at 37 °C 
for 32 h. RNA was extracted from four independent samples for each condition (geneticin-treated, 
untreated). Biotinylated single-strand cDNA targets were prepared from 200 ng of total RNA, using the 
Ambion WT Expression Kit and the Affymetrix GeneChip WT Terminal Labeling Kit according to the 
manufacturer’s protocols. Following fragmentation and end-labeling, 1.9 μg of cDNAs were hybridized 
for 16 h at 45 °C on GeneChip Human Gene 1.0 ST arrays (Affymetrix) interrogating 28,869 genes 
represented by approximately 27 probes spread across the full length of the gene. The chips were 
washed and stained in the GeneChip Fluidics Station 450 (Affymetrix) and scanned with the 
GeneChip® Scanner 3000 7G (Affymetrix) at a resolution of 0.7 µm. Raw data (.CEL intensity files) 
were extracted from the scanned images using the Affymetrix GeneChip Command Console, version 
3.2. CEL files were further processed with Affymetrix Expression Console software version 1.1 to 
calculate probe set signal intensities using Robust Multi-array Average algorithms with default 
settings. Hierarchical clustering was performed using Cluster and TreeView software (http://www-
microarrays.u-strasbg.fr). Functional ontology enrichment of process networks was analysed with the 
MetaCore software (GeneGo, Thomson Reuters). Significance of the difference in expression of each 
gene between treated and untreated samples was tested using the TREAT method and the correction 
of Benjamini-Hochberg for multiple testing was applied in order to take into account the number of 
tests performed. Corrected p-values < 0.05 were considered as significant.  
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Figure S3 Aminoglycoside-induced UPR in Hela cells.  
 
(a–d) qPCR analysis. Hela wild-type cells were treated with geneticin (16 μM) or gentamicin (400 μM) 
and incubated for 24 h. Expression of CHOP (a), BiP (b), and GRP94 (c) mRNA is shown. (d) 
Tunicamycin was use as positive control. Experiments were run in triplicates and means + SD of fold 
induction relative to untreated samples are presented; ***P< 0.005; ****P<0.001. (e) Stress granule 
formation. Hela wild-type cells were treated with geneticin (16 μM) or gentamicin (400 μ M) for 24 h. 
Phosphorylated eIF2α was detected by immunofluorescence. Scale bars: 20 μm. Two representative 
pictures shown for each sample. (f) XBP1 splicing assay. Hela wild-type cells were treated with 
geneticin (16 μM) or gentamicin (400 μM) for 24 h, or left untreated. Products of XBP1 PCR were 
analyzed by gel electrophoresis; unspliced (uXBP1) and spliced (sXBP1) versions of XBP1 are 
indicated. Tunicamycin ( 2.5 μg/mL) was a positive control to induce ER stress; GAPDH was a loading 
control. The asterisk indicates the position of a hybrid amplicon (ref 15). Gen: Geneticin; Gm: 
Gentamicin; Tm: Tunicamycin; UN: Untreated. 
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Figure S4 Effect of tunicamycin on cochlear explants  
 
Control: The specific ER stress-associated pro-apoptotic factor, CHOP (green) is absent from 
untreated organ of Corti explants of CBA/J mice (P2–3). 24 h: After a 24-h incubation, tunicamycin 
(0.07 μg/mL) induced CHOP in the nuclei of most hair cells from base to apex of the organ of Corti. 48 
h: Loss of staining consistent with beginning hair cell death. Green: CHOP, red: Myo 7a stain for hair 
cells, blue: Hoechst 33342 staining for nuclei. The figure represents three different explants at each 
time point. Scale bar: 50 μm. 
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Figure S5 Effect of gentamicin on hair cells in vitro and in vivo 
 
a, b: Effect of gentamicin on hair cells in cochlear explants. (a) Loss of OHCs due to gentamicin 
treatment (3.5 μM for 72 h) showed the typical base-to-apex gradient with most destruction in the 
base. The figure represents six different explants from CBA/J mice. (b) Complete quantification of hair 
cell loss from apex to base of the explant. Data are mean + SD. Red: rhodamine phalloidin to outline 
hair cell structure. Scale bar: 50 μm. 
c: Effect of intratympanic application of gentamicin.  Surface preparations from adult wild-type and 
XBP1
+/-
 mice previously treated with intratympanically applied gentamicin were examined from base to 
apex. Actin staining (red) showed the presence of OHC cuticular plates and stereocilia in all parts of 
the cochlea, except for minor scattered loss at the base. Five wildtype and five XBP1
+/-
 mice were 
treated with gentamicin; the images are representative samples. Scale bar: 10 µm. 
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Figure S6 Distortion product otoacoustic emissions (DPOAE) remain unaltered by 
intratympanic gentamicin treatment   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Animals were anesthetized with ketamine 65 mg/kg, xylazine 3.5 mg/kg, and acepromazine 2 mg/kg 
and body temperature was maintained. The primary tones, F1 and F2, were set at a F2/F1 ratio of 1.2. 
The intensity of F1 (L1) was varied in 5- or 10-dB steps (with the intensity of F1 ranging from 10–80 
dB SPL), and the intensity of F2 (L2) was maintained 10 dB lower than L1. DPOAE were measured at 
2F1 - F2. Tones were presented via two EC1 drivers (TDT) connected through an electret condenser 
microphone (Knowles Acoustics, type FG-23329-P07). TDT System III hardware and SigGen/BioSig 
software were used to present the stimuli and record responses. DPOAE responses in four adult 
XBP1
+/-
 mice were measured before and after gentamicin treatment.  Lines for the four animals are 
distinguished by different symbols. 
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Supplementary Table 1. 
List of analyzed UPR and ER folding machinery genes and human chaperones and 
foldases. 
* Genes considered significantly regulated (p-value ≤ BH correction) 
Gene symbol Other symbols Fold change P-value BH correction 
          
UPR(Lecca, Wagner et al. 2005, Sharma, Jiang et al. 2007, Hetz 2012) 
UPR sensors         
ERN1 IRE1 0.88 0.193 0.013 
EIF2AK3 PERK 1.26 0.033 0.006 
ATF6   1.03 0.778 0.034 
ATF6B   0.68 0.001* 0.001 
  
 
      
UPR Transcription factors 
 
    
ATF3   0.99 0.898 0.041 
ATF4   0.82 0.013 0.004 
ATF6   1.03 0.778 0.034 
ATF6B   0.68 0.001* 0.001 
XBP1   1.30 0.012 0.004 
DDIT3 CHOP 1.51 0.020 0.005 
          
ERAD(Araki and Nagata 2011) 
Processing and targeting 
 
    
EDEM1   0.97 0.913 0.042 
EDEM2   1.04 0.806 0.036 
EDEM3   1.12 0.182 0.012 
PDIA2 PDI, PDIP, PDIR 0.91 0.458 0.022 
HSPA5 BiP, GRP78 2.62 <0.001* <0.001 
HSP90B1 GRP94 1.49 <0.001* <0.001 
DNAJB9 ERdj4, MDG1 1.78 0.003 0.002 
DNAJC10 ERdj5, JPD1 0.82 0.015 0.004 
FOXRED2 ERFAD 0.74 <0.001* <0.001 
PPIB CyclophilinB, CYPB 1.00 0.987 0.049 
OS9  ERLEC2 0.96 0.724 0.032 
ERLEC1 XTP3-B 1.21 0.037 0.006 
SEL1L 
 
1.25 0.061 0.007 
          
Possible retrotranslocation channel 
 
    
SEC61A1 SEC61 1.03 0.845 0.038 
SEC61A2 
 
1.13 0.300 0.017 
SEC61B 
 
1.14 0.141 0.011 
SEC61G 
 
1.57 0.001* 0.001 
DERL1 Derlin 1 1.08 0.458 0.022 
DERL2 Derlin 2 1.48 <0.001* <0.001 
DERL3 Derlin 3 1.43 0.008 0.003 
          
Other possible component or regulator 
 
    
HERPUD1 HERP, Mif1, SUP 2.10 <0.001* <0.001 
Manuscript  120 
  
 
VIMP SELS 1.43 0.004 0.002 
BCAP31 BAP31 1.09 0.442 0.021 
JKAMP HSPC213, JAMP 1.20 0.011 0.004 
DNAJB12 DJ10 0.99 0.961 0.046 
HM13 SPP 0.99 0.949 0.045 
SSR1 TRAP alpha 0.87 0.114 0.010 
SSR2 TRAP beta 1.00 0.984 0.049 
SSR3 TRAP gamma 0.97 0.828 0.037 
SSR4 TRAP delta 0.88 0.176 0.012 
TICAM2 TRAM 1.17 0.082 0.008 
AUP1 
 
1.22 0.002 0.002 
SVIP 
 
1.15 0.212 0.013 
          
E2 ubiquitin-conjugating enzyme      
UBE2K UBC1, HIP2 1.20 0.008 0.003 
UBE2D1 UBCH5 1.42 <0.001* <0.001 
UBE2J1 UBC6 0.96 0.725 0.032 
UBE2J2 
 
1.14 0.154 0.011 
UBE2G1 UBC7 1.04 0.788 0.035 
UBE2G2 
 
1.17 0.090 0.009 
UBE2N UBC13 1.11 0.233 0.014 
          
E3 ubiquitin-ligase      
NEDD4L NEDD4-2 1.15 0.135 0.011 
PARK2 PDJ 0.67 0.001* 0.001 
RNF5 RMA1 1.34 0.001* 0.001 
AMFR RNF45, GP78 0.95 0.638 0.028 
SYVN1 HRD1, DER3 1.28 0.007 0.003 
MARCH6 TEB4, DOA10 0.96 0.772 0.034 
RNF139 HRCA1, TRC8 1.27 0.006 0.003 
TRIM13 CAR, RNF77 1.01 0.971 0.047 
RNF103 KF1 1.09 0.343 0.018 
RNF19A RNF19 1.12 0.212 0.013 
RNF121 
 
1.36 0.003 0.002 
STUB1 CHIP 0.95 0.679 0.030 
          
SKP1-CUL1-F-box (SCF) E3      
SKP1 OCP 1.36 0.006 0.003 
CUL1 cullin-1 1.23 0.004 0.002 
FBXO2 FBG1 0.88 0.160 0.011 
FBXO6 FBG2 0.91 0.247 0.015 
RBX1 RNF75, ROC1 1.09 0.357 0.018 
          
E4 ubiquitin-conjugating enzyme      
UBE4B UFD2 0.90 0.240 0.014 
          
Substrate extraction and recruiting      
VCP p97, ALS14 1.31 0.001* 0.002 
UFD1L UFD1 1.30 0.003 0.002 
NPLOC4 NPL4 1.13 0.187 0.012 
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UBXD family protein      
UBXN6 UBXD1 1.02 0.905 0.042 
UBXN4 UBXD2 1.12 0.226 0.014 
UBXN7 UBXD7 1.31 0.010 0.003 
FAF2 UBXD8 1.47 <0.001* 0.001 
UBXN1 UBXD10 1.02 0.844 0.038 
          
Deglycosylating enzyme      
NGLY1 PNGase 1.11 0.270 0.015 
          
DUB (deubiquitination)      
VCPIP1 DUBA3, VCIP135 1.21 0.011 0.004 
YOD1 DUBA8, YOD1 1.57 <0.001* <0.001 
ATXN3 Ataxin-3 1.12 0.259 0.015 
USP19 
 
1.19 0.071 0.008 
          
Shuttle protein         
UBQLN1 Ubiquilin1 1.18 0.017 0.004 
RAD23A HR23A 0.78 0.004 0.003 
RAD23B HR23B 0.91 0.382 0.019 
          
Ubiquitin receptor      
PSMD4 Rpn10 0.86 0.159 0.011 
PSMC3 Rpt5 0.95 0.686 0.030 
ADRM1 Rpn13 1.13 0.247 0.015 
          
ER Chaperones(Lecca, Wagner et al. 2005, Hebert and Molinari 2007, Araki and Nagata 2011) 
DNAJC1 ERdj1, MTJ1 0.97 0.834 0.037 
SEC63 ERdj2, DNAJC23 0.91 0.343 0.018 
DNAJB11 ERdj3, HEDJ, ERj3 2.21 <0.001* <0.001 
DNAJB9 ERdj4, MDG1 1.78 0.003 0.002 
DNAJC10 ERdj5, JPD1 0.82 0.015 0.004 
TOR1A Torsin A 1.05 0.636 0.028 
SIL1 BAP, ULG5 1.02 0.886 0.040 
HYOU1 GRP170 1.79 <0.001* 0.001 
HSP90B1 GRP94 1.49 <0.001* <0.001 
HSPA5 BiP 2.62 <0.001* <0.001 
CALR Calreticulin 1.50 <0.001* 0.001 
CANX Calnexin 1.10 0.310 0.017 
SERPINH1 HSP47 1.24 0.024 0.005 
LRPAP1 RAP 1.07 0.558 0.025 
LEPRE1 P3H1 0.95 0.641 0.028 
P4HB P4H, ERP59, PDIA1 0.95 0.668 0.029 
DNAJC3 ERdj6 2.21 <0.001* <0.001 
          
ER foldases(Lecca, Wagner et al. 2005, Schroder and Kaufman 2005, Hebert and Molinari 2007, 
Bernasconi and Molinari 2011) 
PDIA3  ERP57, ERP61, ERP60 1.36 0.001* 0.002 
PDIA4 ERP70, ERP72 2.55 <0.001* <0.001 
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DNAJC10 ERdj5 0.82 0.015 0.004 
PDIA5 PDIR 0.97 0.832 0.037 
MUTED ERP46, PDIA15 0.98 0.903 0.042 
PDIA2 PDI, PDIp, PDIr  0.91 0.458 0.022 
PDILT PDIA7 0.93 0.507 0.024 
ERP44 PDIA10, TXNDC4 1.34 0.001* 0.001 
TXNDC12 
ERP18, PDIA16, 
ERP19 
1.17 0.035 0.006 
TMX1 TMX, PDIA11 1.06 0.589 0.026 
TMX2 PDIA12 1.26 0.021 0.005 
TMX3 PDIA13 0.96 0.755 0.033 
TMX4 PDIA14 0.90 0.297 0.016 
PDIA6 P5, ERP5, TXNDC7 1.42 0.002 0.002 
ERO1LB  ERO1B 1.60 0.003 0.002 
ERO1L  ERO1A 0.79 0.004 0.002 
P4HB PDIA1, ERP59 0.95 0.668 0.029 
ERP29 PDIA9, ERP28, ERP31 0.67 <0.001* 0.001 
PPIB CyclophilinB, CYPB 1.00 0.987 0.049 
FKBP2 FKBP13 1.05 0.717 0.032 
FKBP7 FKBP23 1.47 <0.001* 0.001 
FKBP10 FKBP65 0.74 0.002 0.002 
FKBP11 FKBP19 1.14 0.370 0.019 
          
N-linked Glycosylation(Lecca, Wagner et al. 2005, Schroder and Kaufman 2005) 
UGGT1 UGT1 1.00 0.973 0.047 
UGGT2 UGT2 1.09 0.478 0.023 
SDF2    1.50 0.003 0.002 
SDF2L1   2.41 <0.001* <0.001 
MOGS alpha glucosidase I 1.11 0.366 0.019 
GANAB alpha glucosidase II 0.80 0.006 0.003 
MAN1A1 alpha mannosidase I 0.99 0.953 0.046 
MAN2A1 alpha mannosidase II 0.81 0.023 0.005 
ALG12                   
 
1.29 0.008 0.003 
ALG5 
 
1.30 0.006 0.003 
PIGA                     GPI3 1.35 0.012 0.004 
PIGB                      
 
0.87 0.169 0.012 
RPN1 OST1                     1.01 0.942 0.045 
STT3A STT3, ITM1         0.90 0.226 0.014 
DDOST WBP1   0.95 0.653 0.029 
          
Human Chaperones(Kampinga, Hageman et al. 2009) 
 
  
HSPA (Hsp70 chaperones)       
HSPA1A   5.05 <0.001* <0.001 
HSPA1L   4.40 <0.001* <0.001 
HSPA2   1.37 0.005 0.003 
HSPA5 BiP, GRP78 2.62 <0.001* <0.001 
HSPA6   1.65 0.004 0.002 
HSPA7   1.65 0.004 0.002 
HSPA8   1.17 0.021 0.005 
HSPA9   1.00 0.977 0.048 
Manuscript  123 
  
 
HSPA12A   0.92 0.381 0.019 
HSPA12B   0.96 0.680 0.030 
HSPA13   1.05 0.715 0.031 
HSPA14   1.26 0.007 0.003 
          
HSPH (Hsp110 chaperones)       
HYOU1 GRP170 1.79 <0.001* 0.001 
HSPH1   2.70 <0.001* <0.001 
HSPA4   1.48 <0.001* <0.001 
HSPA4L   1.56 <0.001* <0.001 
          
HSPC (Hsp 90 chaperones)       
HSP90AA1   1.43 <0.001* <0.001 
HSP90AA2   1.81 <0.001* <0.001 
HSP90AB1   1.06 0.651 0.029 
HSP90B1 GRP94 1.49 <0.001* <0.001 
TRAP1   0.82 0.016 0.004 
  
 
        
DnaJA (Hsp40 co-chaperones)       
DNAJA1   1.62 <0.001* <0.001 
DNAJA2   1.14 0.121 0.010 
DNAJA3   1.12 0.169 0.012 
DNAJA4   0.99 0.938 0.044 
          
DnaJB (Hsp40 co-chaperones)       
DNAJB1   3.23 <0.001* <0.001 
DNAJB2   0.90 0.376 0.019 
DNAJB3   0.93 0.517 0.024 
DNAJB4   2.09 <0.001* <0.001 
DNAJB5   1.10 0.321 0.017 
DNAJB6   1.22 0.018 0.004 
DNAJB7   0.99 0.921 0.043 
DNAJB8   0.90 0.217 0.014 
DNAJB9   1.78 0.003 0.002 
DNAJB11   2.21 <0.001* <0.001 
DNAJB12   0.99 0.961 0.046 
DNAJB13   1.00 0.963 0.047 
DNAJB14   1.04 0.721 0.032 
          
DnaJC (Hsp40 co-chaperones)       
DNAJC1   0.97 0.834 0.037 
DNAJC2  MPP11 1.19 0.021 0.005 
DNAJC3  ERdj6 2.21 <0.001* <0.001 
DNAJC4   0.82 0.020 0.005 
DNAJC5   1.05 0.693 0.030 
DNAJC5B   0.99 0.946 0.045 
DNAJC5G   1.00 0.984 0.049 
DNAJC6   1.31 0.006 0.003 
DNAJC7   1.10 0.223 0.014 
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DNAJC8   1.55 0.001* 0.001 
DNAJC9   1.22 0.028 0.005 
DNAJC10  ERdj5 0.82 0.015 0.004 
DNAJC11   1.38 0.008 0.003 
DNAJC12   1.11 0.372 0.019 
DNAJC13   0.96 0.781 0.035 
DNAJC14   1.01 0.924 0.043 
DNAJC15   0.98 0.874 0.040 
DNAJC16   0.80 0.015 0.004 
DNAJC17   #N/A #N/A #N/A 
DNAJC18   0.75 0.001* 0.001 
DNAJC19  TIMM14 0.98 0.897 0.041 
DNAJC21   1.03 0.769 0.034 
DNAJC22   0.98 0.868 0.039 
DNAJC24  DPH4 1.15 0.112 0.010 
DNAJC25   1.19 0.023 0.005 
DNAJC27   1.12 0.349 0.018 
DNAJC28   0.96 0.703 0.031 
DNAJC30   0.99 0.972 0.047 
HSCB   1.04 0.776 0.034 
SEC63  ERdj2 0.91 0.343 0.018 
GAK  DNAJC26 1.06 0.638 0.028 
SACS  DNAJC29 1.10 0.328 0.017 
          
HspB (small heat shock proteins)       
HSPB1  HSP25 1.90 0.001* 0.001 
HSPB2  HSP27 0.93 0.532 0.024 
HSPB3  HSPL27 1.07 0.611 0.027 
HSPB6  HSP20 #N/A #N/A #N/A 
HSPB7   0.92 0.466 0.022 
HSPB8   1.42 0.121 0.010 
HSPB9   0.91 0.356 0.018 
HSPB11   1.11 0.290 0.016 
HSPBAP1   1.18 0.049 0.007 
CRYAA   0.88 0.224 0.014 
CRYAB   1.03 0.811 0.036 
          
Chaperonin (Hsp10 and 60)       
HSPD1 HSP60, GROEL 1.15 0.036 0.006 
HSPD1P1   1.36 0.010 0.003 
HSPE1 HSP10, GROES 1.58 <0.001* <0.001 
MKKS   0.99 0.940 0.045 
BBS10   1.30 0.012 0.004 
BBS12   1.15 0.260 0.015 
          
Chaperone regulator       
STIP1   1.72 <0.001* <0.001 
          
CLIPs (ribosome-associated chaperones)       
TCPA1   1.19 0.005 0.003 
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CCT2   1.07 0.525 0.024 
CCT3   1.13 0.133 0.010 
CCT4   1.10 0.264 0.015 
CCT5   1.14 0.047 0.007 
CCT6A   1.26 <0.001* 0.001 
CCT6B   0.97 0.855 0.039 
CCT7   1.13 0.089 0.009 
CCT8   1.10 0.292 0.016 
PFDN1   1.22 0.007 0.003 
PFDN2   1.15 0.088 0.009 
VBP1   1.29 0.009 0.003 
PFDN4   1.21 0.048 0.007 
PFDN5   0.99 0.963 0.047 
PFDN6   1.48 <0.001* 0.001 
DNAJC2   1.19 0.021 0.005 
HSPA14   1.26 0.007 0.003 
BTF3   1.01 0.956 0.046 
NACA   1.01 0.955 0.046 
          
Peptidylprolyl cis-trans Isomerases (PPI)(Gerard, Deleersnijder et al. 2011, Benham 2012) 
FKBP1A   1.04 0.056 0.007 
FKBP1B   1.14 0.197 0.013 
FKBP2   1.05 0.717 0.032 
FKBP3   1.04 0.723 0.032 
FKBP4   1.50 <0.001* 0.001 
FKBP5   1.27 0.003 0.002 
FKBP6   0.88 0.206 0.013 
FKBP7   1.47 <0.001* 0.001 
FKBP8   0.97 0.817 0.036 
FKBP9   0.83 0.060 0.007 
FKBP9L   0.81 0.023 0.005 
FKBP10   0.74 0.002 0.002 
FKBP11   1.14 0.370 0.019 
FKBP14   1.46 0.001* 0.001 
FKBPL   1.02 0.843 0.038 
PIN1   1.15 0.073 0.008 
PIN1P1   #N/A #N/A #N/A 
PIN4   1.18 0.154 0.011 
PPIA   1.08 0.418 0.020 
PPIAL4A   1.02 0.927 0.044 
PPIAL4B   1.00 0.927 0.044 
PPIAL4C   1.00 0.927 0.044 
PPIAL4D   #N/A #N/A #N/A 
PPIAL4E   1.00 0.927 0.044 
PPIAL4F   1.00 0.927 0.044 
PPIAL4G   0.97 0.908 0.042 
PPIB CyclophilinB, CYPB 1.00 0.987 0.049 
PPIC   0.92 0.432 0.021 
PPID   1.59 <0.001* 0.001 
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PPIE   1.19 0.077 0.008 
PPIEL   1.04 0.949 0.045 
PPIF   1.00 0.992 0.049 
PPIG   1.45 <0.001* 0.001 
PPIH   1.37 <0.001* <0.001 
PPIL1   1.17 0.045 0.007 
PPIL2   0.82 0.010 0.003 
PPIL3   0.91 0.304 0.017 
PPIL4   1.42 0.001* 0.001 
PPIL6   0.85 0.095 0.009 
PPWD1   1.10 0.325 0.017 
          
Protein Disulfide Isomerases (PDI)
11
 
PDIA2   0.91 0.458 0.022 
PDIA3   1.36 0.001* 0.002 
PDIA4   2.55 <0.001* <0.001 
PDIA5   0.97 0.832 0.037 
PDIA6   1.42 0.002 0.002 
PDILT   0.93 0.507 0.024 
PDIK1L   0.93 0.502 0.023 
P4HB   0.95 0.668 0.029 
ERP27   0.97 0.880 0.040 
ERP29   0.67 <0.001* 0.001 
ERP44   1.34 0.001* 0.001 
TMX1   1.06 0.589 0.026 
TMX2   1.26 0.021 0.005 
TMX3   0.96 0.755 0.033 
TMX4   0.90 0.297 0.016 
TXNDC5   1.21 0.274 0.016 
TXNDC12   1.17 0.035 0.006 
AGR2   1.07 0.528 0.024 
AGR3   0.97 0.898 0.041 
DNAJC10   0.82 0.015 0.004 
CASQ1   0.98 0.930 0.044 
CASQ2   0.92 0.397 0.020 
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